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The glycine receptor (GlyR) is a ligand-gated ion channel member of the cys-loop 
receptor superfamily, responsible for inhibitory neurotransmission in the brain and spinal 
cord.  Both glycine and the partial agonist taurine act as endogenous ligands of the GlyR. 
Taurine-activated GlyR may have a role in the rewarding effects of drugs of abuse, such 
as ethanol.  As a partial agonist, taurine has a decreased efficacy relative to glycine, 
resulting in a decreased maximum response.  We investigated the effects of ethanol, 
anesthetics, inhalants, and zinc to determine if these allosteric modulators could increase 
the efficacy of the taurine-activated GlyR.  Whole cell recordings of wild type GlyR 
revealed that each of the allosteric modulators potentiated currents generated by 
saturating concentrations of taurine but not glycine, implying an increase in efficacy. 
Zinc is found at GlyR-potentiating concentrations throughout the nervous system, so we 
examined the combinatorial effects of these allosteric modulators with zinc to mimic in 
vivo conditions.  Whole cell recordings revealed that zinc potentiation of saturating 
taurine-generated currents decreased further potentiation by another allosteric modulator, 
indicating no synergistic effects on efficacy.  We next investigated the actions of ethanol 
and isoflurane on the taurine-activated GlyR at the single channel level, finding that both 
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allosteric modulators stabilized the channel open state, increasing the efficacy of the 
taurine-activated GlyR.  We previously identified a mutation in the ligand-binding 
domain of the GlyR (D97R) that produces spontaneously activating channels, on which 
taurine has increased efficacy.  We identified a residue, R131, as a possible binding 
partner of D97 in forming an electrostatic interaction that holds the channel in the closed 
state.  We found that disruption of this interaction results in greatly increased taurine 
efficacy, indicating that efficacy for partial agonists may be determined by agonist ability 
to break this bond early in the activation process following binding.  Thus we find 
differential mechanisms of allosteric modulation and efficacy determinations for the 
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The nervous system contains billions of neurons that form interconnected 
networks necessary for functioning of all other systems.  Information conveyance is 
achieved through both electrical and chemical means.  Neurons use a multitude of ion 
channels in their membranes to propagate electrical signals towards synapses with other 
neurons, where the electrical signal is converted into a chemical signal, with the 
presynaptic neuron releasing neurotransmitters that activate receptors on the postsynaptic 
cell, thus achieving information transfer.  These neurotransmitter receptors are generally 
one of two types, either termed metabotropic and activating signaling cascades utilizing 
guanosine nucleotide-binding proteins, or termed ionotropic and being directly coupled to 
an ion channel in the neuronal membrane.  These ionotropic receptors are also termed 
ligand-gated ion channels (LGICs) as they are directly activated by a chemical signal and 
to distinguish them from the many families of voltage-gated ion channels (VGICs). 
LGICs generally contain an extracellular domain, multiple transmembrane domains, and 
intracellular domains important for functioning of the channel.	

One family of LGICs is the cys-loop receptor superfamily of ion channels.  This 
family contains the nicotinic acetylcholine receptor (nAChR) as its prototypical member, 
being the ion channel first and most studied among this family.  Other family members 
include the γ-aminobutyric acid type A receptor (GABAAR), glycine receptor (GlyR), and 
the serotonin type 3 receptor (5-HT3R).  These receptors are composed of a pentameric 
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arrangement of protein subunits around a central ion conducting pore, and varyingly can 
be composed of all five subunits being identical (homomeric) or differing in protein 
sequence (heteromeric).  Individual subunits in this family generally have similar 
structural components, with a large extracellular domain at the N-terminus, four 
transmembrane domains (TM), an intracellular domain of varying size between TM3 and 
TM4, and an extracellular C-terminus of variable length.  The extracellular domain of 
each subunit in this family contains the characteristic cys-loop, a highly conserved 
sequence of 13 amino acids held into a loop by a cysteine-cysteine disulfide bond.  In the 
pentameric arrangement, TM2 of each subunit lines the ion-conducting pore, with the 
nAChR and 5-HT3R allowing cationic flow and the GABAAR and GlyR allowing anionic 
flow.  	

Structural information regarding this family of ion channels has been achieved by 
studying related ion channels and proteins then using homology modeling to investigate 
the channels that have not been crystallized as of this date.  Initial studies used the crystal 
structure of the acetylcholine binding protein (AChBP) from the great pond snail 
Lymnaea stagnalis (Brejc et al., 2001).  The AChBP is a protein released from glia into 
the synaptic cleft to bind acetylcholine and modulate neuronal transmission.  This snail 
protein is very similar in structure to the extracellular domain of the nAChR, which 
allowed for comparison with other cys-loop family members in terms of ligand binding. 
Subsequent to this characterization, the nAChR found in the electric organ of the marbled 
electric ray Torpedo marmorata was analyzed using electron microscopy to reveal the 
structure of the nAChR pore region (Miyazawa et al., 2003).  Whole prokaryotic ligand 
gated ion channels homologous to human cys-loop receptors were subsequently 
crystallized and used for homology modeling comparison to mammalian channels.  These 
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include channels from the bacterium Gloeobacter violaceus (GLIC) and the 
cyanobacterium Erwinia chrysanthemi (ELIC) (Hilf and Dutzler, 2008; Bocquet et al., 
2009).  More recently, a glutamate activated cys-loop receptor (GluCl) from the 
nematode Caenorhabditis elegans was crystallized, and marked the first crystallized 
receptor known to contain an anion-selective pore responsible for inhibitory 
neurotransmission (Hibbs and Gouaux, 2011).  All structural determinations regarding 
cys-loop receptors that have not been crystallized utilize homology modeling with one or 
more of the previously mentioned structures, and will be assumed in this and following 
chapters.  An example structure of the Torpedo nAChR showing the basic structural 






Figure 1.1 – Structure of a nicotinic acetylcholine receptor	

Structure of the Torpedo nicotinic acetylcholine receptor.  Viewed from inside the 
membrane at the side of the channel.  Different colors denote different subunits.  
Adapted from derivation of the structure (PDB ID: 2BG9) from Unwin N. (2005). 
Refined structure of the nicotinic acetylcholine receptor at 4 Å resolution.  J Mol 
Biol 346: 967.  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Cys-loop receptor pentameric stoichiometry varies among the different receptor 
types.  Receptors may be comprised of five identical subunits (termed homomeric) or a 
combination of different subunits (termed heteromeric).  The number of subunits that can 
form functional channels can vary greatly between the different cys-loop receptors, and 
are usually classified by homology with other receptor subunits.  For example, the 
nAChR has seventeen subunits in five classes, though not all subunits are found in all 
species.  These include 10 α subunits, 4 β subunits, and one each of a δ, ε, and γ 
subunits.  This results in a multitude of subunit combinations possible to create the 
pentameric channel.  However, not all combinations have been found in vivo nor can all 
possible combinations even assemble into functional channels.  For example, to date in 
the case of the nAChR, only the α7 and α8 subunits has been found to form functional 
homomeric channels in humans.  Heteromeric channels are usually comprised of multiple 
α and β subunits that may contain one or more of the other subunit classes.  This 
structural variability also contributes to functional variability both in terms of biophysical 
characteristics of the channels themselves as well as modulation by allosteric compounds. 
In this way, different regions of the nervous system may express specific subtypes of 
these receptors as needed for specialized functioning in that region, though there is often 
overlap.	

The first functional characteristic to examine in cys-loop receptors is ligand 
binding.  A hallmark of the ligand gated ion channels is that they are stably in a closed 
pore confirmation when no ligand is around.  Upon ligand binding, the channel will 
change conformation allowing ionic conductance through the pore.  The channel then 
closes in one of two ways, with ligand unbinding or by entering a desensitized state 
where ligand may be bound but the pore does not conduct ions.  Although some 
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mechanisms for desensitization have been proposed, it is still a poorly understood process 
and may vary between cys-loop receptors.  The ligand-binding domain for cys-loop 
receptors occurs in the large extracellular domain found near the N-terminus of the 
protein.  Generally, ligands bind in the interface between adjacent subunits, with one 
subunit side (the “principal” or + side) comprised of a series of loops and the adjacent 
subunit side (the “complementary” or – side) composed of strands of β-sheets (Brejc et 
al., 2001).  Thus, up to five ligands may bind a single receptor and the subunit 
stoichiometry determines if specific interfaces comprise a  ligand binding site.  The 
extracellular domain must convey ligand binding to the pore region in order for the 
channel to open.  This occurs through a conformational wave of residue motion that 
allows loops from the extracellular domain to interact with the transmembrane regions 
considered next (Purohit et al., 2007).	

The transmembrane domain is comprised of four α-helices with hydrophobic 
residue side chains anchoring the protein in the membrane.  These helices are numbered 
according to the order they occur in the protein’s amino acid sequence.  Although the 
extracellular domain is directly connected to TM1, the extracellular linking region 
between TM2—TM3 has been shown to be important for transmission of the binding 
signal to gating of the pore (Kash et al., 2003).  This may occur due to TM2 lining the 
pore for each subunit.  Unlike other transmembrane helices, TM2 contains hydrophilic 
residues pointing into the pore, creating a strip of hydrophilicity along the hydrophobic 
TM2 helix of each subunit.  In some positions of the pore lining residues there are 
charged amino acids that are of opposite charge to the ions the receptor conducts.  This 
creates rings of charges from the five subunits, that are believed to help attract and 
propagate ions through the pore (Corringer et al., 1999; Gunthorpe and Lummis, 2001). 
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Thus cationic channels like the nAChR have negatively charged amino acid rings in the 
pore, while anionic channels like the GABAAR and GlyR have positively charged amino 
acid rings along the channel pore.	

The large intracellular loop of cys-loop receptors occurs as the linking sequence 
between TM3-TM4 and varies considerably among family members in amino acid 
sequence and length.   Although this region may contain necessary sites for signaling 
cascades and modulation of functioning of these channels, such as phosphorylation sites, 
or motifs necessary for cytoskeleton anchoring, the variability among family members 
leads to differences in functioning among them.  For example, in the nAChR and the 5-
HT3AR these domains seem to form hanging structures around the intracellular pore 
opening with holes connecting through to the cytoplasm that are similar in size to the 
hydrated ions conducted through the channel, thus influencing ion permeation through the 
channel (Miyazawa et al., 1999; Kelley et al., 2003).  As a counter example, while the 
GlyR contains sites for phosphorylation and other signaling similar to other cys-loop 
receptors, the large intracellular loop, specifically in the β subunit, of this channel seems 
to play more of a role in anchoring the protein to certain membrane locations, such as at 
synapses.	

Finally, cys-loop receptors contain a short extracellular C-terminus proceeding 
from TM4.  This C-terminal peptide is quite variable in length among family members 
and generally has not been studied in great detail.  A study of the structure of ELIC 
suggests that while TM1 and TM3 may help to shield and stabilize the pore formed by 
the TM2 domains, TM4 seems to only moderately interact with TM1 and TM3 and does 
not participate in subunit-subunit interactions.  As the generally short C-terminus 
protrudes from TM4, it may have been thought to be unlikely to participate in 
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interactions with other parts of the receptor.  Interestingly, recent research has shed light 
on some possible roles of the C-terminus.  Deletion of the three amino acid C-terminus of 
the 5-HT3AR significantly decreased membrane expression of the receptor, indicating a 
role in formation and stabilization of the mature protein or a binding/recognition site for 
trafficking proteins (Butler et al., 2009).  Additionally, towards the goal of obtaining a 
better understanding of the structure function relationship of cys-loop receptors, 
Corringer’s group created a chimeric channel with the extracellular domain of GLIC and 
the transmembrane domain of the α1 GlyR (Duret et al., 2011).  In order to facilitate 
native interactions between the domains they mutated other sites, including changing the 
C-terminus from the GlyR sequence to that of the GLIC channel.  When mutated back to 
the GlyR terminus in the chimera, the channel had faster desensitization, with a left shift 
in the concentration response curve, indicating a role of the C-terminus in modulating 
channel kinetics.  Further explanation of the GlyR in detail follows in the next section.	

!
1.2 – The Glycine Receptor	

!
As previously mentioned, the GlyR is a member of the cys-loop ligand gated ion 
channel family.  The namesake neurotransmitter that activates it, glycine, has the simplest 
structure of the biological amino acids.  Inhibitory neurotransmission through ligand 
gated ion channels was first proposed by Coombs et al. (1955) who examined IPSP 
inhibition of motor neurons and the anions involved.  Building upon this work, a pair of 
papers from Davidoff, Werman, and colleagues (Davidoff et al. 1967; Werman et al. 
1967) proposed and confirmed glycine’s role as an inhibitory neurotransmitter on 
postsynaptic spinal cord motor neurons of the cat.  Glycine is not an essential dietary 
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component as it can be readily synthesized in the body via two enzymatic pathways.  The 
first pathway utilizes the enzyme serine hydroxymethyltransferase to convert serine and 
tetrahydrofolate to glycine and N5,N10-Methylene tetrahydrofolate and H2O, and is the 
main pathway used in the central nervous system (CNS).  The second reaction occurs in 
the liver by the enzyme glycine synthase (glycine cleavage enzyme) which converts 
N5,N10-Methylene tetrahydrofolate with the cofactors CO2, NH4+, NADH, and H+ to 
glycine, tetrahydrofolate, and NAD+.  The reverse of this second reaction is the major 
catabolic pathway for glycine.  Glycine packed into synaptic vesicles for neurotransmitter 
release comes from both the synthetic pathway mentioned earlier and reuptake of 
released glycine via glycine transporters GLYT1 and GLYT2 (Legendre, 2001). 
Although there is some disagreement as to which transporter is generally expressed more 
on glia vs. neurons, the GLYT2 is the major contributor of extracellular glycine uptake 
into presynaptic boutons despite a lack of expression seen in synapses (Jursky et al., 
1994; Zafra et al., 1995a, 1995b; Poyatos et al., 1997; Spike et al., 1997; Belachew et al., 
2000).  Packaging of glycine into synaptic vesicles is accomplished by the vesicular 
inhibitory amino acid transporter (VIAAT) which also transports GABA (Dumoulin et al., 
1999).	

Like other cys-loop family members, the GlyR is comprised of a pentameric 
arrangement of subunits around a central ion conducting pore.  The GlyR contains a 
strong anion conducting pore, and due to the overwhelming prevalence of the chloride 
anion in vivo, it mainly conducts chloride.  However, the GlyR has been tested for anion 
permeability in vitro, and contains an anion permeability preference of SCN— > NO3— > I
— > Br— > Cl— > F—, which corresponds to the hydration energies of these anions 
indicating that removal of waters of hydration is the major hurdle to ion permeability 
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through the pore (Bormann et al., 1987; Fatima-Shad and Barry, 1993; Lynch, 2004). 
The chloride reversal potential in vivo varies but is usually close to the resting membrane 
potential of neurons.  Thus activation of GlyR at rest don’t drastically change membrane 
voltage but prevent further depolarization away from the chloride resting potential, an 
effect known as shunting inhibition (Lynch, 2004).  During embryonic development, 
GlyR currents can be depolarizing and excitatory before expression of a potassium-
chloride cotransporter (KCC2) that lowers internal concentrations of chloride in mature 
neurons (Stein and Nicoll, 2003). 	

The GlyR contains somewhat less subunit variability compared to other cys-loop 
receptor family members, with only five total identified subunits, four α subunits, and one 
β subunit.  The α subunits have high homology of their sequences on the order of 
80-90% while the β subunit has approximately 47% homology with the α1 subunit, 
though only the first three α subunits and the β are found in humans (Lynch, 2004). 
Thus, the GlyR exists as homomeric α receptors, or heteromeric receptors comprised of 
one member of the α subunit class in conjunction with the β subunit.  Although the β 
subunit is expressed throughout the nervous system, it cannot form a functional channel 
on its own (Malosio et al., 1991).  During development, GlyR exist predominantly as α2 
homomers (Becker et al., 1988), with a switch to α1β heteromers being the predominant 
form in adult neurons (Lynch, 2004).  Although various localization studies have found 
evidence of all mammalian α subunits expressed in the adult in various regions.  For 
instance, the α3 subunit has been implicated in nociceptive signaling in the spinal cord 
(Zeilhofer, 2005).  As mentioned previously, the β subunit seems to anchor the GlyR to 
synaptic locations through its interaction with the scaffolding protein known as gephyrin. 
Clustering of GlyR at synapses through gephyrin binding would indicate that synaptic 
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GlyR are heteromeric receptors containing the β subunit (Kirsch and Betz, 1995). 
However, there is growing evidence for functional homomeric α receptors in perisynaptic 
regions, perhaps acting as autoreceptors or in a neuromodulatory role distinct from 
synaptic transmission.  For example, α2 receptors are preferentially expressed in the 
nucleus accumbens (NAcc) and may play a role in the rewarding effects of alcohol 
consumption which will be discussed later in more detail (Molander et al., 2005; Jonsson 
et al., 2014).  	

Although previously believed to be responsible for inhibitory neurotransmission 
in the spinal cord and brainstem, GlyR have more recently been found in many higher 
brain regions as well.  The β subunit is expressed throughout the brain, but that is not a 
direct indicator of expression of functional channels.  However, studies using antibodies 
against GlyR, in situ hybridization against GlyR transcripts, or electrophysiological 
characterization have found GlyR in regions such as the cerebellum, olfactory bulb, 
hippocampus, basal ganglia, and prefrontal cortex (Araki et al., 1988; van den Pol and 
Gorcs, 1988; Malosio et al., 1991; Waldvogel et al., 2007; Baer et al., 2009; Jonsson et 
al., 2009, 2012;  Lu and Ye, 2011).  GlyRs have also been found to function in the off-
channel of the rod pathway in the retina, the initiation of the acrosome reaction in the 
plasma membrane of the acrosome region of spermatozoa, and may play a role in the 
functioning of pancreatic islet cells, adrenomedullary cells, and the specialized 





Figure 1.2 – Structure of the glycine receptor	

Left:  Homology model of the ligand-binding domain of the α1 GlyR viewed top 
down from the extracellular side of the membrane.  Each color denotes a separate 
subunit.  The principal (+) and complementary (-) sides of the intersubunit 
interface are shown.  Adapted from Lynch JW. (2004). Molecular structure and 
function of the glycine receptor chloride channel.  Physiol Rev 84: 1051.	

Right:  Cartoon representation of a single subunit of the α1 GlyR.  Each circle 
represents a single amino acid residue with the single letter code denoting the 
amino acid inside the circle.  The yellow band denotes the plasma membrane, 
with the residues of the transmembrane domains shown clustered in the 
membrane.  The two cys-loops can be seen in the extracellular domain. Adapted 
from Rajendra et al. (1997). The glycine receptor.  Pharmacol Ther 73: 121.  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As mentioned in Section 1.1, the GlyR structure has not been specifically 
resolved, and thus is always compared to an existing structure like the nAChR or one of 
the non-mammalian channels.  A homology model of the GlyR extracellular domain can 
be seen in Fig 1.2, along with a cartoon representation of a single subunit.  Mutational 
analyses have allowed elaboration on the assumed structural similarities with other cys-
loop receptors.  The ligand-binding domain between adjacent subunits is composed of 
loops A, B, and C on the principal side and β domains D, E, and F on the complementary 
side.  It is believed that the glycine molecule binds in an orientation with its amino group 
towards the principal side, and its carboxylic acid group towards the complementary side. 
The α1 subunit has been the most extensively studied subunit of the GlyR, and references 
to GlyR residues will use the residue number associated with the α1 subunit unless stated 
otherwise.  	

Charged residues from these loops and domains that point into the intersubunit 
interface interact with the end groups of glycine to stabilize the molecule in the binding 
area.  However, a recent study found two residues to be the primary binding partners.  On 
the principal side, E157 provides negative charge to interact with the amino group of 
glycine, and on the complementary side, R65 provides positive charge to interact with the 
carboxylic acid group of glycine (Grudzinska et al., 2005).  Thus, in α homomeric 
receptors, up to five glycine molecules can bind, though only three bound glycine 
molecules are necessary for full activation of the channel (Beato et al., 2004).  For αβ 
heteromers then, the stoichiometry of the subunits would become important if glycine 
could only bind between α subunits.  Evidence has been found for both 3α:2β or 2α:3β 
configurations, with the latter being the currently accepted theory (Langosch et al., 1988; 
Burzomato et al., 2003; Grudzinska et al., 2005).  Interestingly, in the same study 
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suggesting the 2α:3β configuration, the authors also found the corresponding glycine 
binding residues on the β subunit can also participate in stabilizing glycine, suggesting up 
to four possible glycine binding sites.  Recent functional studies utilizing the newer cys-
loop crystal structures have found that even the ββ interface can bind glycine and may be 
important for functional modification of heteromeric GlyR (Dutertre et al., 2012).	

Mutations of additional residues in these binding regions can directly affect 
agonist affinity for the receptor.  When residues F159 and Y161, on the same loop as the 
proposed binding partner E157, are mutated, the resultant receptors have drastic changes 
to agonist affinity for a variety of agonists (Schmieden et al., 1993).  The same is true for 
residues on the complementary subunit, with mutations to the R119 residue causing great 
changes to multiple agonist and antagonist binding (Grudzinska et al., 2005).  The Y202 
residue on loop C has also been implicated in possible ligand binding, as mutations to this 
residue and nearby ones affect receptor sensitivity to glycine, though mutations in this 
region may also affect gating as efficacy of some agonists is increased (Vandenberg et al., 
1992a, 1992b; Rajendra et al., 1995).  Interestingly, loop C is contained within the second 
cys-loop unique to GlyR  that may be involved in communicating binding to the pore in a 
similar way as the conserved cys-loop (Lynch, 2004).  Whole cell electrophysiological 
characterization of these mutants does not allow for distinguishing between pure changes 
to affinity or gating of the receptor, though many studies view mutations of residues near 







Figure 1.3 – Hypothetical cross-section of the glycine receptor pore	

Cartoon model of the GlyR pore, showing the TM2 residues of two subunits. 
Pore-lining residues have white backgrounds.  Positively charged residues are 
shaded yellow and negatively charged residues are shaded blue.  Rings of positive 
charge are denoted by the “+” sign.  Adapted from Lynch JW. (2004). Molecular 




The pore of the GlyR, like other cys-loop receptors, is made up of the TM2 
domain of each subunit.  As mentioned previously, ion selectivity is achieved through 
rings of charged amino acid side chains of the opposite polarity of the ions being 
conducted.  Unlike the cationic channels, the GlyR only has two rings of positively 
charged amino acids formed by arginines.  The first is located at position 252 near the 
intracellular side of the pore, and the second is located at position 271 near the 
extracellular side of the pore.  Additionally the GlyR contains a proline at position 250 
that likely changes the pore geometry compared with the cationic cys-loop receptors that 
do not have this proline.  The pore lining residues between these charged residues are 
generally hydrophilic.  The ring of R252 residues is believed to be in the narrowest part 
of the channel, and thus essential for determining ion selectivity.  Mutations to both the 
nAChR and the 5-HT3R at positions equivalent to the GlyR A251 and T265, along with 
insertion of a proline in the narrow part of the channel, to make the pore more closely 
resemble the GlyR were enough to convert these channels into anion conducting pores 
(Galzi et al., 1992; Gunthorpe and Lummis, 2001).  By probing the pore with various 
anions and examining their size, the pore diameter was determined to be at least 5.2 Å 
(Bormann et al., 1987; Fatima-Shad and Barry, 1993; Rundstrom et al., 1994).  Thus, 
anions are attracted to the extracellular side of the pore, shed their waters of hydration 
along the hydrophilic strip of residues, and pass through the narrowest part of the channel 
according to the exclusion preference listed previously.	

The GlyR exhibits almost no spontaneous activity in the absence of ligand, unlike 
the nAChR (Twyman and MacDonald, 1991).  Thus, ligand binding in the large 
extracellular domain must in some way transmit the occurrence of this binding to TM2 
domains lining the pore to induce gating.  Investigation into a GlyR associated disease 
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helped to elucidate this mechanism.  Hyperekplexia or “startle disease” is a human 
hereditary disorder characterized by exaggerated startle responses to tactile or acoustic 
stimuli, resulting in generalized stiffness.  Hyperekplexia results from mutations that 
reduce GlyR functioning, disrupting inhibitory tone resulting in increased excitability of 
motor neurons.  The most common form of hyperekplexia is due to an autosomal 
dominant mutation in the gene for the GlyR α1 subunit that changes the residue R271 
into either R271L or R271Q (Ryan et al., 1992).  These mutations were shown to 
decrease both agonist sensitivity and single channel conductance (Langosch et al., 1994, 
Rajendra et al., 1994).  Many other hyperekplexia related GlyR mutations have been 
identified, a fair number of which occur at residues in the extracellular loop between TM2 
and TM3 (termed the TM2—TM3 linker), including Y279C, K276E, Q266H, and S267N 
among others (Lynch et al., 1997, Becker et al., 2008).  Interestingly, each of these 
mutations have similar effects on GlyR functioning, causing a decrease in agonist 
sensitivity and changes to generated currents.  The S267N mutation is particularly 
interesting as the residue has been proposed as a site of action for modulation by alcohols 
and volatile anesthetics (Mihic et al., 1997).  In particular, these mutations converted two 
GlyR agonists into competitive antagonists without affecting binding of these compounds 
(Lynch et al., 1997).  This interpretation was supported by kinetic fits of K276E single 
channel currents (Lewis et al., 1998).  As these mutations seemed to affect efficacy 
without affecting ligand binding, this TM2—TM3 linker was proposed to be an important 
domain in channel gate activation (Lynch et al., 1997). 	

Additional evidence suggests how the binding signal is communicated from the 
ligand-binding domain to this crucial TM2—TM3 linker in order to activate the channel. 
Structural analysis of the nAChR pore showed that the loop between β segments 1 and 2 
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(loop 2) interacts with the TM2—TM3 linker to open the pore (Miyazawa et al., 2003). 
Interestingly, a hyperekplexia related GlyR mutation to a residue in loop 2, A52S, results 
in decreased glycine sensitivity similar to TM2—TM3 linker hyperekplexia mutants 
(Saul et al., 1994, Plested et al., 2007).  Functional  characterization of GABAAR mutants 
identified an electrostatic interaction between residues D149 and K279 that was favored 
in the open state of the channel (Kash et al., 2003).  The GABAAR D149 residue lies in 
the cys-loop conserved throughout the superfamily.  The corresponding residues in the 
GlyR, D148 and K276, have also been shown to interact and alter receptor gating in 
similar fashion to the GABAAR experiments (Schofield et al., 2003).  Additionally, the 
short peptide sequence connecting the extracellular domain to TM1 may be involved in 
this transduction process.    The residue R209 in this region of the nAChR was shown to 
interact with E45 of loop 2 through single channel mutational analysis as well as 
structural modeling (Lee and Sine, 2005).  Lee and Sine (2005) also found that residue 
P272 in the extracellular portion of TM2 was able to interact with E45, showing the 
proximity of these three regions and ability for interaction, with each of these residues 
conserved in the GlyR.  Thus, loop 2 and both cys-loops may contact and interact with 
the extracellular loops of the TM domains to transmit the binding signal to the pore.	

Additional evidence of this transition comes from the Auerbach group’s work on 
the nAChR.  They utilize rate-equilibrium free-energy relationships (REFERs) on 
sequential nAChR point mutations to identify a ratio describing that residue’s effects on 
the opening and closing rate constants.  This ratio, termed Φ-value, varies from 0 to 1 
and can be used to group residues in terms of the timing of their movements in the gating 
transition.  A Φ-value of 0 is a late movement and a value of 1 is an early movement. 
Thus residues with similar Φ-values are likely to transition together in the conformation 
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wave of activity from binding to gating (Grosman et al., 2000; Purohit et al., 2007).  A 
mapping of these groupings can be seen in Fig. 1.4 with the extracelluar domain loops in 
the orange region and the TM2—TM3 linker in the green region.  Recent evidence from 
the prokaryotic channels supports this general model of receptor gating.  A recent crystal 
structure of GLIC at neutral pH, believed to be in the resting-closed state, was compared 
to existing GLIC crystal structures, that are believed to be in the open state and a 
secondary closed state where some extracellular domain movement has occurred (termed 
locally closed), to determine a sequence of events from the closed to open states of the 
channel (Sauguet et al., 2014).  In the model of Sauguet et al. (2014) three grouped 
movements make up the transition from the closed to open channel:  First the majority of 
the extracellular domain and the linker to TM1; second the cys-loop, TM2—TM3 linker, 
and the extracellular portions of the TM domains; finally the rest of the TM domains. 
These motions result in an “unblooming” and rotation of the extracellular domain and a 
twisting of the TM domains resulting in channel opening, implicating many of the same 




Figure 1.4 – Φ-values in the nAChR	

An α subunit extracellular and TM domains from the nAChR with domains of 
synchronous Φ-values shown in color.  The upper arrow denotes the ligand-
binding domain with the lower arrow identifying the channel gate.  The domains 
move from earliest to latest with Φ-values as follows:  purple, > 0.90; orange, 
0.75–0.85; green, 0.59–0.72; blue, 0.48–0.57; red, 0.26–0.35; white, no Φ-value.  
Adapted from Purohit et al., 2007. A Stepwise mechanism for acetylcholine 
receptor channel gating. Nature 446:932.  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1.3 – Single Channel Kinetics of the Glycine Receptor	

!
Single channel electrophysiological recording allows the study of the behavior of 
individual ion channels over time, and is still the standard for obtaining such rich 
information about these proteins’ function.  Neher and Sakmann (1976) developed this 
technique of using a glass pipette to isolate a single ion channel in a patch of the 
membrane (later termed patch-clamp), and were the first to observe currents through 
single nAChRs in frog muscle fibers.  Development of this technique led to their award of 
the Nobel Prize in Physiology and Medicine in 1991.  Key to the concept of single 
channel recordings was finding a way to reduce noise from the entirety of the membrane 
so that the very small currents through a single channel could be observed.  Neher and 
Sakmann used a pipette with a very small open diameter, fire polished to have a smooth 
surface, to create a flush seal with the membrane around an ion channel.  Applying a 
small amount of suction decreases any leakage between the glass and membrane interface 
resulting in a seal with gigaohm resistance (gigaseal).  This allowed for recordings of 
single channels with very low background noise, as well as modified variants of the 
technique where a small piece of membrane is pulled from the cell (inside-out and 
outside-out patches) allowing fine control of the solutions on either side of this patch of 
membrane (Hamill et al., 1981).	

Single channel openings occur in clusters of activity enclosed by periods of 
channel desensitization, where ligand may bind to the receptor but no current is 
generated.  Within these clusters, receptors open in bursts of activity that begin when a 
ligand binds and opens the channel and end when the ligand unbinds and the channel is 
closed (Colquhoun and Hawkes, 1977; Pallotta, 1991).  An example of these channel 
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behaviors can be seen in Fig. 1.5.  The distinction between these two groupings is 
important, as closings within bursts are times when the channel is ligand-bound but the 
pore is closed or not conducting ions.  Closings between bursts are indicative of ligand 
unbinding but are still within clusters.  Therefore, two types of closings exist in clusters, 
which convey very different information.  Thus, from recorded single channel currents, a 
lot of information about channel behavior can be obtained.  Rates of ligand binding and 
unbinding can be determined from burst durations.  Conductance of the ion channel can 









Additionally, the length of time of openings and closings (lifetimes) can vary 
greatly over many orders of magnitude and can be used to gain kinetic information about 
channel states.  Open and closed lifetime distribution histograms can be constructed with 
a logarithmic time scale to encompass the wide range of lifetimes seen, plotted against 
the square root of the number of events.  From this distribution, exponential peaks can be 
identified and fit, the sum of which fit the entire distribution, which determine the time 
constants of the different states the channel occupies.  The amplitude of these peaks 
determines the proportion of total open or closed time the receptor spent in each state 
(Pallotta, 1991).  However, determination of these parameters is only useful if it describes 
channel functioning in a way that matches the observed behavior; especially in the case 
of separating the actions of binding and gating as population data from whole cell 
recordings can not distinguish between these phenomena (Colquhoun, 2006).  Thus the 
entirety of the data is fit together and the subsequent states used to create a mechanism 
from which rate constants determining agonist binding and channel gating can be 
determined.  An example of this type of mechanism can be seen in Fig. 1.6. 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Figure 1.5 – Example single channel current tracing with labeled features	

The top tracing shows single channel openings in clusters of activity separated by 
periods of desensitization.  The bottom tracing shows an expanded view of 
activity showing open and closed times within bursts.  Adapted from Pallotta BS. 
1991. Single ion channel’s view of classical receptor theory.  FASEB J 5:2035.  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Figure 1.6 – Example kinetic mechanism of glycine receptor activation	

Transitions from right to left signify ligand (A) binding, while transitions from top 
to bottom signify channel opening (*).  In this mechanism three ligands can bind 
the receptor (R) and one is enough to open the channel.  k+ and k- signify rates of 
ligand binding and unbinding respectively.  β signifies rates of channel opening 
while α signifies channel closing rates.  This mechanism has 12 free parameters 
describing 4 closed states and 3 open states.  Adapted from Beato et al., 2004. The 
activation mechanism of α1 homomeric glycine receptors.  J Neurosci 24:895.  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The first single channel chloride currents recorded through GlyRs were obtained 
from patches pulled from cultured mouse spinal neurons (Hamill et al., 1983).  This study 
examined conductance states of glycine- and GABA-activated channels, and found three 
different conductance states for the GlyR of 45, 31, and 21 pS, with openings displaying 
the highest conductance state occurring the most frequently.  By measuring different 
conductance states elicited by glycine and GABA in these patches, that were unaffected 
by an antagonist of the other ligand, Hamill et al. (1983) provided evidence against a 
previous theory that glycine and GABA activate the same ion channel.  Further 
characterization of conductance states was carried out in heterologously expressed GlyR 
in HEK-293 cells, examining both homomeric and heteromeric channels (Bormann et al., 
1993).  Three conductance states were measured for α1β GlyR in close agreement with 
the Hamill et al. (1983) study, indicating the cultured spinal neurons were indeed 
expressing these heteromeric channels.  However, for the α1 GlyR, five conductance 
states were measured, 86, 64, 46, 30, and 18 pS, with the last three states corresponding 
to those seen in α1β GlyR.  Six conductance states were observed with α2 and α3 
homomeric GlyR with the five seen in α1 GlyR plus a higher conductance state around 
111 pS.  α3β GlyR had the same conductance states as α1β GlyR, while α2β no longer 
have the lowest conductance state in favor of the two highest conductance states seen in 
α2 GlyR.  Interestingly, in all GlyR except the α2B, the highest conductance state 
observed was also the most frequently observed conductance state.	

In an effort to better understand how GlyR conductance states relate to channel 
gating, Twyman and MacDonald (1991) investigated GlyR of cultured spinal neurons 
with varying concentrations of glycine.  They found two conductance states occurred 
most often, a 42 pS main conductance state with a subconductance state of 27 pS, with 
  	
25
both single openings and bursts of each conductance state.  By fitting each conductance 
state separately, they found that three open state exponential components were necessary 
to fit the open dwell time histograms in each conductance state (Twyman and 
MacDonald, 1991).  They also noted that increasing glycine concentration resulted in an 
increase of mean open time for both conductance states, with a shift to spending more 
time in the longer lived open states.  The closed dwell times were also fit by multiple 
components, with the shorter closed times occurring independent of concentration of 
agonist. Thus they proposed a kinetic model of binding and gating, similar to Fig. 1.6, 
with four closed states and three open states, with each subsequent open state 
corresponding to another agonist molecule up to three glycines bound (Twyman and 
MacDonald, 1991).	

Following this study, research into the kinetics of GlyR shifted to heterologous 
expression systems.  Beato et al. (2002) investigated the single channel characteristics of 
the α1 GlyR expressed in HEK-293 cells, reasoning that the five-fold symmetry of the 
homomeric channel could lead to a better understanding of the relationship between 
structure and function.  This study also used a range of concentrations, but to a higher top 
concentration of 10 μM.  The resulting open dwell time histograms were fit with four 
exponential components, with the longest three states having the same time constants as 
those found in the Twyman and MacDonald study.  The fourth state had a much faster 
time constant, and tended to only be prevalent at lower concentrations of glycine.  As the 
recording sensitivity had increased to this point, it was reasoned that the fastest time 
constant state was likely missed in previous studies.  Like the previous study, Beato and 
colleagues found the time constants describing the four open states did not vary greatly 
with increasing concentration of glycine, and that an increase in the mean open time with 
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increasing glycine was due to spending more time in the longer lived open states. 
However, at the highest concentration tested, they found that burst length distributions 
contained a very long lifetime component, where bursts tended to exhibit less single burst 
behavior (Beato et al., 2002).  They fit the data to a kinetic mechanism designed to make 
sense structurally.  As the α1 GlyR has five binding sites, their model contained six 
closed states and five open states to account for each possible glycine binding.  This 
model then predicted that a single glycine molecule bound was sufficient to open the 
channel, though with a greatly reduced efficacy compared to when more glycine 
molecules were bound (Beato et al., 2002).	

Beato and colleagues (2004) followed up on their original study with an 
expansion to include even higher concentrations of glycine, up to 1 mM.  They noted that 
at these higher concentrations, only one conductance level was seen, in contrast to the 
multiple conductance levels seen in other studies.  This may have been due to different 
test systems, receptor types, concentration of agonist, or other possible reasons, though 
this issue has not been resolved as of yet.  Additionally, at high concentrations, burst 
behavior tended to give way to clusters of activity, where long lived open states are 
broken by very short lived closed states, that ended with long lived receptor 
desensitization periods.  The intracluster open probability (Po), defined as the ratio 
between total open time per cluster and cluster length, increased with higher glycine 
concentrations, to a level of 0.96 with 1 mM glycine (Beato et al., 2004).  In agreement 
with this data, only recordings at 10 μM had all three of the previously identified open 
states.  Higher glycine concentrations resulted in increased mean open time with 
receptors spending more time in longer lived open states, up to 1 mM glycine responses 
only being fit by the single longest lived open time component.  Similarly, increasing 
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glycine concentration caused receptors to increase the frequency of the shortest lived 
closed states at the expense of the longer lived closed states.  The data was fit to multiple 
kinetic mechanisms, including three and five open state models, as well as multiple 
variations that looked at cooperativity of subsequent binding events.  Both the three open 
state and five open state models fit the data, though the three open state model gave a 
better prediction of the Hill slope of the Po curve.  When the five open state model was fit 
with the constraint that all gating rate constants for four or five glycine bound was equal 
to those when three glycine were bound, the extra parameters allowed for a slight but 
insignificant improvement to the fit of the data.  Therefore, three bound glycine molecules 
are sufficient to fully gate the channel though four or five glycine can bind (Beato et al., 
2004).	

Following characterization of α1 GlyR single channel behavior, the α1β GlyR 
was examined in HEK-293 cells (Burzomato et al., 2004).  This study used similar 
concentrations of glycine from 10 μM — 1 mM, to investigate fully bound GlyR activity. 
As in the Beato et al. (2004) study, higher glycine concentrations resulted in clusters with 
more time occupying longer lived open states and shorter lived closed states, with the 
highest concentration showing only a single open time component and 94% of 
intracluster closings described by the fastest time constant exponential (Burzomato et al., 
2004).  Multiple kinetic schemes were fit to the data, but despite all open times being fit 
with at most two exponentials, kinetic schemes with only two open states were poor fits 
of the data.  A kinetic mechanism similar to Fig. 1.6 with three open states was then 
found to give a good initial fit of the data.  However, it was reasoned that if extra open 
states were necessary for a better fit of the data, extra closed states may also result in a 
better fit.  Thus many additional kinetic mechanisms were fit with extra closed states 
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modeled as either desensitized states or additional pre-open closed states.  As previous 
kinetic mechanisms had all shown non-independence of subsequent agonist bindings, it 
was reasoned that if these additional closed states were modeled between agonist binding 
and channel opening, then differences in affinity could be modeled between the two 
different closed conformations.  Thus, a change in agonist affinity after glycine binding is 
modeled as a separate closed state from which additional glycine binding occurs 
independently as long as in that same conformation.  This intermediate closed state was 
termed “flipped” and the entire mechanism can be seen in Fig. 1.7 (Burzomato et al., 
2004).  This mechanism contains three open states and seven closed states, but only 16 
free parameters with fewer affinity rates than other models.  This flipped mechanism fit 
the data the best out of the mechanisms tested and was also used to refit the α1 GlyR data 
from the Beato et al. (2004) study.  The flipped mechanism fit was indistinguishable from 
the mechanism used in that study, despite the differences in affinity parameter constraints 
(Burzomato et al., 2004).  The flipped model has also been used to model glycinergic 
IPSCs from spinal cord motorneurons and single channel behavior of the nAChR 
(Burzomato et al., 2004, Lape et al., 2008), thus increasing the complexity of and need 






Figure 1.7 – Flipped kinetic mechanism of glycine receptor activation	

Transitions from right to left signify ligand (A) binding. Transitions from receptor 
in the closed (R) to open (F*) states must first transition to a “flipped” (F) 
conformation.  k+ and k- signify rates of ligand binding and unbinding 
respectively.  β  and α signify rates moving towards and away from channel 
opening respectively, while δ and γ signify rates moving towards and away from 
the flipped state.  This mechanism has 16 free parameters describing 7 closed 
states and 3 open states.  Adapted from Burzomato et al., 2004. Single-channel 
behavior of heteromeric α1β glycine receptors:  An attempt to detect a 
conformational change before the channel opens.  J Neurosci 24:10924.  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1.4 – Partial Agonism of the Glycine Receptor	

!
GlyR can be activated by many agonists other than glycine.  These include ions 
such as cesium, macrocyclic lactones such as ivermectin, and amino acids and their 
derivatives such as alanine, β-alanine, taurine, serine, sarcosine, and GABA (Smith and 
McBurney, 1989; Rajendra et al., 1997; Shan et al., 2001; Lynch, 2004; Zhang et al., 
2009; Dutertre et al., 2012).  However, these compounds vary in the magnitude of 
response generated upon channel activation, with some differing in the method of 
activation.  Agonists that have reduced maximum responses compared to that of glycine 
are generally known as partial agonists.  Of these partial agonists, β-alanine and taurine 
may be of particular importance due to their abundance in the brain (Shibanoki et al., 
1993, Albrecht and Schousboe, 2005).  The mechanisms underlying partial agonism have 
not been fully characterized, as the degree of partial agonism is dependent on subunit 
composition, expression system, and possibly even membrane composition, resulting in 
great variability amongst even similar preparations (Lynch, 2004).  For example, both β-
alanine and taurine can sometimes elicit the same maximum whole cell currents as 
glycine on α1 GlyRs expressed in HEK-293 cells, though the concentration of agonist 
required to achieve the same response is increased (Lynch et al., 1997).  However, β-
alanine and taurine maximum whole cell currents are reduced in comparison to glycine 
when α1 GlyRs are expressed in Xenopus oocytes, with taurine having a larger reduction 
(Schmieden et al., 1992).  In individual experiments, maximum elicited taurine responses 
as a percentage of glycine responses on α1 GlyR in Xenopus oocytes can range from 
approximately 20% to around 75%.  Additionally, on α2 homomeric receptors expressed 
in oocytes, both β-alanine and taurine become much weaker agonists in comparison to 
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glycine responses (Schmieden et al., 1992).  This reduction in partial agonism was seen 
for these compounds in α3 GlyR expressed in HEK-293 cells as well, though both partial 
agonists are weaker on α2 GlyR (Chen et al., 2009).  Despite shifts in the degree of 
partial agonism with subunit or expression system changes, the rank order of agonist 
efficiency seems to be held constant, e.g. glycine > β-alanine > taurine (Lynch, 2004).	

The effects of taurine on GlyR functioning may be of more importance than β-
alanine as taurine may have a role as an endogenous GlyR ligand in the brain (Shibanoki 
et al., 1993; Mori et al., 2002; Albrecht and Schousboe, 2005; Choe et al., 2012).  Taurine 
is the second most abundant amino acid in the brain, found in varying concentrations by 
brain region into the low mM range, with cerebral cortex, basal ganglia, and 
hypothalamus among the regions containing high concentrations of taurine (Palkovits et 
al., 1986; Banay-Schwartz et al., 1993; Albrecht and Schousboe, 2005).  However, 
taurine has also been shown to be released from glia, where internal concentrations may 
reach up to ~20 mM (Shibanoki et al., 1993; Mori et al., 2002; Albrecht and Schousboe, 
2005; Choe et al., 2012).  Taurine is known to be released due to osmotic pressure 
(Albrecht and Schousboe, 2005; Choe et al., 2012), but release can also be induced in 
hippocampus through activation of NMDA receptors (Shibanoki et al., 1993; Mori et al., 
2002) and this release can occur through non-osmotic mechanisms (Rodriguez-Navarro et 
al., 2009).  	

Although release of taurine does not guarantee action on GlyR in vivo, some 
studies have found evidence for taurine-activated currents on GlyR in hippocampus, 
hypothalamus, and nucleus accumbens.  Strychnine-sensitive currents in hippocampal 
CA3 pyramidal neurons were increased by guanidinoethanesulfonic acid (GES), a taurine 
reuptake inhibitor, but not by sarcosine, a glycine reuptake inhibitor (Mori et al., 2002). 
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This study also found that GlyR were not involved in evoked synaptic currents, thus 
taurine may act on hippocampal GlyRs to regulate inhibitory tone (Mori et al., 2002). 
Blockade of osmotic release mechanisms or cellular depletion of taurine was found to 
excite neurons in the supraoptic nucleus of the hypothalamus, indicating glial release of 
taurine regulates inhibitory tone in this area as well (Choe et al., 2012).  In the nucleus 
accumbens , a brain region believed to be important in reward and addiction, taurine may 
act in modulating the rewarding effects of drugs of abuse.  Acute administration of 
alcohol increases taurine concentration in the NAcc by well over 100% (Dahchour et al., 
1996), and taurine perfused into the NAcc causes a release of dopamine that can be 
blocked by strychnine (Ericson et al., 2006).  Recently, Ericson et al. (2011) found that 
the dopamine release into NAcc associated with the rewarding effects of ethanol required 
an increase in taurine in this area, as inhibiting taurine release blocked the subsequent 
release of dopamine.	

Partial agonists have been studied in kinetic models to better differentiate their 






           Equation 1.2	

Where β is the rate constant of channel opening and α is the rate constant of channel 
closing.  Determining efficacy for partial agonists using single channel studies is of great 
importance as whole cell concentration response curves can not distinguish between 
effects of binding and gating (Colquhoun, 1998); as seen in the equation for the effective 
concentration giving 50% of the maximum response (EC50), a common parameter used to 
compare concentration response curves:	

EC50 = Kd/(1 + E)	
 	
 	





Partial agonism would then be described by a decrease in efficacy caused by either a 
decrease in β, an increase in α, or both.  Subsequently, the efficacy at high concentrations 






   Equation 1.4	

The Po then can be used to differentiate the max response seen between agonists.  A study 
by Lewis et al. (2003) looked at kinetic parameters for glycine, β-alanine, and taurine 
activation of α1 homomeric GlyR expressed in HEK-293 cells, and found that the partial 
agonists had reduced β compared to glycine with no change in α.  Thus glycine had a 
high efficacy of 16 and a Po of 0.94, while β-alanine and taurine had efficacies of 8.4 and 
3.4 with Po of 0.89 and 0.77 respectively, in agreement with the high maximum effect of 
these partial agonists on HEK-293 whole cell GlyR currents (Lewis et al., 2003).	

However, a study investigating taurine activated α1β GlyR at the single channel 
level found that partial agonism is determined earlier than the final opening transition. 
Unlike the Lewis study, Lape et al. (2008) fit single channel openings over a range of 
concentrations of both glycine and taurine with the flip kinetic mechanism (Fig. 1.7) used 
previously in the Burzomato et al. (2004) study.  They determined the efficacy (Equation 
1.2) of both the transition from the flipped state to the open state, and the closed state to 
the flipped state which they termed F.  Comparing these model fits between glycine and 
taurine activated GlyR revealed that when fully bound (high concentration of agonist), E 
for both glycine and taurine was high (20 and 9.2 respectively).  These efficacies would 
result in Po values of 0.95 for glycine and 0.90 for taurine, which is incongruent with 
taurine acting as a partial agonist.  However, the F values were very different between 
glycine and taurine (27 and 0.15 respectively).  This placed the determination of partial 
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agonism earlier than the final opening transition, with taurine favoring the closed state 
over the flipped state; however when the flipped state was obtained for either agonist, 
transitions to the open state were heavily favored.  Including both transitions from closed 
to open leads to a Po calculation of:	

Po = EF/(1+F + EF)	
 	
 	
       Equation 1.5	

Using Equation 1.5 gives a Po of 0.95 for glycine and 0.53 for taurine, which matches 
with previous data on taurine partial agonism (Lape et al., 2008).  This study also found 
similar results for the partial agonist tetramethylammonium (TMA) on the nAChR, 
providing evidence that this early determinant of partial agonism may be generalizable to 
the cys-loop receptor family (Lape et al., 2008).	

The Lape study also revealed another interesting feature of taurine activation of 
GlyR.  In their kinetic mechanism, Lape et al. (2008) ignored flip and open transitions for 
the singly liganded GlyR.  They were able to fit these transitions with rate constants for 
glycine, but taurine concentrations less than 1 mM did not produce reliable openings. 
Thus, they fit only the doubly and triply liganded rate constants, as they believed at these 
high concentrations only these two bound states were likely to occur.  Although the 
doubly liganded state may not have been very prevalent, it was clear that the γ2 rate 
constant was extremely high for taurine.  This results in the GlyR doubly liganded by 
taurine almost never being able to attain the flipped state (Lape et al., 2008).  The 
implication being that the taurine-bound GlyR needs to be fully liganded to open.  If this 
is indeed the case, comparisons of taurine and glycine at low concentrations are 
comparing different phenomena.	

In light of this evidence placing the root of partial agonism early in the transitions 
from closed to open, it is of interest to determine where in the GlyR structure these 
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differences are determined.  The extracellular domain is a good candidate as binding 
causes a conformational wave of activity that allows extracellular loops to interact with 
the TM domains to open the pore (Lynch, 2004; Purohit et al. 2007).  Taurine binding 
may induce less of a conformational change or align the extracellular domain in such a 
way that interaction with the TM2-TM3 linker is possible but difficult.  Interestingly, 
charge reversal mutations to residues E53 and D57 in loop 2 have been shown to change 
taurine from a partial agonist into an antagonist (Absalom et al., 2003).  Additionally, a 
charge reversal mutation in the intersubunit interface of residue D97 that renders the 
receptor spontaneously active turns taurine into an equally efficacious agonist as glycine, 
while a mutation in the TM domains at residue K281 that also results in a spontaneously 
active GlyR does not change taurine efficacy (Welsh et al., In Prep.).	

!
1.5 – Allosteric Modulation of the Glycine Receptor	

!
An allosteric modulator is generally thought of as a compound that binds 
somewhere other than the active site that changes function of the protein in a positive or 
negative way, i.e. favoring one conformation over another.  This definition was useful 
when describing enzymes where the catalytic site is the active site and any compound 
that binds elsewhere and favors the active or inactive forms of the enzyme could be 
considered an allosteric modulator; however, defining allosterism for ion channels 
becomes a more complex problem (Colquhoun, 1998).  For example, is the pore region 
where ions flow through the channel the active site, or is the active site the ligand binding 
site which begins the process of channel activation?  Additionally, if the Φ-analysis of 
Purohit et al. (2007) and the flip mechanism of Burzomato et al. (2004) and Lape et al. 
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(2008) are taken into consideration, an ion channel can exist in multiple discreet states; 
thus, is it necessary examine the effects of a compound on each state?  Some receptors 
have co-agonist sites that are required to activate the channel but bind somewhere other 
than the ligand, so are these compounds allosteric modulators?  Many of these concerns 
have not been addressed in the literature, as allosteric modulation has been used to mean 
a great many things (Colquhoun, 1998).  Thus here we will define an allosteric modulator 
as anything that binds the GlyR at a site other than the agonist binding site and modulates 
the activity of the channel.	

The GlyR has many compounds that fit this definition of allosteric modulators, 
including divalent cations, alcohols, halogenated compounds, cannabinoids, 
neurosteroids, tropeines, plant derived poisons, and even other proteins (Lynch, 2004; 
Yevenes and Zeilhofer, 2011).  A large amount of research has been done into the binding 
locations and functional effects of almost all of these compounds, though complete 
understanding of the actions of these compounds has not yet been achieved.  Some of 






Ethanol (ethyl alcohol), commonly known as alcohol, is a drug consumed in 
beverages throughout the world and has been for most of human history (McGovern et 
al., 2004).  Alcohol is commonly used, with over half of Americans identifying as current 
drinkers (Johnston et al., 2013b).  The highest levels of binge drinking were found among 
young adults, with more minors using alcohol than tobacco or illicit drugs (Johnston et 
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al., 2013a, 2013b).  However, the potential for abuse of alcohol is high, with abuse 
leading to large impacts at the individual and societal levels.  The United States Centers 
for Disease Control and Prevention (CDC) estimate alcohol-attributable deaths due to 
excessive use to average ~88,000 per year.  This makes excessive alcohol use the third 
leading cause of lifestyle choice related deaths in the United States (Mokdad et al., 2004). 
Therefore, an understanding of the mechanisms behind alcohol actions are necessary to 
effectively develop treatment for and aid in prevention of alcohol abuse.	

Alcohol is known to be a CNS depressant which results in behavioral 
disinhibition, but at the molecular level it has a wide variety of targets throughout the 
brain that include ion channels of the cys-loop family, including the GlyR.  However, the 
diversity of targets has complicated the interpretation of which molecular effects are 
relevant to the behavioral phenotypes.  Recent evidence has indicated alcohol effects on 
GlyR in vivo may mediate some of the rewarding effects of ethanol.  GlyR are found in 
the NAcc, where drug induced dopamine release is believed to modulate the rewarding 
properties of these drugs (Waldvogel et al., 2007; Soderpalm and Ericson, 2013; Jonsson 
et al., 2014).  Infusion of glycine into the NAcc increased the concentration of dopamine 
there and decreased alcohol consumption in alcohol-preferring rats, while infusion of the 
GlyR antagonist strychnine decreased dopamine release in NAcc (Molander et al., 2005). 
Additionally, a glycine reuptake inhibitor Org 25935, which would increase the amount 
of glycine present extracellularly, decreased ethanol intake in rats in agreement with the 
previous study (Molander et al., 2007).	

Ethanol effects on GlyR have been well characterized at the whole cell level. 
Ethanol potentiates GlyR responses generated by low concentrations of glycine in a 
concentration dependent manner, ranging from biologically relevant recreational 
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concentrations to anesthetic doses (Mascia et al., 1996a).  However, ethanol potentiation 
of glycine currents decreases with increasing glycine concentration to the point of having 
no effect on saturating concentrations of glycine (Mascia et al., 1996a).  Ethanol action 
was greater on α1 GlyR than α2 GlyR, and the α1 mutant GlyR A52S had responses 
similar to α2 GlyR, indicating a possible role of this residue in ethanol action (Mascia et 
al, 1996a).  Further investigation of ethanol binding to GlyR was carried out by Mihic et 
al. (1997), who created various chimeric channels comprised of pieces of α1 GlyR and 
GABAA-ρ1 subunits, which are less sensitive to the effects of ethanol.  Investigation of 
these chimera led to the identification of two residues important in the actions of ethanol, 
S267 and A288 in the TM2-TM3 region (Mihic et al., 1997), which were believed to line 
a water filled pocket separate from the pore where ethanol could bind.  S267 mutations 
could affect the potentiation by ethanol as a function of side chain residue size, yielding 
information about the size of this binding pocket as large residue side chains converted 
ethanol from potentiating to inhibiting GlyR responses (Ye et al., 1998).  Similar 
characterization of the A288 residue revealed this residue was a crucial determinant of 
volatile anesthetic sensitivity, indicating a common binding pocket for alcohols and 
volatile anesthetics (Mihic et al., 1997; Yamakura et al., 1999).	

At the single channel level, few studies have investigated the effects of ethanol on 
GlyR.  Eggers and Berger (2004) examined GlyR in outside-out patches pulled from rat 
hypoglossal motor neurons.  Ethanol was found to enhance GlyR currents by increasing 
binding rates and decreasing unbinding rates when fit with a simple kinetic model 
(Eggers and Berger, 2004).  A more recent study examining the effects of ethanol on 
single channel GlyR currents was carried out with low concentrations of glycine and two 
concentrations of ethanol.  Ethanol increased duration of burst activity without affecting 
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open or closed dwell times by decreasing unbinding of glycine (Welsh et al., 2009). 






Anesthetics are a broad group of compounds that produce a similar group of 
physiological effects including analgesia, amnesia, immobility, hypnosis, and sedation. 
They are widely used in clinical settings to induce these effects for surgery and other 
medical procedures, and can be administered as an injection or via inhalation, where 
inhalational anesthetics are usually volatile halogenated compounds.  Although most 
anesthetics are not available to the general public, they do have the potential for abuse 
mainly with anesthesiologists who have access to the them.  A study by Wilson et al. 
(2008) found that 22% of anesthesiologist training programs had at least one case of 
inhalational anesthetic abuse, with only 22% of abusers able to return to practice.  Like 
alcohol, anesthetics cause a depression of nervous system functioning, though they are 
much more potent in their effects, with high concentrations leading to a risk of death.  In 
order to equate effective concentrations of various anesthetics, a measure of potency was 
developed known as the minimum alveolar concentration (MAC), defined as the 
concentration at which 50% of patients are unable to respond to a painful stimulus (Eger 
et al., 1965).	

Like ethanol, anesthetics can affect a large number of targets, though direct 
binding of anesthetics to proteins was only shown in the last 30 years.  Originally 
anesthetics were thought to work by disruption of the lipid bilayer comprising the cell 
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membrane, where compounds with higher lipid solubility would exhibit higher potency 
as an anesthetic (Franks and Lieb, 1997).  This idea, known as the Meyer-Overton 
hypothesis was called into question when compounds were found that had increased lipid 
solubility without an increase in anesthetic potency (Pringle et al., 1981; Mihic et al., 
1994), as well as the finding that clinically relevant concentrations of anesthetics had 
almost undetectable effects on membrane fluidity (Franks and Lieb, 1982).   This led 
Franks and Lieb to search for anesthetics acting by binding directly to proteins to elicit 
their effects (Franks and Lieb, 1982).  They subsequently showed that a variety of 
anesthetics, alcohols, and other compounds could directly bind to and inhibit a 
completely soluble protein, firefly luciferase, devoid of any lipid (Franks and Lieb, 1984).  	

As mentioned previously, Mihic et al. (1997) found residues S267 and A288 in 
the TM2-TM3 region of the α1 GlyR that are important for ethanol and anesthetic 
binding.  Subsequent research into these residues confirmed their importance for 
anesthetic action.  S267C mutant GlyR responses were potentiated by anesthetics, but 
when covalently bound and potentiated by propyl-methanethiosulfonate (PMTS), a thiol 
reagent that forms a disulfide bond with a cysteine to mimic binding of an alcohol to this 
residue, anesthetics no longer potentiated GlyR responses (Mascia et al., 2000). 
Additionally, the S267I mutant GlyR, which negates ethanol potentiation was shown to 
retain anesthetic potentiation of responses; however, ethanol was found to competitively 
inhibit anesthetic potentiation of the mutant receptor responses (Beckstead et al., 2001). 
These studies showed that binding to discrete residues in this pocket for alcohols and 







Inhalants are a broad group of volatile chemical compounds which can be inhaled 
to produce a rapid but quickly reversible high (Evans and Balster, 1991).  Inhalants have 
no common defining structural characteristics, as a loose definition of inhalants can also 
include alcohols and anesthetics.  The recent distinction between inhalants and these 
other drugs comes from differences among use patterns and ease of obtaining the drugs. 
The inhalants then are usually solvents which are legally obtained in many household 
items.  The ease with which they are obtained combined with the rapid high have led to 
the highest prevalence of abuse of these drugs being amongst young teens and 
adolescents.  Inhalants have the second highest prevalence of use among this age group, 
and are often the first drug tried for adolescents (Johnston et al., 2013a).	

The inhalant toluene, like other drugs of abuse, causes a release of dopamine into 
the NAcc (Riegel et al., 2007), and has modulatory effects on other receptors also 
affected by ethanol (Bale et al., 2002; Del Re et al., 2006).  Thus it was likely that 
inhalants exhibiting similar effects to GlyR modulators would themselves modulate 
GlyRs.  Inhalant modulation of GlyR functioning was shown for both halogenated 
solvents like 1,1,1-trichloroethane (TCE) and trichloroethylene (TCY) and aromatic 
compounds like toluene (Beckstead et al., 2000).  Testing of these compounds on mutant 
GlyRs previously identified to alter ethanol and anesthetic potentiation altered inhalant 
modulation as well, and ethanol antagonism of an inhalant on one such mutant was 
similar to antagonism seen for anesthetics, indicating inhalants bind in the same pocket as 







The divalent cation zinc may be unique as a GlyR modulator in that it is biphasic 
in its modulation of GlyR currents.  At low concentrations up to ~10 μM, zinc potentiates 
GlyR responses, while at concentrations above this range, zinc inhibits GlyR responses 
(Laube et al., 1995, 2000; Harvey et al., 1999).  Zinc has been studied extensively for its 
effects on GlyR functioning because it may have physiological relevance.  Zinc is present 
throughout the brain at nM concentrations in the range of potentiation for GlyR 
(Frederickson et al., 2006b).  Zinc has been found to be released by some synaptic 
terminals, the most well studied being the glutamatergic mossy fiber synapse in the 
hippocampus (Frederickson, 1989).  However, there is evidence of zinc co-localization 
with glycine in presynaptic terminals of lamprey spinal cord (Birinyi et al., 2001).  While 
it was originally thought that zinc concentration could reach into the high μM range with 
release (Lynch, 2004), recent calculations of zinc concentration following synaptic 
release determined that concentrations never exceed 10 μM, at the end of the potentiating 
range for GlyR (Frederickson et al., 2006a).	

The biphasic nature of zinc modulation for the GlyR arises from two separate 
binding sites, a high affinity potentiating site and a low affinity inhibitory site (Laube et 
al., 1995).  The inhibitory site was identified in the intersubunit interface, where H109 
from the principal subunit and H107 from the complementary subunit both act to stabilize 
zinc.  Mutation of these two residues to alanines were enough to abolish zinc inhibition of 
GlyR functioning.  Conformation that the zinc ions are stabilized between subunits rather 
than within each subunit was achieved by expressing single mutation H107A and H109A 
subunits with each other to abolish intrasubunit but retain intersubunit zinc coordination. 
These heteromeric mutant GlyR retained zinc inhibition similar to that seen in wild type 
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(WT) GlyR (Nevin et al., 2003).  These histidine residue can be seen in Fig. 1.2 as the 
pink colored histidine side chains in the lumen of the ligand-binding domain pentamer.	

The potentiation binding site for zinc has been more elusive to discover. 
Functional characterization of GlyR potentiation by zinc revealed that zinc increases 
mean open time and burst durations, by increasing the occurrence of longer lived open 
states and decreasing glycine unbinding (Laube et al., 2000).  This suggested the zinc 
potentiating site might be in the extracellular domain near the ligand-binding domain.  In 
agreement with this hypothesis, Laube et al. (2000) found that the residue D80 was 
important for zinc potentiation of GlyR responses.  However, while the mutant GlyR 
D80A was able to abolish zinc potentiation of glycine-activated GlyR, it had no effect on 
zinc potentiation of taurine-activated GlyR (Lynch et al., 1998).  This study also 
investigated various residues throughout the TM2-TM3 region, but no mutation was able 
to abolish zinc potentiation of both glycine and taurine activated GlyR currents (Lynch et 
al., 1998).  Kinetic analysis of zinc potentiation of taurine activated GlyR revealed that 
zinc was able to increase taurine efficacy, an effect not seen for glycine (Laube et al., 
2000).  This led to speculation that the activation mechanism for the two agonists were 
separate, and thus zinc would modulate the two pathways separately.	

However, two subsequent studies give evidence of an alternative zinc potentiating 
site.  The first found mutations in the β sheets of the extracellular domain near the 
external perimeter of the domain.  Three residues, E192, D194, and H215 were found to 
abolish zinc potentiation of glycine and taurine activated GlyR currents (Miller et al., 
2005).  These mutations were all made on a H107N background to eliminate the 
possibility of zinc inhibition, though high concentrations of zinc still caused inhibition of 
glycine and taurine activated GlyR currents (Miller et al., 2005).  Thus the interpretation 
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of zinc effects on these mutants is somewhat muddled.  However, a recent study looking 
at a hyperekplexia mutation of W170S GlyR found that while these receptors behaved 
relatively similar to wild type GlyR, zinc potentiation of glycine, β-alanine, and taurine 
activated GlyR currents was greatly reduced or abolished all together (Zhou et al., 2013). 
This W170 residue resides near those found in the Miller study, thus this external region 





1.6 – Dissertation Aims	

!
The objective of the research presented in this dissertation was to investigate 
allosteric modulation of the taurine activated GlyR to elucidate differences in glycine vs. 
taurine activation and the nature of partial agonism.  This objective was divided into the 
following three specific aims.	

!
Aim 1.  To examine differential modulation of the GlyR when activated by taurine vs. 
glycine.  The hypothesis to be tested was that ethanol, anesthetics, inhalants, and zinc 




Aim 2.  To investigate the kinetic mechanisms underlying allosteric modulation of the 
taurine activated GlyR.  The hypothesis to be tested was that ethanol and the anesthetic 
isoflurane would enhance the taurine activated GlyR by stabilizing the open state.	

!
Aim 3.  To investigate the effects of an intersubunit electrostatic bond and its 
implications for partial agonist activation of the GlyR.  The hypothesis to be tested was 
that a mutation at residue R131 would destabilize the closed state and thus increase the 





2.0 | MATERIALS AND METHODS	

!
2.1 – Molecular Biology	

!
Human wild type GlyR subunit cDNA was previously subcloned into a modified 
pBK-CMV vector modified to delete the region coding for the lac promoter and the lacZ 
start codon (Mihic et al., 1997).  The GlyR cDNA is under the control of a 
Cytomegalovirus (CMV) promoter that allows the α1 subunit to be expressed in 
heterologous expression systems, and the vector contains a gene conferring resistance to 
the antibiotic kanamycin.  GlyR cDNAs were produced using supercompetent XL1-Blue 
E. Coli (Stratagene) that were transformed with the plasmid and grown on LB agar plates 
containing 50 μg/ml kanamycin to select for transformed cells.  From these plates, 
individual colonies were selected and used to inoculate LB broth which was subsequently 
allowed to grow overnight in a shaker incubator.  Plasmid cDNA was isolated using 
either Mini or Maxi prep kit protocols (Qiagen).  Isolated plasmid was tested for 
concentration and quality using a NanoDrop spectrophotometer (Thermo Scientific). 
Plasmid samples with an A260/A280 ratio determined to be near 1.8 were considered 
acceptable for use in heterologous expression systems.	

Point mutations to the α1 GlyR subunit cDNA sequence were made using a 
QuickChange Mutagensis kit (Stratagene).  Custom oligonucleotide primers (Integrated 
DNA Technologies) were designed to contain the point mutation(s) in the middle of the 
primer sequence.  Primers were combined with template α1 GlyR cDNA and a high 
fidelity DNA polymerase, and run through a thermocycling protocol that led to 
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production of new plasmids that incorporated the primers coding for the point 
mutation(s).  The original template cDNA was digested using the DpnI restriction 
enzyme.  Resulting primers were grown in supercompetent XL1-Blue E. Coli and 
isolated as described above.  Samples were sent for sequencing using a dideoxy 
fluorophore method to verify incorporation of the mutation.	

!
2.2 – Xenopus Oocyte Harvesting, Isolation, and cDNA Injection	

!
Xenopus laevis frogs were purchased from Xenopus Express (Homosassa, FL) or 
Nasco (Fort Atkinson, WI) and housed at 19°C on a 12 h light/dark cycle.  Surgeries were 
performed in accordance with the Association for Assessment and Accreditation of 
Laboratory Animal Care regulations.  Briefly, frogs were anesthetized, a small incision 
was made through the lower abdomen and a portion of ovary was removed and placed in 
a modified Barth’s saline (MBS) solution.  Incision was closed with sutures and frogs 
were allowed to recover for future oocyte harvesting, up to two more times.	

Harvested oocytes were placed in a hypertonic isolation media to slightly shrink 
the oocytes and loosen the thick protective membrane.  Forceps were used to manually 
remove the thecal and epithelial layers from stage V and VI oocytes.  Isolated oocytes 
were than placed in a collagenase solution for 10 min to remove the follicular layer. 
Fully isolated oocytes were then washed with and placed in an isotonic MBS solution.	

cDNA constructs used for oocyte injection were diluted to 50 ng/μl using sterile 
deionized water (diH2O).  An injector tip (10-15 μm) was created by pulling a piece of 
capillary glass using a Sutter Intruments P-30 Flaming/Brown Puller.  The injector was 
backfilled with mineral oil and attached to a Drummond Nanoject II injector.  cDNA to be 
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injected was front loaded into the injector tip.  The animal poles of oocytes were impaled 
with the injector tip and 30 nl of cDNA (1.5 ng) was injected near the nucleus of each 
oocyte.  Injected oocytes were then placed into 96-well plates containing incubation 
media that had been sterilized by passage through a 0.22 μm filter.  The plates were 
stored in the dark.  Oocytes expressed GlyR within ~24 h, and all electrophysiological 
measurements were made within 1-7 days of cDNA injection.	

!
2.3 – Two-Electrode Voltage-Clamp of Xenopus Oocytes	

!
Before electrophysiological recording, oocytes were placed in a 100 ml bath with 
the animal poles facing upwards.  Εlectrodes were pulled from capillary glass using a 
Sutter Instrument P-97 Flaming/Brown Micropipette Puller to tip resistances of 0.5-10 
MΩ.  Glass electrodes were filled with 3 M KCl and used to impale the animal pole of 
oocytes.  Cells were voltage-clamped at –70 mV using an OC-725C oocyte clamp 
(Warner Instruments, Hamden, CT) and perfused with MBS or MBS + drug solutions at a 
rate of 2 ml/min using a Masterflex USA peristaltic pump (Cole Parmer Instrument Co., 
Vernon Hills, IL) through 18-gauge polyethylene tubing.  A waste line removed build up 
of the excess fluids from the chamber.  One of the electrodes measures the voltage of the 
cell while the other injects current in order to maintain a set potential.  Activation of the 
GlyRs opens the channels and allows chloride ions to flow outward.  The voltage 
electrode detects this flux as a depolarizing force, causing the current electrode to inject 
negative current in order to keep the cell clamped at the desired voltage.  This feedback 
loop occurs continuously while the output from the amplifier is acquired at a rate of 1 
kHz using a Powerlab 4/30 digitizer with LabChart version 7 software (ADInstruments, 
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Bella Vista, NSW, Australia).  All drug applications were followed by 6-15 min washout 
periods to allow for complete receptor resensitization.  All concentrations reported are the 
bath concentrations to which the oocytes were exposed.	

!
2.4 – Patch Clamp Electrophysiology	

!
Patch clamp electrophysiology was used to record currents from outside-out 
patches pulled from Xenopus oocytes expressing either mutant or WT GlyRs.  Before 
outside-out patches can be pulled, the vitelline membrane must be removed to obtain a 
proper seal.  Thus, prior to recording, the oocyte was placed in a high-osmolarity 
stripping solution to aid in manual removal of the vitelline membrane using forceps. 
Once removed, the oocyte was transferred to the recording chamber filled with external 
solution, using a Pasteur pipette being careful to ensure that the oocyte is not exposed to 
the air.  The oocyte was turned in the bath, so that the animal pole faced upwards towards 
the recording electrode, and allowed to adjust to the external solution for at least 5 min. 
Thick-walled borosilicate glass (WPI, Sarasota, FL) was pulled using a P-97 Flaming/
Brown Micropipette Puller (Sutter Instruments) to form patch pipettes.  These pipettes 
were coated with wax or with Sylgard 184 (Dow Corning, Midland, MI) just above the 
tips and fire-polished with an MF-830 Microforge (Narishige, Japan) to obtain a smooth 
tip with resistances of 5 to 15 MΩ.  Pipettes were then tip-filled with internal solution by 
applying suction to the back of the electrode while the tip was held in a bead of internal 
solution resting on a piece of Parafilm (Pechiney Plastic Packaging Company, Chicago, 





 Outside-out patches were held at –80 mV, and recordings were made according to 
standard methods (Hamill et al., 1981) using an Axopatch 200B amplifier (Molecular 
Devices, Sunnyvale, CA).  First, a slight positive pressure was applied to the electrode 
before it was lowered into the bath to prevent clogging of the tip.  The electrode tip was 
moved into close proximity with the edge of the oocyte such that the positive pressure 
began to dimple the membrane.  The tip was then slowly pressed against the oocyte until 
a small increase (0.5-1 MΩ) in tip resistance was observed.  Positive pressure was 
released and the membrane was allowed to seal around the electrode tip until a resistance 
of at least 1 GΩ was measured.  In order to obtain a gigaseal, it was often necessary to 
apply a small amount of negative pressure to the electrode.  Once a gigaseal was 
achieved,  the “Zap” button was pressed to break into the cell.  This was visible by a drop 
in the measured resistance, and the electrode was then slowly pulled away from the 
oocyte until a patch was pulled from the membrane and re-sealed resulting in a resistance 
again exceeding 1 GΩ.  The outside out patch configuration results in the extracellular 
patch membrane facing into the bath while the intracellular side of the patch membrane 
faces the interior of the patch pipette.  The amplifier gain was then increased to 50x and 
the holding current was set to –80 mV.	

Agonist and drug solution were prepared in external solution before being 
perfused over outside-out patches using an SF-77B Perfusion Fast Step apparatus 
(Warner Instruments, Hamden, CT).  The bath chamber was continuously filled using a 
50 ml syringe containing external solution, via gravity flow.  A vacuum line attached to 
an L-shaped metal piece of tubing in a separate portion of the recording chamber 
provided an outlet and maintained a steady bath level.  Solutions were loaded in 20 ml 
glass syringes that were held above the recording chamber and connected to one of three 
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manifolds with polyethylene tubing.  The output of the manifold was connected to a piece 
of three-barrel square glass and its tip was submerged in the bath.  Bubbles were expelled 
from each line that was in use to ensure that the gravity flow delivery worked properly 
and that bubbles would not break patch seals.  The three-barrel glass was moved and 
placed where the patch was directly under the middle chamber perfusing external 
solution.  Rapid re-positioning of the perfusion barrel could be achieved to switch the 
patch from external solution perfusion to solution + drug perfusion when necessary. 
Steady state patches remained in the solution for the duration of the recording.	

The analog output of the Axopatch 200B was filtered at 10 kHz though the 
internal 4-pole lowpass Bessel filter and then again at 10 kHz through an external 8-pole 
lowpass Bessel filter.  This signal was then digitized at 50 kHz with a Digidata 1322A 
(Molecular Devices) and recorded on a PC hard drive using the Clampex program from 
the pClamp 9 software suite (Molecular Devices).  Membrane voltage, sampling rate, and 




2.5 – Analysis of Macroscopic Currents	

!
Macroscopic currents of the peak amplitude resulting from GlyR activity in 
Xenopus oocytes were measured in the LabChart software program and recorded in an 
Excel spreadsheet (Microsoft, Redmond, WA).  These values were grouped according to 
condition and the mean and standard error of the mean (SEM) were determined. 
Statistical analyses were performed using SigmaPlot 11.0 software (Systat Software, San 
Jose, CA).  Differences between treatment groups were considered significant when p < 
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0.05 following appropriate statistical tests as indicated.  Concentration-response data 
were fit using the following four-parameter Hill equation in SigmaPlot 11.0.	

y = min + (max – min)/(1+(x/EC50)–Hillslope)	
 	
  Equation 2.1	

!
2.6 – Analysis of Single Channel Data	

!
Single-channel data were analyzed using the single-channel analysis programs in 
QuB (Qin et al., 2000a, 2000b).  The data were converted in the Clampfit program 
(Molecular Devices) to a QuB-compatible format for clean up and analysis. 
Preprocessing of the data involved removal of noise spikes and other errant signals, 
baseline correction, and the deletion of multiple openings (when present).  The current 
amplitude and standard deviation used to represent the open and closed states was 
determined by selecting only clusters of activity by eye and removing any channel 
desensitization periods, plotting the amplitudes, and fitting two Gaussian functions.  The 
mean amplitude corresponding to the open state was used to determine the conductance 
using Ohm’s Law (Equation 1.1).   The tracings were then idealized using the segmental-
k-means algorithm (Qin et al., 2000a, 2000b).  Data were initially idealized with a simple 
two-state C↔O model.	

This initial idealization was then fit with multiple exponentials added sequentially 
to a star model (closed state as the center) using the maximum interval likelihood (MIL) 
method after imposing a dead time resolution of 60 μS.  MIL fits the open and closed 
dwell time histograms with the following probability density function:	

f(t) = Σ aiτi-1e –t/τi	
 	
 	




  The appropriate numbers of open and closed components in this star model were 
determined by increased log likelihood, a measure of the quality of fit.  The data were 
then re-idealized using this model and used for dwell-time analyses. Dwell-time 
distributions were constructed and fit with a mixture of exponential components again 
using the MIL function, after the data had been binned using a log-time abscissa axis and 
a square-root count/total ordinate axis.  The mean open and closed times were calculated 
as the weighted mean of the time constants according to the following function:	





  Equation 2.3	

The probability of the channel being in the open state (Po) during a cluster was 
determined as a ratio of the total open time and the total cluster duration for each patch.	

Po = Meanopen(nevents/2)/(Meanopen(nevents/2) + Meanclosed(nevents/2))	
  Equation 2.4	

This method of determining Po was used by Burzomato et al. (2004) and provides an 
accurate estimate of Po without assumption of any particular kinetic model. Mean values 
for all parameters were calculated individually per patch and then averaged for each 
condition.  Statistical analyses were performed using SigmaPlot 11.0 software (Systat 
Software, San Jose, CA), using appropriate statistical tests as indicated.	

!
2.7 – Chemicals and Preparation of Drug Solutions	

!
All reagents used were purchased from Sigma-Aldrich (St. Louis, MO) with the 
exception of isoflurane which was obtained from Anaquest (New Providence, NJ).  All 
solutions were made up in filtered diH2O.  All drug solutions were made up in MBS or 
external solution as appropriate.  Loss of volatile compounds through tubing and 
evaporation from the bath was previously measured (Mihic et al., 1994; Yamakura et al., 
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1999; Beckstead et al., 2000, 2002), and accounted for when making up these solutions. 
Thus all concentrations reported are the bath concentrations to which the GlyR were 
exposed.  Volatile solutions were made by pipetting the appropriate volume of drug into 




All buffers were pH adjusted with HCl, NaOH, or CsCl as appropriate.  The 
recipes for all buffers are as follows:	

!
MBS — 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 10 mM HEPES, 0.82 mM 
MgSO4·7H2O, 0.33 mM Ca(NO3)2, and 0.91 mM CaCl2, pH 7.5	

Isolation Media — 108 mM NaCl, 1 mM EDTA, 2 mM KCl, and 10 mM HEPES	

Collagenase Solution — 83 mM NaCl, 2 mM MgCl2, and 5 mM HEPES, 0.5 mg/ml 
Sigma Type 1A collagenase	

Incubation Media — MBS + 2 mM sodium pyruvate, 0.5 mM theophylline, 10 U/ml 
penicillin, 10 mg/l streptomycin, and 50 mg/l gentamicin	

Stripping Solution — 200 mM sodium methyl sulfate, 20 mM KCl, 10 mM HEPES, and 
1 mM MgCl2·6H2O, pH 7.4	

External Solution — 100 mM NaCl, 2 mM KCl, 1 mM MgCl2·6H2O, 10 mM HEPES, 2 
mM CaCl2, pH 7.4	







3.0 | POSITIVE ALLOSTERIC MODULATORS DIFFERENTIALLY 







The glycine receptor (GlyR) is responsible for the majority of neuronal inhibition 
in the brainstem and spinal cord but is also found in a variety of higher brain regions, 
such as the basal ganglia, cerebellum, hippocampus, and the prefrontal cortex (Lynch, 
2004; Baer et al., 2009; Lu and Ye, 2011).  It is a member of the Cys-loop family of 
ligand gated ion channels composed of five subunits that co-assemble around a central 
ion-conducting pore.  Many compounds are known modulators of the GlyR, including 
alcohols, volatile anesthetics, zinc, and inhaled drugs of abuse (Lynch, 2004), and the 
GlyR has been implicated in their effects in vivo (Downie et al., 1996; Beckstead et al., 
2000; Yamashita et al., 2001; Cheng and Kendig, 2002; Molander et al., 2005, 2007). 
Ethanol (EtOH) is the second most widely abused drug behind tobacco, and its use leads 
to depression of nervous system functioning.  Volatile anesthetics are characterized by 
their propensities to readily vaporize at room temperature and, like ethanol, to cause 
central nervous system depression. In the clinical setting, they produce a myriad of 
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effects, including analgesia, amnesia, immobility, hypnosis, and sedation.  Inhalants are a 
heterogeneous class of industrial solvents that are often abused by adolescents because 
they quickly produce a rapidly reversible high (Evans and Balster, 1991).	

Ethanol, anesthetics, and inhalants enhance GlyR function in a concentration-
dependent manner.  They act by left-shifting the glycine concentration-response curve, 
thus decreasing the EC50 of glycine (Mascia et al., 1996a; Mihic, 1999; Beckstead et al., 
2000; Welsh et al., 2010).  Thus, these compounds enhance currents elicited by low 
concentrations of glycine but have minimal effects at saturating concentrations of glycine 
(Mascia et al., 1996a; Beckstead et al., 2000; Welsh et al., 2010).  These modulators are 
thought to bind in a water-filled pocket near the second transmembrane domain of each 
subunit of the GlyR (Mihic et al., 1997; Yamakura et al., 1999; Beckstead et al., 2001; 
Roberts et al., 2006).	

At a saturating concentration, taurine acts as a partial agonist with ~50% efficacy 
in activating the GlyR compared with glycine.  This refers to the proportion of time the 
receptor spends in the open state (Po) while agonist is bound.  At saturating 
concentrations, glycine and taurine produce Po values of 0.96 and 0.54, respectively 
(Lape et al., 2008).  Ethanol, anesthetics, and inhalants have no effects at saturating 
concentrations of glycine, and one reason for this may be attributed to the GlyR already 
spending ~95% of its time in the open state.  Such a ceiling effect would not be expected 
to occur with saturating concentrations of taurine.  Another possibility is that these 
allosteric modulators do not affect Po, as suggested by a recent single channel study con- 
ducted by Welsh et al. (2009) and, in which case, no enhancement of GlyR function 
should be observed in the presence of a maximally effective concentration of taurine.  In 
light of recently obtained evidence of a role for taurine as a GlyR activator in vivo 
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(Dahchour et al., 1996; Mori et al., 2002; Ericson et al., 2006, 2011; Rodríguez-Navarro 
et al., 2009), we tested ethanol, anesthetics, and inhalants for their enhancing effects on 
taurine-activated GlyR.  In addition, if enhancement were to be seen at saturating taurine 
concentrations, it would suggest differences in the mechanisms of allosteric modulation 
of receptors activated by full versus partial agonists.	

!
3.2 – Materials and Methods	

!
Isolation, injection, and two-electrode voltage-clamp of Xenopus oocytes were 
described in Chapter 2.  Specific methods pertaining to the experiments in this chapter are 
outlined below.	

All chemicals were purchased from Sigma-Aldrich (St. Louis, MO). Xenopus 
laevis were obtained from Nasco (Fort Atkinson, WI) and housed at 19°C on a 12-h light/
dark cycle.  During surgery performed in accordance with the Association for Assessment 
and Accreditation of Laboratory Animal Care regulations, portions of ovaries were 
removed and placed in isolation media containing 108 mM NaCl, 1 mM EDTA, 2 mM 
KCl, and 10 mM HEPES.  Forceps were used to manually remove the thecal and 
epithelial layers from stage V and VI oocytes.  The oocyte follicular layer was removed 
using a 10 min incubation in 0.5 mg/ml type 1A collagenase (Sigma-Aldrich) in buffer 
containing 83 mM NaCl, 2 mM MgCl2, and 5 mM HEPES.  Animal poles of oocytes 
were injected with 30 nl of the glycine α1-receptor subunit cDNA (1.5 ng/30 nl) in a 
modified pBK-cytomegalovirus vector (Mihic et al., 1997) by the “blind” method of 
Colman (1984), using a micropipette (10–15 μm tip size) attached to an electronically 
activated microdispenser.  For α1β experiments, a 1:30 ratio of α to β cDNAs was 
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injected to ensure incorporation of the β subunit.  Oocytes were stored in the dark at 19°C 
in 96-well plates containing modified Barth’s saline (MBS) [88 mM NaCl, 1 mM KCl, 
2.4 mM NaHCO3, 10 mM HEPES, 0.82 mM MgSO4·7H2O, 0.33 mM Ca(NO3)2 , 0.91 
mM CaCl2 at pH 7.5] supplemented with 2 mM sodium pyruvate, 0.5 mM theophylline, 
10 U/ml penicillin, 10 mg/l streptomycin, and 50 mg/l gentamicin and sterilized by 
passage through a 0.22 μm filter.  Oocytes expressed the wild-type and S267F (Ye et al., 
1998) GlyR within 24 h, and all electrophysiological measurements were made within 5 
days of cDNA injection.  Replacement of a serine residue with phenylalanine at residue 
267 within the second transmembrane segment of the α1 subunit yields the S267F 
mutant.	

Before electrophysiological recording oocytes were placed in a 100-μl bath with 
the animal poles facing upwards and impaled with two high-resistance (0.5–10 MΩ) 
glass electrodes filled with 3 M KCl.  Cells were voltage clamped at –70 mV using an 
OC-725C oocyte clamp (Warner Instruments, Hamden, CT) and perfused with MBS at a 
rate of 2 ml/min using a Masterflex USA peristaltic pump (Cole Parmer Instrument Co., 
Vernon Hills, IL) through 18-gauge polyethylene tubing.  All drug solutions were 
prepared in MBS.  When saturating concentrations of agonists were applied, applications 
lasted for 15 s for the short-application experiments and for 13 min for the long-
application experiments.  Sub-maximally effective concentrations of agonist (glycine or 
taurine) were applied for 60 s.  Modulators were either pre-applied to oocytes for 30 s 
before being co-applied with agonist for an additional 15 s for short-application 
experiments or co-applied with agonist for 60 s for long-application experiments.  All 
drug applications were followed by 6 to 10 min washout periods to allow for complete 
receptor resensitization.  Loss of volatile compounds through tubing and evaporation 
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from bath was previously measured (Mihic et al., 1994; Yamakura et al., 1999; Beckstead 
et al., 2000, 2002).  All concentrations reported are the bath concentrations to which the 
oocyte was exposed.  Currents were acquired using either a Powerlab 4/30 digitizer with 
LabChart version 7 software (ADInstruments, Bella Vista, NSW, Australia) or a strip-
chart recorder (Cole Parmer Instrument Co.) with a < 0.5-s full-scale pen movement 
response time.  Peak currents were measured and used in data analysis.  Currents 
observed in the presence of agonist plus modulators were compared with currents 
generated by agonist alone.	

Experimental values are listed as the mean ± SEM.  Significant differences 
between experimental conditions were determined using paired or unpaired t-tests, the 
Wilcoxon signed rank test or the Mann-Whitney rank sum test as indicated.  Equation 2.1 
was used to fit agonist and agonist + isoflurane concentration-response curves to 
determine the half-maximally effective concentrations (EC50).  SigmaPlot version 11.0 






3.3.1 – PREINCUBATION OF ALLOSTERIC MODULATORS IS NECESSARY TO UNMASK 
TRUE EFFECTS OF THESE COMPOUNDS ON GLYR FUNCTIONING	
!
The enhancing actions of ethanol, volatile anesthetics, and inhaled drugs of abuse 
were compared for their effects on currents generated by glycine versus taurine on wild-
type α1-homomeric GlyRs.  We first tested 1.1 mM isoflurane for its abilities to enhance 
GlyR function in receptors activated by glycine or taurine (Fig. 3.1).  As expected, 
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isoflurane left-shifted the glycine concentration-response curve without having any effect 
at maximally effective glycine concentrations.  Isoflurane also left-shifted the taurine 
concentration-response curve but also markedly increased the effects of maximally 
effective taurine concentrations.	

We previously examined the effects of ethanol on GlyR using short and long 
applications of saturating concentrations of glycine or taurine (Welsh et al., 2010) and 
found minor enhancing effects during long applications of the latter.  In these long-
application experiments, ethanol was applied for 60 s and thus had sufficient time to 
equilibrate within its binding pocket.  In experiments involving brief applications of 
saturating concentrations of agonists, the peak current is reached in less than 100 ms in 
our hands, concurrent with rapid desensitization of the GlyR.  If ethanol is co-applied 
with agonist, the ethanol may not have sufficient time to reach equilibrium within the 
binding pocket.  Therefore, we first tested whether preincubation of modulator was 
necessary for this equilibrium to occur before desensitization predominated, allowing us 
to see the full effects of the modulator on the activated GlyR.  Because isoflurane was 
previously shown to have enhancing effects on saturating concentrations of taurine 
(Downie et al., 1996), we chose to use the structurally similar anesthetic enflurane for 
these experiments.  Fig 3.2A, left panel, shows sample tracings of the effects of 100 mM 
taurine co-applied with 1.2 mM enflurane for 15 s, with 15 s applications of 100 mM 
taurine alone (before and after application).  The tracing in the right panel shows the 
effects of a 30-s preincubation of 1.2 mM enflurane immediately before co-application 
with taurine.  Co-application of 100 mM taurine plus 1.2 mM enflurane resulted in a 99.4 
± 14% increase in current above that produced by 100 mM taurine alone (Fig. 3.2B). 
However, preincubation of 1.2 mM enflurane before co-application with 100 mM taurine 
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resulted in a current 209 ± 24.4% above that produced by taurine alone, suggesting that 
preincubation with anesthetics is required for enflurane to come to equilibrium with 
receptors before agonist is co-applied.  There was a statistically significant effect of 
preincubation [t(4) = 9.3, p < 0.001]. 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Figure 3.1 – Isoflurane decreases agonist EC50 and increases taurine mediated peak 
currents	

Isoflurane shifts α1-homomeric GlyR glycine and taurine concentration-response 
curves to the left and increases the maximal response to the partial agonist.  Open 
symbols represent glycine-mediated responses, and filled symbols show taurine-
mediated responses.  Circles represent agonist applied alone, with squares 
showing agonist + 1.1 mM isoflurane.  Each line is a logistic fit to the respective 
set of data.  Glycine activation of the GlyR produced an EC50 of 0.54 mM with a 
Hill coefficient (nH) of 1.2. The addition of 1.1 mM isoflurane decreased the EC50 
to 0.13 mM and an nH of 1.2. Taurine alone had an EC50 of 6.9 mM, with an nH of 
0.9, decreasing to an EC50 of 1.1 mM and an nH of 1.0 in the presence of 
isoflurane. Data are shown as mean ± SEM of 4 oocytes.  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Figure 3.2 – Preincubation enhances the potentiating effects of enflurane on taurine-
activated GlyRs	

A) sample tracings showing enflurane potentiation of taurine responses with and 
without preincubation. The left tracing shows co-application of 100 mM taurine 
and 1.2 mM enflurane, with applications of taurine alone (before and after). The 
right tracing shows the effect of preincubation with 1.2 mM enflurane, 
immediately followed by co-application of 100 mM taurine and 1.2 mM 
enflurane. Again bracketed by taurine alone. Horizontal bars over tracings indicate 
the time of exposure to taurine or enflurane. B) summary of the effects of 100 mM 
taurine and 1.2 mM enflurane with and without preincubation. The y-axis 
represents the percentage increase in current observed in the presence of enflurane 
compared with that produced by taurine alone. Data are shown as mean ± SEM of 
5 oocytes. ***, p < 0.001. 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3.3.2 – ETHANOL POTENTIATES GLYR CURRENTS ACTIVATED BY MAXIMALLY 
EFFECTIVE CONCENTRATIONS OF TAURINE BUT NOT GLYCINE	
!
We have previously demonstrated that ethanol acts as an allosteric modulator by 
left-shifting glycine and taurine concentration-response curves without an effect when 
maximally effective concentrations of either glycine or taurine were tested (Welsh et al., 
2010).  Here, we further investigated the effects of ethanol on maximally effective 
concentrations of glycine and taurine using two different experimental designs.  Since we 
showed that preincubation was necessary to reveal the full enhancing effect of enflurane 
(Fig. 3.2), we also tested ethanol using the same preincubation experimental design (Fig. 
3.3A).  Preincubation of 200 mM ethanol for 30 s was immediately followed by co-
application with a maximally effective concentration of agonist (10 mM glycine or 100 
mM taurine) for 15 s.  Each co-application was preceded and followed by 15 s 
applications of glycine or taurine as appropriate (Fig. 3.3A).  Ethanol (200 mM) slightly 
inhibited the glycine response, decreasing the peak current by 15.2 ± 5% (Fig. 3.3B).  In 
contrast, ethanol moderately increased the peak taurine current by 42.2 ± 7.6%.  The 
taurine + ethanol response was significantly different from the glycine + ethanol response 
[t(5) = 8.81, p < 0.001].	

We next examined the effects of ethanol using a saturating concentration of 
agonist applied for 10 min to allow for a pseudo-equilibrium between the open and 
desensitized states of channels to become established before the co-application of ethanol 
(Fig. 3.3C).  After a 10 min application of either 10 mM glycine (Fig. 3.3C, top) or 100 
mM taurine (Fig. 3.3C, bottom), 200 mM ethanol was co-applied for 1 min followed by 
agonist alone for 2 min.  The effects of ethanol were similar to those seen in the 
preincubation experiment but to a lesser degree.  Ethanol had a negligible effect on the 
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saturating 10 mM glycine response (0.3 ± 12.3%) while potentiating the saturating 100 
mM taurine response by 23.6 ± 7.6% (Fig. 3.3D), although these responses were not 





Figure 3.3 – Ethanol affects currents elicited by maximally effective concentrations 
of taurine but not glycine	

A) tracing showing the effects of maximally effective concentrations of glycine and taurine 
applied with or without 200 mM EtOH. 30 s preincubations with 200 mM EtOH were followed 
immediately by 15 s applications of either 10 mM glycine or 100 mM taurine + EtOH. Each of 
these applications was preceded and followed by applications of agonist tested. Horizontal bars 
over tracings indicate time of exposure to glycine, taurine, or EtOH. B) summary of the effects of 
EtOH as seen in A. The y-axis is the percentage change in current with EtOH compared to that 
produced by agonist alone. Data are shown as mean ± SEM of 6 oocytes. ***, p < 0.001. C) 
sample tracings showing the effects of 200 mM EtOH co-applied with saturating concentrations 
of glycine or taurine, after the neurotransmitters had been applied for 10 min. Top: 10 mM 
glycine was applied for 10 min followed immediately by co-application of 10 mM glycine plus 
200 mM EtOH for 1 min. Bottom: Same as top tracing but 100 mM taurine instead of glycine. D) 
summary of the effects of EtOH as seen in C. The y-axis is the percentage change in current 
observed with EtOH compared to the glycine or taurine current immediately preceding EtOH co-
application. Data are shown as mean ± SEM of 4–5 oocytes.  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3.3.3 – VOLATILE ANESTHETICS POTENTIATE GLYR CURRENTS ACTIVATED BY 
MAXIMALLY EFFECTIVE CONCENTRATIONS OF TAURINE BUT NOT GLYCINE	
!
We next examined the effects of volatile anesthetics using the same experimental 
protocols used for ethanol.  The concentrations of volatile anesthetics tested were 1.5 mM 
chloroform, 0.55 mM isoflurane, 0.5 mM halothane, 1.2 mM enflurane, and 1.76 mM 
desflurane.  In Fig. 3.4A, desflurane was preapplied for 30 s before co-application with a 
saturating concentration of either glycine or taurine.  None of the anesthetics tested in this 
manner showed any effect on 10 mM glycine responses, but all markedly enhanced 
currents elicited by 100 mM taurine (Fig. 3.4B).  Each anesthetic showed significantly 
greater potentiation of maximal taurine responses compared with maximal glycine 
responses.  Chloroform [Wilcoxon Signed-Rank Test W = 28, Z = 2.4, p < 0.05], 
isoflurane [t(6) = 8.32, p < 0.001], halothane [t(6) = 3.11, p < 0.05], enflurane [t(6) = 
6.31, p < 0.001], and desflurane [t(5) = 3.61, p < 0.05] all produced significantly greater 
enhancement of maximal taurine responses.	

The results for experiments involving long exposures to saturating concentrations 
of agonists were similar to the preincubation experiments, with marked potentiation of 
100 mM taurine responses and minimal effects on 10 mM glycine responses (Fig. 
3.4C,D).  Again, for each anesthetic, potentiation of maximal taurine responses was 
significantly increased compared with their effects on maximal glycine responses. 
Chloroform [Mann-Whitney U-Test U = 0, n1 = n2 = 4, p < 0.05], isoflurane [t(6) = 3.38, 
p < 0.05], halothane [Mann-Whitney U-Test U = 6, n1 = 6, n2 = 8, p < 0.05], enflurane 
[t(7) = 5.51, p < 0.001], and desflurane [t(8) = 3.7, p < 0.01] displayed significantly 





Figure 3.4 – Anesthetics affect currents elicited by maximally effective 
concentrations of taurine but not glycine	

A) sample tracing of maximally-effective concentrations of glycine and taurine applied ± 1.76 
mM desflurane. The tracing shows 30 s preincubations with desflurane followed immediately by 
15 s applications of 10 mM glycine or 100 mM taurine + desflurane. Each application was 
preceded and followed by applications of agonist alone. Horizontal bars over tracings show time 
of exposure to glycine, taurine, or desflurane. B) summary of the effects of anesthetics on 
maximally effective concentrations of glycine or taurine as in A. The y-axis is the percentage 
change in current with anesthetic compared to agonist alone. Data are shown as mean ± SEM of 
6–7 oocytes per anesthetic. C) sample tracings showing the effects of 0.5 mM halothane co-
applied with saturating concentrations of glycine or taurine after the agonist had been applied for 
10 min. Top: 0.5 mM halothane co-applied with 10 mM glycine after a 10 min exposure to 
glycine. Bottom: Same as top with 100 mM taurine instead of glycine. D) summary of the effects 
of anesthetics during long applications with saturating agonist. The y-axis is the percentage 
change in current with anesthetic compared to agonist current measured immediately before 
anesthetic co-application. Data are shown as mean ± SEM of 4–8 oocytes per anesthetic. *, p < 
0.05, **, p < 0.01, ***, p < 0.001 for glycine vs. taurine.  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3.3.4 – INHALANTS POTENTIATE GLYR CURRENTS ACTIVATED BY MAXIMALLY 
EFFECTIVE CONCENTRATIONS OF TAURINE BUT NOT GLYCINE	
!
The inhaled drugs of abuse, toluene, 1,1,1-trichloroethane (TCE), and 
trichloroethylene (TCY) were also assayed using the same experimental protocols as 
before.  The bath concentrations of these inhalants were 0.42 mM toluene, 0.56 mM TCE, 
and 0.39 mM TCY.  Fig. 3.5A,C, shows tracings of these experiments by use of a sample 
inhalant in each case.  Each of the inhalants slightly inhibited 10 mM glycine responses 
while potentiating 100 mM taurine responses in preincubation experiments (Fig. 3.5B). 
All three inhalants displayed significantly greater enhancement of maximal taurine 
responses: toluene [t(4) = 4.31, p < 0.05], TCE [t(5) = 3.58, p < 0.05], and TCY [t(6) = 
6.65, p < 0.001].	

The results for the long exposures to saturating concentrations of agonists were 
similar to the preincubation experiments, with marked potentiation of 100 mM taurine 
responses observed but small effects on 10 mM glycine responses, with the exception of 
TCY (Fig. 3.5D).  TCY produced a potentiation of maximal glycine and maximal taurine 
responses that were not significantly different [t(8) = 0.36, p > 0.7], although the TCY + 
glycine responses were highly variable (Fig. 3.5D).  For toluene [t(10) = 3.59, p < 0.01] 
and TCE [t(9) = 3.38, p < 0.01], potentiation of maximal taurine responses was 





Figure 3.5 – Inhalants affect currents elicited by maximally effective concentrations 
of taurine but not glycine	

A) tracing demonstrating the effects of maximally effective concentrations of glycine and taurine 
applied ± 0.39 mM TCY. The tracing shows 30 s preincubations with TCY followed immediately 
by 15 s applications of 10 mM glycine or 100 mM taurine + TCY. Each application was preceded 
and followed by applications of agonist alone. Horizontal bars over tracings indicate time of 
exposure to glycine, taurine, or TCY. B) summary of the effects of inhalants on maximally 
effective agonist as in A. The y-axis is the percentage change in current with inhalant compared to 
glycine or taurine applied alone. Data are shown as mean ± SEM of 5–7 oocytes for each 
inhalant. C) sample tracings showing the effects of 0.56 mM TCE co-applied with saturating 
concentrations of glycine or taurine, after the agonist had been applied for 10 min. Top: 0.56 mM 
TCE was co-applied with 10 mM glycine after 10 min exposure to saturating glycine. Bottom: the 
same for a sustained application of 100 mM taurine instead of glycine. D) summary graph of the 
effects of inhalants during long applications of saturating agonist. The y-axis is the percentage 
change in current with inhalant compared to the current seen immediately before inhalant co-
application. Data are shown as mean ± SEM of 4–8 oocytes. *, p < 0.05, **, p < 0.01, ***, p < 
0.001 for glycine vs. taurine.  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3.3.5 – ALLOSTERIC MODULATORS POTENTIATE HETEROMERIC GLYR CURRENTS 
ACTIVATED BY MAXIMALLY EFFECTIVE CONCENTRATIONS OF TAURINE BUT NOT 
GLYCINE	
!
We performed the same experimental protocol of modulator preincubation 
followed by short application of agonist on α1β heteromeric GlyR to confirm that the 
modulator effects seen on the homomeric α1 GlyR were also seen in the presence of the 
β subunit.  For these experiments, we chose a representative compound from each of the 
categories of modulators tested previously.  Ethanol, desflurane, and TCY were used at 
the same bath concentrations as in the previous experiments.  Fig. 3.6A shows tracings of 
the effects of 1.76 mM desflurane on maximally effective concentrations of both glycine- 
and taurine-mediated currents.  Fig. 3.6B shows a summary of the effects of each 
compound tested, with all three compounds showing negligible effects on maximal 
glycine responses and large potentiating effects on maximal taurine responses. 
Potentiation of maximal taurine responses was significantly greater than for glycine for 
all three modulators:  ethanol [Wilcoxon Signed-Rank Test W = 45, Z = 2.7, p < 0.01]; 





Figure 3.6 – Positive allosteric modulators affect α1β heteromeric GlyR in a similar 
manner to homomeric α1 GlyR	

A) sample tracing demonstrating the effects of maximally effective concentrations 
of glycine and taurine applied ± 1.76 mM desflurane. The tracing shows 30 s 
preincubations with desflurane followed immediately by 15 s applications of 
either 10 mM glycine or 100 mM taurine + desflurane. Each of these applications 
was preceded and followed by applications agonist alone. Horizontal bars over 
tracings indicate time of exposure to glycine, taurine, or desflurane. B) summary 
of the effects of 200 mM ethanol, 1.76 mM desflurane, or 0.39 mM TCY on 
applications of maximally effective concentrations of agonist. The y-axis is the 
percentage change in current with modulator compared to agonist alone. Data are 
shown as mean ± SEM of 8–9 oocytes for each modulator tested. **, p < 0.01, 
***, p < 0.001 for glycine vs. taurine.  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3.3.6 – ANESTHETICS AFFECT DESENSITIZATION RATES OF TAURINE-ACTIVATED GLYR 
BUT NOT GLYCINE-ACTIVATED GLYR	
!
We compared tracings from the brief application experiments to contrast the 
effects of modulators on desensitization rates after activation by glycine or taurine.  Fig. 
3.7 shows sample tracings for four of the modulators tested: ethanol, isoflurane, 
desflurane, and TCY.  None of the modulators affected desensitization rates after receptor 
activation by glycine, which was expected because none of the modulators had large 
effects on glycine peak currents in these brief application experiments.  However, both 
isoflurane and desflurane markedly increased desensitization rates when GlyR was 
activated by taurine.  A summary of the effects of modulators on glycine- and taurine-
mediated desensitization is provided in Table 3.1.  We hypothesized that there might be a 
direct correlation between the degree of potentiation of peak responses produced by 
allosteric modulators and their effects on desensitization.  Fig. 3.8 shows that, as the 
modulator-induced percentage enhancement of peak current responses increases, so does 





Figure 3.7 – Anesthetics increase desensitization rates of taurine- but not glycine-
activated GlyR	

Each set of the sample tracings shown depicts 15 s applications of agonist + 
modulator as well as the agonist-alone tracings that preceded and followed the 
agonist + modulator application. Oocytes were preincubated with modulators for 
30 s before the incubations with agonists. For each set of tracings all responses 
were normalized to the peak response produced by the first application of glycine 
or taurine. Each column contains one of four different allosteric modulators: 
ethanol, isoflurane, desflurane, or TCY. Each row shows one of the agonists 
tested, glycine (black) or taurine (blue). Tracings are color coded by compound, 




Table 3.1 – The effects of positive allosteric modulators on glycine- and taurine-
activated GlyR desensitization rates	

Currents were measured at the peak responses and 5 s later. The percentage drop 
in current observed within 5 s in the presence of the modulator was divided by the 
percentage drop seen in the absence of the modulator, multiplied by 100, and then 
had 100 subtracted to indicate the percentage change in desensitization produced 
by the modulator. Data are shown as the mean ± SEM of 5–7 oocytes per 
modulator per agonist. *, p < 0.05 for glycine vs. taurine.	
! !
Modulator Glycine Taurine
Ethanol 2.3 ± 4.5% 16.3 ± 10.5%
Chloroform* -4.5 ± 2.5% 120.0 ± 58.4%
Isoflurane* 3.6 ± 1.9% 68.6 ± 14.0%
Halothane 3.9 ± 6.2% 104.5 ± 52.5%
Enflurane* 20.5 ± 4.7% 128.3 ± 39.1%
Desflurane* 2.9 ± 5.8% 136.2 ± 83.2%
Toluene 2.3 ± 9.4% -4.9 ± 10.1%
TCE 6.7 ± 11.4% 27.6 ± 19.4%
TCY* -4.9 ± 6.4% 56.4 ± 23.1%
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Figure 3.8 – Correlation between the degree of positive allosteric modulator 
enhancement of peak current levels and desensitization rates	

A) correlation between positive allosteric modulator effects on peak current 
percentage potentiation and desensitization rate for glycine-activated GlyR. Each 
data point is from a single oocyte and a single modulator according to the color 
key shown. The x-axis is the percentage change in peak current produced by 
modulator, and the y-axis is the percentage change in desensitization rate seen 
with each modulator. The solid line is a linear regression through the data set with 
r = 0.67. Each modulator was tested on 5–7 oocytes. B) correlation between 
positive allosteric modulator effects on percentage potentiation and 
desensitization rate for taurine-activated GlyR. The axes and color coding are the 
same as in A. The solid line is a linear regression through the data set with r = 
0.87. Each modulator was tested on 5–7 oocytes.  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3.3.7 – ALLOSTERIC MODULATOR POTENTIATION OF TAURINE-ACTIVATED GLYR 
RESPONSES ARE EQUALLY CONCENTRATION DEPENDENT AT LOW AND HIGH TAURINE 
CONCENTRATIONS	
!
We next investigated the differences in the magnitudes of effects of the volatile 
anesthetics and the inhaled drugs of abuse.  Although all drugs in both categories showed 
enhancing effects when applied with maximal concentrations of taurine, the degree of 
potentiation was much larger for the volatile anesthetics than that for the inhaled drugs of 
abuse.  We further examined this difference by testing whether the degree of efficacy 
inherent in each compound was simply concentration dependent by comparing sample 
modulators from each group.  From the anesthetics, we chose isoflurane because of its 
high potentiation of maximal taurine responses coupled with a small error in the 
preincubation experiments, and from the inhalant class, we chose toluene because of its 
relatively low enhancement of maximal taurine effects in the preincubation experiments. 
For this experiment, the concentration of taurine producing a 5 to 10% effect (EC5–10) of 
a maximally-effective taurine response was first determined in each oocyte.  The 
concentrations of isoflurane and toluene producing ~200% potentiation of the EC5–10 
response were determined next (Fig. 3.9A).  These concentrations of isoflurane and 
toluene were then tested using the maximally-effective concentration of taurine (EC100), 
and the effects of isoflurane and toluene were compared (Fig. 3.9B).  Concentrations of 
0.42 mM toluene and 0.28 mM isoflurane produced ~200% potentiation of the EC5–10 
taurine response.  When tested at EC100 taurine concentrations, isoflurane potentiated the 
taurine response by 107.7 ± 16.4%, and toluene potentiated the taurine response by 93.4 






Figure 3.9 – Equi-effective concentrations of modulators at a low taurine 
concentration also have equal efficacy at a saturating taurine 
concentration	

A) concentrations of toluene and isoflurane that yield an ~200% potentiation of 
EC5–10 taurine were determined. Tracing shows the effect of EC5–10 taurine ± 
several concentrations of isoflurane or toluene. Toluene (0.42 mM) potentiated 
EC5–10 taurine ~200%, whereas 0.55 mM isoflurane potentiated to a higher 
degree, and 0.28 mM isoflurane produced ~200% potentiation of EC5–10 taurine. 
Taurine applications preceded and followed each co-application with a modulator. 
Horizontal bars above tracings indicate the times of exposure to taurine, toluene, 
or isoflurane at the concentrations indicated. B) sample tracing demonstrating the 
enhancing effects of the toluene and isoflurane concentrations found in A, but co-
applied with a saturating concentration (EC100) of taurine. co-applications of 
taurine and modulator were preceded and followed by applications of taurine. C) 
summary of the effects seen in B. The y-axis is the percentage increase in current 




3.3.8 – MUTATIONS THAT AFFECT ALCOHOL BINDING HAVE SIMILAR EFFECTS ON THE 
GLYCINE- AND TAURINE-ACTIVATED GLYR	
!
Lastly, we investigated whether mutation of a residue in the second 
transmembrane segment of the α1 subunit previously shown to alter alcohol modulation 
of glycine-activated GlyR would similarly affect receptors activated by taurine.  Fig. 3.10 
shows that ethanol, isoflurane, and TCE had minimal effects on S267F homomeric α1 





Figure 3.10 – The S267F mutation in the second transmembrane segment of the α1 
subunit similarly affects modulator enhancement of glycine- and 
taurine-mediated GlyR function	

The effects of 200 mM ethanol, 0.55 mM isoflurane, or 0.56 mM TCE were 
assayed with EC5–10 concentrations of glycine or taurine. The y-axis represents the 
percentage change in current observed in the presence of modulator compared 
with that produced by glycine or taurine applied alone. Data are shown as mean ± 






Glycine receptors, traditionally thought to be responsible for inhibitory 
neurotransmission only in the brainstem and spinal cord, are also found in higher brain 
regions (Lynch, 2004).  As a result, they have come to be considered possible sites of 
action for ethanol, volatile anesthetics, and inhaled drugs of abuse (Mihic, 1999; Bowen 
et al., 2006; Franks, 2008; Lubman et al., 2008; Chau, 2010; Yevenes and Zeilhofer, 
2011).  After release, the postsynaptic GlyR is initially exposed to millimolar 
concentrations of glycine, which then rapidly decrease.  Enhancement of GlyR function 
by allosteric modulators is not seen at millimolar glycine concentrations because these 
compounds left-shift glycine concentration response curves and exert their greatest 
effects at low glycine concentrations (Downie et al., 1996; Mascia et al., 1996a; 
Beckstead et al., 2000).  Thus, allosteric modulators function to extend the durations of 
synaptic effects at the GlyR.  The partial agonist taurine may be an endogenous ligand at 
GlyR expressed in the hippocampus (Shibanoki et al., 1993; Mori et al., 2002), nucleus 
accumbens (Dahchour et al., 1996; Ericson et al., 2006, 2011), and the ventral tegmental 
area (Wang et al., 2005) where glycine has also been shown to work.  This suggests the 
possibility that ethanol, volatile anesthetics, and inhaled drugs of abuse exert some of 
their effects through the taurine-activated GlyR and that these responses may differ from 
those of receptors activated by glycine.	

On the basis of the importance of modulator preincubation as shown in Fig. 3.2, 
we replicated the saturating agonist and ethanol experiments that we had performed 
previously (Welsh et al., 2010) but with modifications to the experimental design.  We 
previously tested whether ethanol had any effects on applications of saturating agonist 
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concentrations on the GlyR, and as expected, 200 mM ethanol had no effects on 
saturating glycine responses or on responses elicited by brief applications of a maximally 
effective concentration of taurine (Figs. 2 and 3A in Welsh et al., 2010).  However, during 
a long application of a saturating concentration of taurine, 100 mM ethanol seemed to 
have a small enhancing effect (Fig. 3B in Welsh et al., 2010).  Therefore, we tested the 
effect of preincubation of 200 mM ethanol in a short application protocol and compared 
its effects with those in the long application experiments.  We used this concentration of 
ethanol to allow us to compare results with the approximately equivalent anesthetizing 
concentrations used for the anesthetics that we also tested.  With preincubation of 
ethanol, followed by a brief co-application with agonist, we found no effects on 
saturating glycine responses and modest (~40%) potentiating effects in the presence of a 
saturating concentration of taurine.  Ethanol had no effect when combined with glycine, 
consistent with previous findings that ethanol does not affect the Po for individual 
glycine-activated GlyRs (Welsh et al., 2009).  However, the modest potentiation of 
taurine-activated currents suggests that ethanol does increase Po when receptors are 
activated by this partial agonist.  An increase in single channel conductance could 
conceivably also explain the potentiation seen here, but it is unlikely given that partial 
and full agonists elicit the same conductance (Gardner et al., 1984; Lewis et al., 2003). 
In addition, ethanol does not affect unitary conductance of glycine-activated GlyRs 
(Welsh et al., 2009).	

We sought to further examine the effects of ethanol by co-applying it with 
maximally effective concentrations of glycine or taurine for 10 min.  During constant 
exposure to a saturating agonist concentration, essentially all receptors enter a fully 
liganded state, thus minimizing any possible modulator effects on agonist binding or 
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unbinding.  When fully liganded, the GlyR exists in one of the three general states: 
closed, open, or desensitized.  Channel activity is observed as a cluster of transitions 
between closed and open states terminated by receptor desensitization (Beato et al., 
2004).  Upon resensitization in the presence of a saturating concentration of agonist, the 
receptor will almost immediately initiate a new cluster of opening/closing events, 
meaning that for all practical purposes, all transitions leaving the desensitized state 
almost instantly lead to a fully liganded open state.  Thus, long applications of saturating 
concentrations of agonist result in a pseudo-equilibrium of clusters of channel-opening 
events separated by sojourns into desensitized states, with no receptors found in the 
closed unliganded state.  Any increases in current produced by allosteric modulators 
under these conditions could not be attributed to changes in agonist association or 
dissociation rates.  Positive allosteric modulators must instead be acting by increasing the 
rates of entering (or decreasing the rates of leaving) open states within clusters to increase 
Po or by increasing the rates of leaving (or decreasing the rates of entering) desensitized 
states.  Ethanol did not affect currents elicited by long applications of glycine, consistent 
with our previous data showing that ethanol only affects glycine unbinding rates (Welsh 
et al., 2009).  However, ethanol did seem to slightly potentiate taurine-mediated currents 
during long applications (Fig. 3.3C,D).  This is not attributed to ethanol decreasing the 
rates of desensitization (Fig. 3.7; Table 3.1), so the most parsimonious explanation is that 
ethanol modestly affects taurine-activated intracluster Po.	

We next performed these same experiments using a series of inhaled anesthetics. 
For these experiments, we tested the alkyl halides chloroform and halothane and the 
halogenated ethers isoflurane, enflurane, and desflurane.  None of the anesthetics tested 
had any effects on glycine-mediated currents in the brief application experiments, but all 
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produced striking (>150% potentiation) effects on taurine-mediated currents (Fig. 3.4). 
Similar to Downie et al. (1996), we found that isoflurane has no effects on maximally 
effective glycine concentrations but enhances maximal taurine currents.  Because the 
anesthetics enhanced the rates of taurine- but not glycine-mediated desensitization (Fig. 
3.7), this suggests that they increase Po.  If anything, one would expect a slowing of 
desensitization to increase peak heights.  These structurally dissimilar anesthetics had 
very similar effects, suggesting a common mechanism of action.  Lastly, we tested the 
effects of three inhaled drugs of abuse using the same experimental design, finding that 
the inhalants produced enhancement of taurine-mediated currents and desensitization 
rates similar to those seen with ethanol.	

The different classes of modulators we tested produced variable enhancement of 
taurine-activated GlyR currents.  We hypothesized that this may be simply attributed to 
differences in the concentrations used.  To test this, we compared the weakly enhancing 
inhaled drug of abuse toluene with the strongly enhancing anesthetic isoflurane.  We first 
identified the concentrations of each that produced ~200% potentiation of the effects of 
low (EC5-10) concentrations of taurine.  We next tested those modulator concentrations 
using a maximally effective taurine concentration, observing almost identical effects of 
the two.  Thus, these classes of modulators may all act via a similar mechanism to 
enhance taurine currents.  The greater percentage enhancement seen at low taurine 
concentrations probably reflects the dual effects of allosteric modulators on taurine 
unbinding as well as increasing Po, whereas only the latter effect was observed at a 
maximally effective taurine concentration.	

In summary, all modulators tested produced enhancement of peak current 
responses elicited by a saturating concentration of taurine but not glycine.  In addition, 
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enhancement of desensitization rates was seen when modulators were applied with 
taurine but not glycine.  Allosteric modulators potentiate both taurine- and glycine-
elicited currents when either agonist is present at low concentrations.  However, the 
concentration of either agonist found at the GlyR in vivo is probably high either through 
the synaptic release of glycine or the osmotic release of taurine.  The effects of these 
modulators on saturating concentrations of taurine are especially interesting given that 
taurine is the second most abundant amino acid in the brain (Albrecht and Schousboe, 
2005) and has also been shown to be released through an osmoresistant calcium-mediated 
mechanism in the hippocampus (Rodríguez-Navarro et al., 2009).  Our findings suggest 
that allosteric modulators differentially affect the time courses of synaptic events at GlyR, 





4.0 | PHYSIOLOGICAL CONCENTRATIONS OF ZINC REDUCE 






The glycine receptor (GlyR) is a member of the cys-loop receptor superfamily of 
ligand-gated ion channels.  It has a pentameric structure composed of either α 
(homomeric) or α & β (heteromeric) subunits arranged around a central anion-conducting 
pore.  GlyR are responsible for the majority of fast inhibitory neurotransmission in the 
brainstem and spinal cord, with γ-aminobutyric acid type A (GABAA) receptors primarily 
fulfilling this role in the brain.  However, GlyR are also found in many brain regions 
including the hippocampus, NAcc and prefrontal cortex (Baer et al., 2009; Jonsson et al., 
2012, 2009; Lu and Ye, 2011; Lynch, 2004; Malosio et al., 1991; van den Pol and Gorcs, 
1988; Waldvogel et al., 2007).  Because GlyR are found in brain regions associated with 
hypnosis, memory, and the rewarding properties of drugs of abuse, it is reasonable to 
hypothesize that these receptors may play a role in the effects of these agents in vivo.	

A wide variety of compounds act as allosteric modulators of the GlyR, including 
alcohols, inhaled drugs of abuse and anesthetics, neurosteroids, tropeines, divalent 
cations, and many others (Beckstead et al., 2000; Cheng and Kendig, 2002; Downie et al., 
1996; Harvey et al., 1999; Laube et al., 1995; Molander et al., 2007, 2005; Yamashita et 
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of zinc reduce taurine-activated GlyR responses to drugs of abuse. Neuropharmacol 
75:286–294.  Copyright © 2013 Elsevier Ltd. All rights reserved.!
al., 2001; Yevenes and Zeilhofer, 2011).  Thus, the GlyR has emerged as a logical target 
for the possible development of pharmacological agents to treat substance abuse (Tipps et 
al., 2010).  Allosteric modulators exert their greatest enhancing effects on low 
concentrations of glycine that are unlikely to be seen at GlyR in vivo except at the 
initiation or tail-end of synaptic events or perhaps at extrasynaptic receptors (Scimemi 
and Beato, 2009).  Indeed these compounds have negligible effects when tested with 
saturating concentrations of glycine (Kirson et al., 2012; McCracken et al., 2010).	

The sulfonic acid taurine acts as a partial agonist at the GlyR, possessing 
approximately 50% of the efficacy of glycine (Lape et al., 2008).  Taurine is the second 
most abundant amino acid in the brain, and has been implicated as an endogenous ligand 
of the GlyR in multiple brain regions (Albrecht and Schousboe, 2005; Dahchour et al., 
1996; Ericson et al., 2006; Mori et al., 2002; Rodríguez- Navarro et al., 2009).  Although 
glycine receptors are found synaptically in a variety of brainstem nuclei (Ferragamo et 
al., 1998; Lim et al., 2000) and in cerebellum (Dieudonne, 1995) they are also found 
extrasynaptically, where taurine and β-alanine may be acting as the endogenous agonists 
(Mori et al., 2002).  Taurine may reach concentrations as high as 20 mM in astrocytes, 
from which it is released by osmoregulatory mechanisms (Albrecht and Schousboe, 
2005).  Extracellular taurine concentrations measured by micro-dialysis range from 1 to 
100 μM but, by their nature, likely underestimate concentrations found locally around 
astrocytes.	

Taurine plays a role in the effects of ethanol in the NAcc (Ericson et al., 2011). 
Although allosteric modulators have no effects when tested using saturating 
concentrations of full agonists at the GlyR, this is not true when saturating concentrations 
of partial agonists are tested (Albrecht and Schousboe, 2005; Kirson et al., 2012; 
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Scimemi and Beato, 2009).  In this paper we examined the possible interactions of these 
allosteric modulators with the ubiquitous GlyR modulator, zinc, on glycine- and taurine-
activated GlyR.	

Zinc modulation of the GlyR is biphasic in nature, with concentrations below 10 
μM enhancing responses, while higher concentrations inhibit GlyR functioning (Harvey 
et al., 1999; Laube et al., 2000, 1995; McCracken et al., 2010).  Zinc is present at low and 
variable levels in standard buffer solutions (Kay, 2004; McCracken et al., 2010), and is 
also present throughout the brain at low nM concentrations known to potentiate GlyR 
responses (Frederickson et al., 2006a, b; McCracken et al., 2010).  Although zinc is 
packaged into some synaptic vesicles, even upon release concentrations remain below 10 
μM (Frederickson et al., 2006a).  Zinc modulation of the glycine-activated GlyR has been 
extensively studied but the interactions between zinc and the taurine-activated GlyR have 
not been characterized to the same extent, especially in conjunction with ethanol or other 
modulators. Previous studies of zinc modulation of taurine-activated GlyR responses 
focused on adding zinc at both enhancing and inhibiting concentrations, without 
controlling for the background zinc likely to be found at biologically-relevant 
concentrations (Laube et al., 2000).  In this study we further characterize zinc 
modulation, as well as compare zinc’s interactions with other allosteric modulators on the 
glycine- vs. taurine-activated GlyR.	

!





Isolation, injection, and two-electrode voltage-clamp of Xenopus oocytes were 
described in Chapter 2.  Specific methods pertaining to the experiments in this chapter are 
outlined below.	

All chemicals were purchased from Sigma–Aldrich (St. Louis, MO) except 
isoflurane which was obtained from Anaquest (New Providence, NJ).	

Xenopus laevis were obtained from Nasco (Fort Atkinson, WI) and housed at 
19°C on a 12-h light/dark cycle.  During surgery, performed in accordance with the 
Association for Assessment and Accreditation of Laboratory Animal Care regulations, 
portions of ovaries were removed and placed in isolation media containing 108 mM 
NaCl, 1 mM EDTA, 2 mM KCl, and 10 mM HEPES.  Forceps were used to manually 
remove the thecal and epithelial layers from stage V and VI oocytes.  The oocyte 
follicular layer was removed using a 10 min incubation in 0.5 mg/ml type 1A collagenase 
in buffer containing 83 mM NaCl, 2 mM MgCl2, and 5 mM HEPES.  Animal poles of 
oocytes were injected with human glycine α1, α2, α1β or α2β receptor subunit cDNAs 
(1.5 ng/30 nl) in a modified pBK-cytomegalovirus vector (Mihic et al., 1997), using a 
micropipette (10–15 μm tip size) attached to an electronically-activated microdispenser. 
When heteromeric receptors were to be studied, α and β subunit cDNAs were injected in 
a 1:20 α:β concentration ratio to ensure incorporation of the β subunits into receptors. 
Oocytes were stored in the dark at 19°C in 96-well plates containing modified Barth’s 
saline (MBS) [88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 10 mM HEPES, 0.82 mM 
MgSO47·H2O, 0.33 mM Ca(NO3)2, 0.91 mM CaCl2 at pH 7.5] supplemented with 2 mM 
sodium pyruvate, 0.5 mM theophylline, 10 U/ml penicillin, 10 mg/l streptomycin and 50 




Oocytes expressed GlyR within 24 h, and all electrophysiological measurements 
were made within 5 days of cDNA injection.  Before electrophysiological recording, 
oocytes were placed in a 100 μl bath with the animal poles facing upwards and impaled 
with two high-resistance (0.5–10 MΩ) glass electrodes filled with 3 M KCl.  Cells were 
voltage-clamped at –70 mV using an OC-725C oocyte clamp (Warner Instruments, 
Hamden, CT) and perfused with MBS at a rate of 2 ml/min using a Masterflex USA 
peristaltic pump (Cole Parmer Instrument Co., Vernon Hills, IL) through 18-gauge 
polyethylene tubing.  All drug solutions were prepared in MBS, MBS + 2.5 mM tricine, 
or MBS + 100 nM ZnCl.  When saturating concentrations of agonists were applied, 
applications lasted for 15 s for the short application experiments and for up to 26 min for 
the continuous application experiments.  For experiments using submaximal 
concentrations of taurine, concentrations that yielded 5 percent of the maximally-
effective taurine response (EC5) were applied for 30 s.  For short application experiments, 
modulators were co-applied with agonists following a 30 s preincubation of modulator 
alone.  For continuous application experiments, modulators were co-applied with agonist 
for 2 min following agonist application alone.  All drug applications during short 
application experiments were followed by 6–10 min washout periods to allow for 
complete receptor resensitization.  Loss of volatile compounds through tubing and 
evaporation from bath was previously measured (Beckstead et al., 2002, 2000; Mihic et 
al., 1994; Yamakura et al., 1999).  All concentrations reported are the bath concentrations 
to which the oocytes were exposed.  Data were acquired at a rate of 1 kHz using a 





Peak currents were measured and used in data analysis.  Currents observed in the 
presence of agonist plus modulators were compared with currents generated by agonist 
without the modulator of interest present.  Experimental values are listed as the mean ± 
SEM.  Significant differences between experimental conditions were determined using 
ANOVA or repeated measures ANOVA and post-hoc tests, as indicated. SigmaPlot 






4.3.1 – CHELATION OF ENDOGENOUS ZINC DECREASES RESPONSES TO TAURINE	
!
We previously showed that various allosteric modulators of GlyR, such as ethanol 
and some anesthetics, have different effects on currents generated by saturating 
concentrations of glycine versus taurine (Kirson et al., 2012).  In order to compare zinc 
modulation of GlyR currents generated by maximally-effective concentrations of glycine 
and taurine, we compared currents generated by co-applications of agonist and either 100 
nM zinc or 2.5 mM of the zinc chelator tricine with currents generated by agonist alone. 
Fig. 4.1A shows a sample tracing of successive 15 s applications of 10 mM glycine in the 
presence of a background concentration of zinc, 2.5 mM tricine, or 100 nM zinc.  Fig. 
4.1B shows the same experimental protocol as in A but with 100 mM taurine instead 
employed as the agonist.  Addition of 100 nM zinc enhanced saturating taurine currents 
almost 60% (Fig. 4.1C) while leaving saturating glycine-mediated currents unchanged. 
Elimination of background levels of zinc in the perfusion buffer by co-application of 
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tricine decreased saturating taurine currents while having no effects on saturating glycine 
currents.  A two-way ANOVA showed a significant interaction effect between the 
concentration of zinc in the buffer and the agonist tested [F(1,37) = 34.4, p < 0.001].  A 
Student-Newman-Keuls (SNK) multiple comparison post-hoc test showed significant 
differences between glycine and taurine both in the presence of 2.5 mM tricine [q = 4.6, p 
< 0.01] and 100 nM zinc [q = 7.1, p < 0.001], as well as a significant effect of zinc 
concentration when taurine was the agonist [q = 12.3, p < 0.001].	

We next looked at the effects of zinc modulation using saturating agonist 
concentrations that were applied continuously for 10 min, followed by 2 min co-
applications of agonist and either 2.5 mM tricine or 100 nM zinc.  This continuous 
agonist application approach allows for channels to equilibrate between the open and 
desensitized states (Fig. 4.2A,B).  Under these conditions all receptors have bound 
agonist and are either activated (opening) or desensitized.  In this experimental paradigm 
the effects of modulators can thus only be due to their effects on channel opening/closing 
kinetics (Po) or desensitization/resensitization rates and not on possible effects on agonist 
affinity.  As seen in Fig. 4.2C, the effects exhibited by zinc trended in the same directions 
as those seen in Fig. 4.1C, but to a smaller degree.  Co-application of 100 nM zinc 
produced greater potentiation of saturating taurine currents compared to saturating 
glycine currents.  Co-application of tricine showed a decrease in saturating taurine 
responses compared to a negligible increase in saturating glycine.  Similar to the short 
application experiments, a two-way ANOVA showed a significant interaction effect 
between the concentration of zinc in the buffer and the agonist tested [F(1,16) = 34.3, p < 
0.001].  A SNK multiple comparison post-hoc test revealed significant differences 
between glycine and taurine both in the presence of 2.5 mM tricine [q = 7.1, p < 0.001] 
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and 100 nM zinc [q = 4.6, p < 0.01], as well as a significant effect of zinc concentration 





Figure 4.1 – Zn2+ affects currents elicited by maximally-effective concentrations of 
taurine but not glycine	

A) tracings showing the effect of a maximally-effective concentration of glycine 
applied in the presence or absence of Zn2+. The tracing shows 15 s co-applications 
of 10 mM glycine with either 2.5 mM tricine or 100 nM Zn2+ following a 30 s 
preincubation with tricine or Zn2+. Each application was preceded and followed 
by applications of 10 mM glycine alone in buffer containing background levels of 
Zn2+. Horizontal bars over tracings indicate time of exposure to glycine, tricine, or 
Zn2+. 10 min washouts separated agonist applications. B) tracing showing the 
effect of a maximally-effective concentration of taurine applied in the presence or 
absence of Zn2+. The tracing follows the same protocol as in panel A. Horizontal 
bars over tracing indicate time of exposure to taurine, tricine, or Zn2+. C) 
Summary of the effects of Zn2+ on maximally-effective concentrations of glycine 
or taurine. The y-axis represents the percent current potentiation observed in the 
presence or absence of Zn2+ compared with that produced by glycine or taurine in 




Figure 4.2 – Zn2+ affects currents elicited by long exposures to maximally-effective 
concentrations of taurine but not glycine	

A) Sample tracing showing the effects of 2.5 mM tricine or 100 nM Zn2+ co-
applied with saturating concentrations of glycine after 10 min of continuous 
glycine application. Two minute applications of 10 mM glycine in either 2.5 mM 
tricine or 100 nM Zn2+ were preceded and followed by 10 mM glycine in buffer 
containing background levels of Zn2+. Horizontal bars over the tracing indicate 
time of exposure to glycine, tricine, or Zn2+. B) Sample tracing showing the 
effects of 2.5 mM tricine or 100 nm Zn2+ co-applied with saturating 
concentrations of taurine, after 10 min of continuous taurine application. The 
tracing follows the same protocol as in panel A. Horizontal bars over the tracing 
indicate time of exposure to taurine, tricine, or Zn2+. C) Summary of the effects of 
maximally-effective concentrations of glycine or taurine in the presence or 
absence of Zn2+ during continuous agonist exposures. The y-axis is the percent 
current enhancement observed in the presence or absence of Zn2+ compared with 
the glycine or taurine current level immediately preceding tricine or zinc co-
application. Data are shown as mean ± SEM of 4–6 oocytes. *, p < 0.05. 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4.3.2 – ZINC AND ETHANOL INTERACTIONS	
!
Physiologically-relevant low nM concentrations of zinc enhance ethanol 
modulation of GlyR currents generated by submaximal but not maximally-effective 
concentrations of glycine (McCracken et al., 2010).  As these two modulators are likely 
to be present concurrently at GlyR in vivo, we compared the effects of enhancing 
concentrations of zinc on ethanol modulation of GlyR activated by maximally-effective 
glycine or taurine concentrations.  We first looked at the effects of 15 s co-applications of 
maximally-effective concentrations of agonist and 200 mM ethanol in the presence of 
background levels of zinc and also in the presence of 2.5 mM tricine or 100 nM zinc. 
Fig. 4.3A shows that ethanol modulation of the maximally-effective taurine response is 
present in all three different zinc concentrations.  However, 100 nM zinc significantly 
decreased [Two-way Repeated Measures (RM) ANOVA with SNK multiple comparison 
procedure; q = 5.0, p < 0.01; q = 4.6, p < 0.01, respectively] the degree of ethanol percent 
potentiation of a saturating taurine concentration compared to the potentiation seen in 
either the background zinc level or after zinc chelation.  In background levels of zinc, or 
in the presence of 2.5 mM tricine, or 100 nM zinc, 200 mM ethanol produced 
significantly greater enhancement of responses in saturating taurine than glycine [q = 
12.9, p < 0.001; q = 11.6, p < 0.001; q = 8.3, p < 0.001, respectively], as there was 
negligible inhibition of glycine currents observed instead (Fig. 4.3B).  The same trends 
were observed using 50 mM ethanol, just with a lower degree of ethanol potentiation 
(Fig. 4.3C) [q = 3.85, p < 0.05, comparing taurine alone with taurine plus zinc].	

We next looked at the combined effects of zinc and ethanol on receptors 
comprised of different subunits.  The heteromeric α1β GlyR is the predominant adult 
form found in brainstem and spinal cord of mammals and is likely to be found 
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synaptically, as the β subunit is involved in anchoring the GlyR via its interactions with 
gephyrin (Kirsch and Betz, 1995).  As shown in Fig. 4.4A, the effects of combined 
ethanol and zinc on the heteromeric channel exhibit the same trends as those seen on the 
homomeric channel but with slightly increased enhancement of taurine currents for the 
heteromeric channel.  A two-way RM ANOVA with SNK multiple comparison procedure 
showed ethanol potentiation of currents in 100 nM zinc significantly decreased from both 
background zinc [q = 3.8, p < 0.05] and 2.5 mM tricine [q = 3.1, p < 0.05], as well as 
significantly greater ethanol percent potentiation of taurine vs.glycine currents [q = 7.5, p 
= 0.001].  We also performed equivalent experiments on α2 homomeric (Fig. 4.4B) and 
α2β (Fig. 4.4C) heteromeric receptors.  Two-way RM ANOVAs with SNK multiple 
comparison procedures showed significantly greater ethanol percent potentiation of 
taurine vs.glycine currents [α2, q = 7.14, p < 0.01; α2β, q = 4.6, p < 0.05]. We found that 
taurine had very low efficacy on GlyR containing α2 subunits: 13.2 ± 5.4% in α2 
homomers and 6.1 ± 1.4% in α2β heteromeric GlyR, compared to the effects produced by 





Figure 4.3 – Zn2+ affects ethanol potentiation of currents elicited by maximally-
effective concentrations of taurine but not glycine	

A) tracings showing the effect of Zn2+ on brief applications of maximally-
effective concentrations of taurine. Taurine (100 mM) was co-applied with 200 
mM ethanol for 15 s following a 30 s preincubation with 200 mM ethanol. 
Ethanol applications were flanked by 15 s applications of taurine applied alone. 
Series of applications were carried out in buffer containing background levels of 
Zn2+, 2.5 mM tricine or 100 nM Zn2+. Horizontal bars over tracings indicate time 
of exposure to taurine, tricine, Zn2+ or ethanol. B) Summary of the effects of 200 
mM ethanol on maximally-effective concentrations of glycine or taurine in the 
presence of a background level of Zn2+, the absence of Zn2+ produced by tricine, 
or the addition of 100 nM Zn2+. The y-axis is the percent current potentiation with 
ethanol co-application, in background Zn2+, 2.5 mM tricine or 100 nM Zn2+. Data 
are shown as mean ± SEM of 6 oocytes. C) Summary of the effects of 50 mM 
ethanol on maximally-effective concentrations of taurine in the presence of a 
background level of Zn2+, the absence of Zn2+ produced by tricine, or the addition 
of 100 nM Zn2+. The y-axis is the percent current potentiation with ethanol co-
application, in background Zn2+, 2.5 mM tricine or 100 nM Zn2+. Data are shown 
as mean + SEM of 8 oocytes. *, p < 0.05. 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Figure 4.4 – Zinc/ethanol interactions on GlyR composed of a variety of 
different subunits	

Summaries of the effects of ethanol on brief applications of maximally-effective 
concentrations of glycine or taurine in the presence of a background level of Zn2+, 
the absence of Zn2+ produced by tricine, or the addition of 100 nM Zn2+ on the 
α1β GlyR (A) α2 GlyR (B) or α2β GlyR (C). The y-axes represent the percent 
current potentiation observed with ethanol co-application, in background Zn2+, 2.5 




4.3.3 – ZINC AND ISOFLURANE INTERACTIONS	
!
Because biologically-relevant concentrations of zinc affect ethanol potentiation of 
saturating taurine currents, we investigated other allosteric modulators of the GlyR for 
zinc-modulator interactions.  The inhaled volatile anesthetic isoflurane was tested using 
the same experimental protocols as those used for ethanol.  Fig. 4.5A shows the results of 
15 s co-applications of 0.55 mM isoflurane with either 10 mM glycine or 100 mM taurine 
in the presence of background levels of zinc, 2.5 mM tricine or 100 nM zinc.  As for 
ethanol, isoflurane potentiation of saturating taurine currents in either background zinc or 
2.5 mM tricine were very similar, while the addition of 100 nM zinc significantly 
decreased the isoflurane percent potentiation from those levels [Two-way RM ANOVA 
with SNK multiple comparison procedure; q = 4.1, p < 0.02; q = 4.4, p < 0.05, 
respectively].  Saturating glycine-mediated currents were minimally affected by 
isoflurane whether in background levels of zinc, 2.5 mM tricine, or 100 nM zinc. 
Isoflurane enhancement was significantly different between glycine and taurine in the 
presence of a background level of zinc [q = 7.4, p < 0.001] and in 2.5 mM tricine [q = 





Figure 4.5 – Zn2+ decreases isoflurane and toluene potentiation of currents elicited by 
maximally-effective concentrations of taurine but not glycine	

These experiments were carried out in the same manner as the ethanol 
experiments described in Fig. 4.3. A) Effect of isoflurane on currents elicited by 
brief applications of maximally-effective glycine (10 mM) or taurine (100 mM) in 
the presence or absence of Zn2+. Agonist was co-applied with 0.55 mM isoflurane 
for 15 s following a 30 s preincubation with 0.55 mM isoflurane. Data are shown 
as mean + SEM of 6 oocytes. B) Effect of toluene on currents elicited by brief 
applications of maximally-effective glycine (10 mM) or taurine (100 mM) in the 
presence or absence of Zn2+. Agonist was co-applied with 0.42 mM toluene for 15 
s following a 30 s preincubation with 0.42 mM toluene. Data are shown as mean 
± SEM of 4 oocytes. *, p < 0.05. 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4.3.4 – ZINC AND TOLUENE INTERACTIONS	
!
The next allosteric modulator tested was the inhaled drug of abuse toluene.  Fig. 
4.5B shows the results of the brief co-applications of 0.42 mM toluene with either 10 mM 
glycine or 100 mM taurine in the presence of background levels of zinc, 2.5 mM tricine, 
or 100 nM zinc.  Toluene had negligible effects on 10 mM glycine currents and its effects 
on 100 mM taurine currents were similar to effects seen with ethanol and isoflurane. 
Again, similar to ethanol and isoflurane, toluene percent potentiation of saturating 
taurine-mediated currents was significantly reduced in the presence of 100 nM zinc, 
compared to the other two zinc conditions [Two-way RM ANOVA with SNK multiple 
comparison procedure; q = 6.3, p < 0.002; q = 5.7, p < 0.002, respectively].  Toluene 
enhancement of saturating taurine was significantly greater than effects on saturating 
glycine in background levels of zinc [q = 8.8, p < 0.001], 2.5 mM tricine [q = 7.2, p < 
0.001], and 100 nM zinc [q = 3.3, p < 0.05].	

!
4.3.5 – ZINC & ETHANOL INTERACTIONS AT A LOW TAURINE CONCENTRATION	
!
We previously found that zinc enhances ethanol potentiation of low 
concentrations of glycine, and that the degree of ethanol enhancement is reduced when 
zinc is chelated by tricine (McCracken et al., 2010).  Although we saw minor ethanol 
effects with changing zinc levels at saturating concentrations of glycine, we did see 
changes in ethanol potentiation of saturating concentrations of taurine based on the level 
of zinc present (Fig. 4.2B).  Thus we extended the observations made in the McCracken 
et al. (2010) paper, this time using EC5 concentrations of taurine.  We first tested whether 
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ethanol potentiation of EC5 taurine currents in α1 GlyR depends on the concentration of 
zinc.  Fig. 4.6A shows that when zinc is chelated with tricine, the degree of ethanol 
potentiation of EC5 taurine-mediated currents is the same as EC5 glycine-mediated 
currents for both 50 mM and 200 mM ethanol.  We next tested if chelation of zinc 
significantly reduces ethanol potentiation of EC5 taurine-mediated currents as it does for 
glycine-mediated currents.  Fig. 4.6B shows the results of 200 mM ethanol effects on 
EC5 glycine and taurine currents, with and without the addition of 2.5 mM tricine.  With 
no differences between agonists, ethanol potentiation was significantly lower in 2.5 mM 
tricine compared to background levels of zinc [Two-way ANOVA with SNK multiple 





Figure 4.6 – Zn2+ affects ethanol potentiation of low concentrations of full and 
partial agonists	

A) Ethanol potentiation of the effects of 5% maximal (EC5) glycine- or taurine-
mediated currents in the presence of 2.5 mM tricine (i.e., in the absence of Zn2+). 
EC5 glycine and taurine were co-applied with either 50 mM or 200 mM ethanol 
following a 30 s preincubation with ethanol. Data are shown as mean + SEM of 5 
oocytes. B) Ethanol potentiation of EC5 glycine and taurine is enhanced by Zn2+. 
EC5 glycine or taurine were co-applied with 200 mM ethanol following 
preincubation with ethanol, in the presence of either background Zn2+ (left two 
bars) or 2.5 mM tricine (right two bars). Data are shown as mean + SEM of 9 
oocytes. *, p < 0.05. 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4.3.6 – ZINC/MODULATOR INTERACTION EFFECTS ON DESENSITIZATION RATES	
!
We next looked at the effects of changing zinc concentration on desensitization 
rates.  Desensitization rates were determined by comparing the peak current to that 
measured five seconds post-peak for saturating glycine and taurine currents, in the 
presence of background levels of zinc or in the presence of 2.5 mM tricine or 100 nM 
zinc.  Changing the zinc concentration did not affect the desensitization rates of glycine-
activated currents in α1 GlyR (Fig. 4.7A).  Taurine-mediated desensitization was 
significantly slower than for glycine-mediated currents in background zinc [Two-way 
ANOVA with SNK multiple comparison procedure; q = 8.5, p < 0.001], as well as in 2.5 
mM tricine [q = 10.4, p < 0.001], and in 100 nM zinc [q = 4.2, p < 0.01].  Additionally, 
desensitization of taurine-mediated currents in 2.5 mM tricine and 100 nM zinc were 
significantly different [q = 3.7, p < 0.05].	

Because drugs of abuse and zinc are likely to be found concomitantly at receptors 
in vivo, we examined the effects of different allosteric modulators on desensitization rates 
in the presence of background zinc, 2.5 mM tricine, or 100 nM zinc.  Fig. 4.7B shows the 
desensitization rates produced by 10 mM glycine and 100 mM taurine applied with 200 
mM ethanol in the three different zinc concentrations.  Taurine + ethanol current 
desensitization was significantly slower than that seen in glycine + ethanol currents in 
background zinc [Two-way RM ANOVA with SNK multiple comparison procedure; q = 
7.7, p < 0.001], 2.5 mM tricine [q = 11.0, p < 0.001], and 100 nM zinc [q = 5.1, p < 0.01]. 
Additionally, desensitization of glycine + ethanol currents in 2.5 mM tricine and 100 nM 
zinc were significantly different [q = 4.3, p < 0.05].	

Fig. 4.7C shows the results for desensitization experiments involving isoflurane. 
Desensitization was similar for 10 mM glycine with 0.55 mM isoflurane currents and 100 
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mM taurine with 0.55 mM isoflurane currents, with the only significant difference found 
between glycine + isoflurane and taurine + isoflurane in 100 nM zinc buffer [Two-way 
RM ANOVA with SNK multiple comparison procedure; q = 3.5, p < 0.05].  Fig. 4.7D 
shows the effects of toluene on desensitization mediated by either glycine or taurine. 
There was a significant effect of agonist [Two-way RM ANOVA with SNK multiple 





Figure 4.7 – Zn2+ levels do not significantly affect desensitization of glycine- or 
taurine-activated glycine receptors.	

A) Zn2+ does not affect the rate of desensitization produced by maximally-
effective glycine or taurine. Percent decrease in peak current observed 5 s post-
peak is graphed for each agonist/Zn2+ level combination. Data are shown as mean 
+ SEM of 26–35 oocytes. B) Zn2+ and ethanol do not affect the rate of 
desensitization produced by maximally-effective glycine or taurine. Percent 
decrease in peak current seen 5 s post-peak in the presence of 200 mM ethanol is 
graphed for each agonist/Zn2+ level combination. Data are shown as mean + SEM 
of 6 oocytes. C) Zn2+ levels have no effect on isoflurane changes in desensitization 
rates of taurine-activated glycine receptor currents. Percent decrease in peak 
current observed 5 s post-peak in the presence of 0.55 mM isoflurane is graphed 
for each agonist/Zn2+ level combination. Data are shown as mean + SEM of 6 
oocytes. D) Zn2+ and toluene do not interact to affect desensitization rates of 
maximally-effective glycine and taurine. Percent decrease in peak current seen 5 s 
post-peak in the presence of 0.42 mM toluene is graphed for each agonist/Zn2+ 






The dopaminergic projection from the ventral tegmental area (VTA) to the nAcc 
is critical to the perception of the rewarding properties of drugs of abuse, and ethanol’s 
actions on the GlyR may be particularly important in these brain regions.  For example, 
extracellular dopamine levels increase in the NAcc following ethanol (Imperato and Di 
Chiara, 1986) or glycine (Molander et al., 2005) administration and glycine perfusion 
into the NAcc of rats decreases alcohol consumption (Molander et al., 2005).  Many 
volatile agents such as isoflurane and toluene also have abuse liability (Johnston et al., 
2012; Wilson et al., 2008).  Toluene also increases extracellular dopamine levels in the 
VTA and NAcc when perfused into the former (Riegel et al., 2007).  Most studies 
examining the effects of these agents on GlyR functioning do so by determining the 
effects of single modulators in isolation.  However, since zinc is ubiquitous in 
cerebrospinal and interstitial fluids at GlyR-potentiating levels, the effects of drugs of 
abuse on GlyR in vivo will always be seen in combination with zinc effects.  In fact one 
could go so far as to say that studying these compounds in the absence of zinc would 
represent an artificial situation unlikely to be found in vivo.  Since taurine and glycine 
may act as GlyR agonists in brain regions such as the NAcc, we examined the effects of 
combinations of allosteric modulators on GlyR activated by these agonists.  Maximally-
effective concentrations of taurine but not glycine were affected by zinc chelation (Figs. 
4.1, 4.2).  This is likely the result of glycine producing a very high probability of channel 
opening (intra-cluster Po ~ 1), with maximally-effective concentrations keeping the 
channel open almost 100% of the time before it desensitizes, regardless of the presence of 
any allosteric modulator.  As a partial agonist, taurine has a much lower Po (~0.5) at 
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maximally-effective concentrations (Lape et al., 2008), allowing for zinc to exhibit its 
enhancing effects.  The zinc potentiation seen after 10 min of continuous taurine 
perfusion could be attributable to zinc: (1) increasing Po; (2) enhancing conductance; (3) 
decreasing the desensitization rate or; (4) increasing the rate of GlyR resensitization. 
Previous studies performed using low agonist concentrations show that zinc does increase 
Po but it does not affect conductance (Laube et al., 2000).  Our data (Fig. 4.7A) shows 
that zinc can also increase the desensitization rate in taurine-activated GlyR, which would 
tend to counteract its Po enhancing effects.  In this way, zinc acts in a very similar fashion 
to other GlyR allosteric modulators (Kirson et al., 2012).  The decrease in responses seen 
when zinc is chelated by tricine suggests that sub-maximal glycine responses and all 
taurine responses are overestimated when not controlling for background zinc 
concentrations in buffer solutions.	

Because zinc is ubiquitous in the CNS, the effects of any drugs of abuse or other 
allosteric modulators of interest on GlyR functioning require comparison in the presence 
and absence of potentiating concentrations of zinc.  In the presence of a maximally-
effective concentration of glycine, changing the zinc concentration had no effect on 
responses for any of the modulators tested, since 10 mM glycine has already produced a 
maximal response.  However, effects on maximally-effective concentrations of taurine 
were expected and seen.  If zinc and other positive modulators were acting in an additive 
or synergistic manner, we would expect the 100 nM zinc condition to give a higher 
degree of potentiation than our standard buffers, with chelation of zinc by 2.5 mM tricine 
giving a lower degree of potentiation than both other conditions.  However we did not 





Chelation of zinc with tricine did not change the alcohol, isoflurane, or toluene 
potentiation of a maximally-effective taurine concentration when compared to the effects 
seen in the presence of background levels of zinc (Figs. 4.3B, 4.5A, 4.5B).  However, at 
sub-maximal concentrations of glycine or taurine, chelation of background zinc does 
decrease ethanol potentiation of GlyR responses (Fig. 4.6B).  The most parsimonious 
explanation for the lack of change seen at higher levels of taurine would be that 
background levels of zinc during those particular experiments were low.  However, the 
addition of 100 nM zinc to buffers, ensuring that the concentration of zinc is in the 
potentiating range, led to a significant reduction in the ethanol, isoflurane, and toluene 
potentiation of taurine-activated GlyR responses (Figs. 4.3B, 4.5A, 4.B).  This finding 
cannot be explained by simple competition between modulators as zinc is not believed to 
bind the receptor at the same locations as alcohols, anesthetics, and inhalants (Beckstead 
et al., 2000; Laube et al., 2000; Lynch et al., 1998; Mihic et al., 1997; Yamakura et al., 
1999).  However, zinc does increase the Po of the taurine-activated GlyR (Laube et al., 
2000), in effect mimicking the glycine-bound GlyR.  When this occurs and the GlyR Po 
approaches 1 any other positive modulator present will as a result produce decreased 
percent enhancement compared to when less zinc is present.	

Since the α2 subunit appears to be expressed at higher levels than α1 in higher 
brain regions (Jonsson et al., 2012) we studied ethanol/zinc interactions on a variety of 
different GlyR subtypes activated by taurine vs. glycine (Figs. 4.3B, 4.4A–C).  The α2-
containing receptors were previously shown to be less sensitive to ethanol (Mascia et al., 
1996a), and zinc (Miller et al., 2005), than those that contain α1 subunits and this was 
also reflected in our experiments using a maximally-effective concentration of taurine. 
We performed these experiments in the absence and presence of the β subunit which 
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anchors the GlyR to gephyrin in the synapse (Kirsch and Betz, 1995).  Badanich et al. 
(2013) found that in the orbitofrontal cortex, where α2-containing GlyR are thought to 
predominate (Jonsson et al., 2012), there was no effect of the glycine receptor antagonist 
strychnine on neuronal holding current, but strychnine did antagonize ethanol-induced 
changes in holding current and spike firing.  The most parsimonious explanation for these 
findings is that there are insufficient extracellular glycine or taurine concentrations to 
significantly affect holding current, unless ethanol is present.  It is reasonable to 
hypothesize that ethanol promotes the release of glycine or taurine and it may also then 
enhance the effects of these compounds on the GlyR, although the Badanich et al. (2013) 
study does not address the relative importance of each phenomenon.  If taurine is the 
responsible agonist then our findings raise two possible complicating issues.  First, like 
Shmieden et al. (1992), we found that, relative to glycine, taurine has very low efficacy 
on α2-containing GlyR, much lower than its efficacy on α1-containing GlyR.  Even at 
saturating concentrations, taurine could at best have only modest effects on α2 GlyR 
function.  The next issue is that ethanol weakly enhances taurine-mediated currents in α2 
and α2β GlyR.  These findings are difficult to reconcile with the possibility that the 
effects seen in the Badanich et al. (2013) study are mediated by taurine on α2-containing 
receptors in the orbitofrontal cortex.  Further studies addressing these issues are 
warranted.	

In summary, low concentrations of zinc potentiated GlyR responses from 
maximally-effective concentrations of taurine but not glycine.  Chelation of zinc reduced 
GlyR responses produced by maximally-effective concentration of taurine but not 
glycine, and thus any experiments conducted in the absence of zinc chelation will tend to 
overestimate taurine efficacy.  This would also be true when sub-maximal glycine 
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concentrations are used.  At the low concentrations tested, zinc decreased the enhancing 
effect of taurine-mediated responses for all drugs of abuse tested when applied in 
combination with them.  As taurine is likely to be an endogenous GlyR ligand in brain 
regions affected by these compounds, the presence of low concentrations of zinc in these 
regions results in GlyR responses that are not the result of a simple summation of 
responses to single modulators, and this needs to be taken into consideration when 
investigating the role of the GlyR in vivo.  It is highly likely that previously published 
studies of this receptor have in reality been studying the zinc-modulated GlyR.  To truly 
understand how allosteric modulators act at the GlyR one must examine their actions in 
the context of the physiological milieu at the receptor, reflecting in vivo conditions, as 






5.0 | SINGLE CHANNEL ANALYSIS OF ETHANOL AND 







Glycine receptors (GlyR) are responsible for the majority of inhibitory 
neurotransmitter in the brainstem and spinal cord, but are also found in higher brain 
regions such as the hippocampus, nucleus accumbens (NAcc), and prefrontal cortex (van 
den Pol and Gorcs, 1988; Malosio et al., 1991; Lynch, 2004; Waldvogel et al., 2007; Baer 
et al., 2009; Jonsson et al., 2009, 2012; Lu and Ye, 2011).  GlyRs are a member of the 
cys-loop ligand gated ion channel superfamily, and are comprised of a pentameric 
arrangement of subunits that form a central anion-conducting pore.  Many different 
compounds can modulate GlyR functioning, including alcohols, volatile anesthetics, and 
more (Lynch, 2004; Yevenes and Zeilhofer, 2011).  Some of the behavioral effects of 
these compounds have been shown to be mediated by GlyR, as would be expected given 
GlyR expression in the regions important for these effects (Yamashita et al., 2001; 
Molander et al., 2005, 2007; Badanich et al., 2013).	

Alcohols and volatile anesthetics enhance GlyR-mediated currents in a 
concentration dependent manner (Mascia et al., 1996a, 1996b).  At the whole cell level, 
this results in left shifts of the concentration response curve with no effect on currents 
generated by maximally-effective concentrations of glycine (Welsh et al., 2010; Kirson et 
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al., 2012).  At the single channel level, ethanol enhancement of GlyR-mediated currents 
results from ethanol decreasing glycine unbinding rates with no change to open 
probability (Po), thus simply increasing durations of burst activity (Eggers and Berger, 
2004; Welsh et al., 2009).	

The sulfonic acid taurine acts as a partial agonist of the GlyR, having ~50% the 
efficacy seen at activating the channel compared to glycine (Lape et al., 2008).  However, 
taurine is the second most abundant amino acid in the brain, and taurine release has been 
found to activate GlyR (Dahchour et al., 1996; Mori et al., 2002; Albrecht and 
Schousboe, 2005; Ericson et al., 2006; Choe et al., 2012).  GlyRs have been implicated in 
mediating the effects of multiple drugs of abuse, and interestingly, taurine-mediated GlyR 
activation has been found to play a role in the rewarding effects of ethanol (Molander et 
al., 2005, 2007; Ericson et al., 2011; Jonsson et al., 2014).  Unlike glycine-mediated 
GlyR currents, taurine-mediated GlyR currents are enhanced at maximally-effective 
concentrations of taurine, at the whole cell level, by many different modulators (Kirson et 
al., 2012, 2013).  However, little research has been done into the effects of ethanol and 
other drugs of abuse on the taurine-activated GlyR at the single channel level.  	

Here we report on studies conducted on human α1 homomeric GlyR expressed in 
Xenopus oocytes, investigating various single channel parameters for modulation of 
taurine-mediated GlyR activation by ethanol and the volatile anesthetic isoflurane.  We 
examined channel conductance, open dwell times, and closed dwell times, determining 
that ethanol and isoflurane enhance taurine-activated GlyR by stabilizing the open state, 





5.2 – Materials and Methods	

!
Isolation, injection, and patch clamp electrophysiology of Xenopus oocytes were 
described in Chapter 2.  Specific methods pertaining to the experiments in this chapter are 
outlined below.	

Outside-out patches were pulled from the animal pole of Xenopus oocytes 
expressing α1 homomeric WT GlyRs.  Prior to recording, the oocyte was placed in a 
high-osmolarity stripping solution to aid in manual removal of the vitelline membrane 
using forceps.  Patch pipettes were pulled from thick-walled borosilicate glass (WPI, 
Sarasota, FL) using a P-97 Flaming/Brown Micropipette Puller (Sutter Instruments). 
Pipettes were coated with wax or with Sylgard 184 (Dow Corning, Midland, MI) just 
above the tips and fire-polished with an MF-830 Microforge (Narishige, Japan) to obtain 
a smooth tip with resistances of 5 to 15 MΩ.  Outside-out patches were held at –80 mV, 
and recordings were made according to standard methods (Hamill et al., 1981) using an 
Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA).  Data was digitized at 50 
kHz with a Digidata 1322A (Molecular Devices), low-pass filtered at 5 kHz, and recorded 
on a PC hard drive using pClamp 9 software (Molecular Devices).  Taurine and drug 
solutions were prepared in external solution + 2.5 mM tricine (to chelate free zinc) before 
being perfused over outside-out patches using an SF-77B Perfusion Fast Step apparatus 
(Warner Instruments, Hamden, CT). 	

Data were analyzed using the single channel analysis programs in QUB (Qin et 
al., 2000a, 2000b); version 1.5.0.0 was used for preprocessing, open/closed dwell time 
analysis, and kinetic modeling.  Tracings were first baseline-corrected and clusters were 
selected by eye that only had one channel present.  These clusters were idealized using 
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the segmental-k-means (SKM) algorithm (Qin et al., 2000a, 2000b).  Data were initially 
idealized with a simple two-state C ↔ O model.  Multiple exponentials were 
subsequently fit and added sequentially to form a star model (closed state as the center) 
using the maximum interval likelihood (MIL) method after imposing a deadtime 
resolution of 60 μS.  When this model was complete, as determined by log likelihood, the 
data were re-idealized and used for dwell time analyses.  Dwell time distributions were 
constructed using a log time x-axis and a square-root count/total y-axis, and fit with a 
mixture of exponentials components using the MIL function.  Clusters were defined as 
being separated by closed-time durations equal to or longer than 10 ms, based on 
previously determined τcrit values (Welsh et al., 2009).  Po values were determined using 
Equation 2.4.  Statistical analyses were performed using SigmaPlot version 11.0 (Systat 






5.3.1 – ETHANOL AND ISOFLURANE DO NOT AFFECT TAURINE-ACTIVATED GLYR 
SINGLE CHANNEL CONDUCTANCE	
!
Single channel experiments were conducted on outside-out patches pulled from 
Xenopus oocytes expressing the human homomeric α1 GlyR.  Patches were exposed to 
200 mM ethanol or 0.55 mM isoflurane co-applied with 100 mM taurine and compared to 
patches exposed to 100 mM taurine alone.  This saturating concentration of taurine was 
chosen to maximize channel opening (Lape et al., 2008) and appropriately examine the 
effects of these modulators on this partial agonist.  100 mM taurine alone or in 
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combination with one of the modulators produced clearly defined clusters of channel 
activity as seen in Fig. 5.1.  Conductance of taurine-activated GlyR was 89 ± 3.4 pS (n = 
5), and although decreased slightly in the presence of modulator, conductance was not 
significantly affected by ethanol [t(11) = 2.00, p > 0.05] or isoflurane [t(8) = 2.30, p ≥ 





Figure 5.1 – Sample tracings of taurine-activated GlyR alone and with ethanol or 
isoflurane	

Representative tracings show ~2 s of single channel homomeric α1 GlyR 
responses to 100 mM taurine (A), 100 mM taurine + 200 mM EtOH (B), or 100 
mM taurine + 0.55 mM isoflurane (C). The red line above each top trace denotes 






Figure 5.2 – Ethanol and isoflurane do not affect taurine-activated GlyR 
conductance	

Conductance level (pS) is graphed for each condition. Taurine-activated GlyR 
conductance was 89 ± 3.4 pS as seen in the white bar. Ethanol (light grey bar) and 
isoflurane (dark grey bar) slightly decreased conductance to 78 ± 3.8 pS and 80 ± 
2.3 pS respectively, though these decreases were not significant. Data are shown 
as mean + SEM of 5–8 patches.  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5.3.2 – ETHANOL AND ISOFLURANE INCREASE TAURINE-ACTIVATED GLYR MEAN OPEN 
TIME WITHOUT AFFECTING MEAN CLOSED TIME	
!
When saturating taurine is applied alone, GlyR exhibit a mean open time of 0.90 
± 0.10 ms (n = 5).  When co-applied with ethanol or isoflurane, mean open time is 
significantly increased to 1.46 ± 0.14 ms [t(11) = 2.86, p < 0.05] and 2.80 ± 0.78 ms [t(8) 
= 2.43, p < 0.05] respectively (Fig. 5.3A).  However, neither ethanol nor isoflurane 
significantly affected mean closed time of taurine-activated GlyR [ethanol: t(11) = 1.03, p 
> 0.30; isoflurane: t(8) = 1.53, p > 0.15].  Although mean closed time of taurine-activated 
GlyR (0.60 ± 0.20 ms) was decreased by both ethanol (0.41 ± 0.08 ms) and isoflurane 





Figure 5.3 – Ethanol and isoflurane significantly increase mean open time of taurine-
activated GlyR	

A) Summary graph showing effects of ethanol (light grey bar) and isoflurane 
(dark grey bar) on mean open time of the taurine activated GlyR. Both modulators 
significantly increased mean open time of channels. B) Summary graph showing 
effects of ethanol (light grey bar) and isoflurane (dark grey bar) on mean closed 
time of the taurine activated GlyR. Neither modulator had a significant effect on 






5.3.3 – ETHANOL AND ISOFLURANE INCREASE THE LIKELIHOOD OF THE SECOND 
LONGEST OPEN TIME	
!
Open dwell time data are adequately described using three exponential 
components for all conditions.  Sample open dwell-time histograms from individual 
patches are shown in Fig. 5.4A for all three experimental conditions.  A two-way 
ANOVA revealed each open lifetime is significantly different amongst the three 
components (τs) [F(2,38) = 31.8, p < 0.001] as expected.  A Bonferroni post-hoc test 
found neither modulator affected the average durations of the first two open dwell-times, 
while the longest lived open dwell-time was changed with ethanol and isoflurane [t(11) = 
5.06, p < 0.001; t(8) = 3.11, p < 0.01; respectively].  However, this difference was largely 
due to the error in the taurine alone data.  The third open dwell-time could not be fit for 
all patches.  Addition of modulator increased the prevalence of the third open dwell-time 
from 20% of taurine patches to 63% and 80% of ethanol and isoflurane patches 
respectively.  Both ethanol  (68.5 ± 5.8%) and isoflurane (68.7 ± 4.0%) significantly 
increased the likelihood of the second longest lived open time [Two-way ANOVA with 
Bonferroni post-hoc: t(11) = 4.37, p < 0.001; t(8) = 3.95, p < 0.001; respectively] from 
taurine (32.3 ± 6.9%), while significantly decreasing the likelihood (ethanol, 25.0 ± 7.0%; 
isoflurane, 20.9 ± 4.8%) of the shortest lived open time [t(11) = 5.01, p < 0.001; t(8) = 
4.96, p < 0.001; respectively] when compared to taurine alone (66.6 ± 7.2%).  Both 
modulators also increased the likelihood of the longest lived open time (ethanol, 6.5 ± 
3.2%; isoflurane, 10.5 ± 4.8%) compared to taurine alone (1.2 ± 1.1%), but these 






Figure 5.4 – Ethanol and isoflurane increase the likelihood of the second longest 
open time	

A) Representative histograms demonstrating the fits for the open dwell-times. 
Each condition was fit using three open time components (τs). In each graph, the 
thinner lines describe the individual dwell-time exponential functions and the 
thicker line is a fit of the total data. The red line denotes 1 ms for visual aid of 
differences of fit. B) Neither modulator affected average duration of open dwell-
times. C) Both ethanol and isoflurane increase the likelihood of the second longest 
open time while decreasing the likelihood of the shortest lived open time. Data are 





5.3.3 – ETHANOL AND ISOFLURANE HAVE NO EFFECT ON CHANNEL INTRACLUSTER 
CLOSED DWELL-TIME COMPONENTS	
!
Intracluster closed dwell-times are adequately fit by three exponential components 
(τs) in all conditions tested.  Sample closed dwell-time histograms for all conditions can 
be seen in Fig. 5.5A.  Again as expected, there was a significant difference in the duration 
of the three closed dwell-time components [F(2,42) = 91.8, p < 0.001].  Neither ethanol 
nor isoflurane affected the duration of the closed times [F(2,42) = 0.24, p > 0.75] (Fig. 






Figure 5.5 – Ethanol and isoflurane have no effect on closed dwell-time components	

A) Representative histograms demonstrating the fits for the closed dwell-times. 
Each condition was fit using three closed time components (τs). In each graph, the 
thinner lines describe the individual dwell-time exponential functions and the 
thicker line is a fit of the total data. The red line denotes 1 ms for visual aid of fits. 
B) Neither modulator affected average duration of closed dwell-times. C) Neither 
modulator affected likelihood of the closed time components. Data are shown as 





5.3.3 – ETHANOL AND ISOFLURANE INCREASE INTRACLUSTER PO	
!
Ethanol and isoflurane increased mean open time by increasing the likelihood of 
longer lived open time components (Fig. 5.3, 5.4).  However, neither modulator tested 
had any effects on closed time components (Fig. 5.5).  Thus, when intracluster open 
probability (Po) was calculated as a ratio of open time to total cluster time, both ethanol 
(0.78 ± 0.03) and isoflurane (0.89 ± 0.02) significantly increased Po [ethanol: t(11) = 2.37, 
p < 0.05; isoflurane: t(8) = 4.098, p < 0.01] compared to the taurine-activated GlyR Po 
(0.63 ± 0.06).  This increase can be seen in Fig. 5.6 below.  These increases in Po 
correspond to taurine efficacies (E) of 3.55 for ethanol and 8.09 for isoflurane, increased 





Figure 5.6 – Ethanol and isoflurane increase taurine-activated GlyR Po	

Intracluster Po is shown for 100 mM taurine alone (white bar), and with ethanol 
(light grey bar) or isoflurane (dark grey bar).  Both ethanol and isoflurane 







Ethanol and volatile anesthetics act as nervous system depressants and produce a 
variety of behavioral effects including memory loss, loss of consciousness at high 
concentrations, and have reinforcing properties through modulation of the mesolimbic 
dopamine system believed to be responsible for reward.  In many of the brain areas 
responsible for these behavioral effects, functional GlyR have been found (Yamashita et 
al., 2001; Molander et al., 2005, 2007; Badanich et al., 2013) and taurine may act as an 
endogenous ligand for these GlyR (Dahchour et al., 1996; Mori et al., 2002; Ericson et 
al., 2006, 2011; Choe et al., 2012).  Thus, here we have examined the effects of two of 
these compounds, ethanol and isoflurane, on the single channel properties of the GlyR 
when activated by taurine instead of glycine.	

We have previously shown that allosteric modulators have differential effects on 
GlyR responses when activated by different agonists (Kirson et al., 2012, 2013). 
However, in these whole cell experiments we were only able to suggest the effects of 
these compounds at the single channel level.  Here we have performed these single 
channel experiments and find that both ethanol and isoflurane increase GlyR open state 
likelihoods when activated by taurine, consistent with our previous data.  Although the 
longest lived open state appeared to differ with modulator present, this is due to the low 
occurrence of this open time in the taurine alone condition.  Interestingly, both of the 
modulators tested increased the occurrence of this longer lived state, in agreement with 
the rest of the data suggesting a stabilization of longer lived open times.  This again 
shows differences in allosteric modulator effects on GlyR that are agonist dependent.  In 
single channel investigations into the effects of ethanol on the glycine-activated GlyR, no 
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changes to open times were seen.  Ethanol exerted its potentiating effects of GlyR 
currents by decreasing the rate of glycine unbinding (Eggers and Berger, 2004; Welsh et 
al., 2009).  Thus, at the single channel level, ethanol enhancement of GlyR functioning is 
dependent on which agonist activates it.  Interestingly, while the mechanism with which 
ethanol and isoflurane increase taurine activated GlyR open states is similar, the degree to 
which these changes occur is consistent with isoflurane being a more potent modulator at 
the whole cell level (Kirson et al., 2012).  	

It is worth considering the possible effects of isoflurane on glycine-gated GlyR at 
the single channel level.  As this modulator has no effects on currents generated by 
maximally-effective concentrations of glycine (Kirson et al., 2012), it is likely isoflurane 
would not stabilize GlyR open states at saturating concentrations, as glycine already 
displays a very high Po.  However, at sub-maximal concentrations of glycine, where there 
is no ceiling effect of Po, isoflurane does appear able to increase mean open time and Po 
(Roberts, 2005).  Then, are effects of these compounds at high concentrations of taurine 
important?  	

In examining the nature of partial agonism on the GlyR, Lape et al., (2008) 
examined both glycine- and taurine-activated GlyR at the single channel level with 
varying concentrations of agonist.  Interestingly, when their data was fit to a kinetic 
mechanism, they found states corresponding to three bindings of agonist, be it glycine or 
taurine.  However, taurine-mediated GlyR openings were rare at low concentrations, 
leading to a fit of only gating constants with at least two taurine bound.  In fact, the rate 
constants found for transitions to the open state when only two taurine are bound were 
low while rates governing the transition to the closed state were exceptionally high (Lape 
et al., 2008).  Thus, at any concentration of taurine where two molecules are bound to the 
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GlyR, it is far more likely another taurine will bind before the channel can open. 
Therefore, where the taurine-activated GlyR is concerned, only saturating concentrations 
of agonist are useful in studying to ensure channel opening.  Glycine-activated GlyR can 
still open with only a single glycine bound, thus modulator effects are more difficult to 
interpret when comparing between glycine and taurine.  For example, at a whole cell 
level, low concentrations of glycine elicit currents generated by an amalgam of GlyR 
occupied by one or more glycine molecules, while currents generated by taurine are 
likely exclusively from a subpopulation of fully occupied GlyR (at least three taurines 
bound).  Additionally in vivo measured release of taurine can increase the extracellular 
concentration tenfold; at synaptic or perisynaptic regions, this can result in saturating 
concentrations of taurine at GlyR (Albrecht and Schousboe, 2005; Scimemi and Beato, 
2009).  As we used only saturating concentrations of taurine, we did not attempt to fit the 
data to one of the currently accepted kinetic models of GlyR activation, as we have 
eliminated any affinity rate constant consideration.  Instead we desired to examine the 
effects of these compounds on a descriptive model of the data only.	

In summary, we have investigated the effects of ethanol and isoflurane on the 
saturating taurine-activated GlyR at the single channel level, and found both modulators 
increase taurine efficacy at opening the GlyR.  Additionally, these effects are distinct 
from effects on glycine-activated GlyR at the concentrations of agonist likely to be seen 
in vivo.  As more evidence accumulates for the physiological role of the taurine-activated 
GlyR, utilizing the nature of differential GlyR modulation when taurine is the agonist will 





6.0 | DISRUPTION OF AN INTERSUBUNIT ELECTROSTATIC 






The glycine receptor (GlyR) is an anion conducting member of the cys-loop 
receptor superfamily of ligand-gated ion channels (LGICs).  The GlyR is composed of a 
pentameric arrangement of subunits around the ion conducting pore.  Each subunit 
contains a large extracellular domain, four transmembrane domains (TM), and a large 
intracellular domain between TM3 and TM4.  In the pentameric arrangement, TM2 of 
each subunit lines the pore.  The ligand-binding domain lies in between extracellular 
domains of adjacent subunits, and is comprised of loops from each side of the interface 
(Lynch, 2004; Grudzinska et al., 2005).  Ligand binding causes a conformational change 
that allows loops from the extracellular domain to contact the TM regions and cause 
opening of the channel (Langosch et al., 1994; Rajendra et al., 1995; Lynch et al., 1997; 
Lynch, 2004; Lee and Sine, 2005).  Analysis of the contribution of individual residues to 
the gating reaction in the related nicotinic acetylcholine receptor (nAChR), revealed that 
groupings of residues of this channel move in concert, in a conformational wave of 
activity from agonist binding to gating of the pore (Purohit et al., 2007).	

GlyR can also be activated by the endogenous sulfonic acid taurine, which may be 
the endogenous ligand for extrasynaptic GlyR in some brain areas (Mori et al., 2002). 
Taurine acts as a partial agonist at the GlyR, having a decreased maximum response to 
taurine when compared to glycine (Schmieden et al., 1992; McCool and Botting, 2000; 
Lape et al., 2008; Welsh et al., 2010; Kirson et al., 2012).  A recent study examining the 
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single channel characteristics of the α1β GlyR found that taurine was less efficacious at 
transitioning the receptor from a bound closed state to an intermediate closed state prior 
to the final gating step (Lape et al., 2008).  Taurine reduction in transitioning to this 
“fllipped” state results in taurine having an efficacy of opening the channel that is ~50% 
that of glycine.  This kinetic model places the root of partial agonism earlier than the final 
gating step and when considered in combination with the Φ-analysis of the 
conformational wave of activity from binding to gating (Purohit et al., 2007), this 
suggests that partial agonist efficacy may be determined early after ligand binding.	

Previously we identified a charged residue, D97 in the α1 homomeric GlyR, 
pointing into the intersubunit interface (from the principal subunit) that is highly 
conserved throughout the cys-loop receptor superfamily (Beckstead et al., 2002).  A 
charge swap mutation at this residue (D97R) results in a channel that can sporadically 
spontaneously open (Beckstead et al., 2002).  Single channel characterization of the 
D97R mutant found that clusters of spontaneous activity had an open probability (Po) of 
0.91, almost identical to the Po of 0.90 for glycine on wild type GlyR and the Po of 0.96 
for glycine on homomeric GlyR (Lape et al., 2008; Todorovic et al., 2010).  We recently 
found that taurine-activated D97R clusters have a Po of 0.98, transforming taurine from a 
partial agonist to one with high efficacy (Welsh et al., In prep).  We previously found that 
spontaneous activity in this mutant is due to disruption of an intersubunit electrostatic 
bond with residue R119 on the adjacent (complementary) subunit, proposed to aid in 
keeping the receptor in the closed state (Todorovic et al., 2010).  A double charge reversal 
mutation of these residues (D97R/R119E) repaired this electrostatic interaction and 
resulted in decreased spontaneous activity  (Todorovic et al., 2010).  However, this 
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R119E mutation greatly right shifted concentration response curves, leading us to 
question whether the R119 residue was the true bond partner for the D97 residue.	

On the basis of updated computer models of the GlyR extracellular domain 
(Trudell J, personal communication with Mihic SJ), we identified a residue, R131, in the 
intersubunit interface as a possible alternate binding partner for D97.  Thus, we 
investigated a charge reversal mutation of this residue, R131D, at the whole cell and 
single channel levels, under the hypothesis that a mutation to this residue would result in 
spontaneous activity of GlyR, and that taurine would have an increased efficacy on this 





6.2 – Materials and Methods	

!
Isolation, injection, and patch clamp electrophysiology of Xenopus oocytes were 
described in Chapter 2.  Specific methods pertaining to the experiments in this chapter are 
outlined below.	

All chemicals were purchased from Sigma-Aldrich (St. Louis, MO). Xenopus 
laevis were obtained from Nasco (Fort Atkinson, WI) and housed at 19°C on a 12-h light/
dark cycle.  Portions of ovaries were removed and placed in isolation media.  Forceps 
were used to manually remove the thecal and epithelial layers from stage V and VI 
oocytes.  The oocyte follicular layer was removed using a 10 min incubation in 0.5 mg/
ml type 1A collagenase (Sigma-Aldrich) solution.  Animal poles of oocytes were injected 
with 30 nl of the wild type (WT) or mutant glycine α1-receptor subunit cDNA (1.5 ng/30 
nl) in a modified pBK-cytomegalovirus vector (Mihic et al., 1997) by the “blind” method 
of Colman (1984), using a micropipette (10–15 μm tip size) attached to an electronically 
activated microdispenser.  Oocytes were stored in the dark at 19°C in 96-well plates 
containing incubation media.  Oocytes expressed the wild-type, R131D, and D97R/
R131D GlyR within 24 h, and all electrophysiological measurements were made within 5 
days of cDNA injection.	

For whole cell recordings, oocytes were impaled in the animal pole with two 
high-resistance (0.5–10 MΩ) glass electrodes filled with 3 M KCl.  Cells were voltage 
clamped at –70 mV using an OC-725C oocyte clamp (Warner Instruments, Hamden, CT) 
and perfused with MBS at a rate of 2 ml/min using a Masterflex USA peristaltic pump 
(Cole Parmer Instrument Co., Vernon Hills, IL) through 18-gauge polyethylene tubing. 
All drug solutions were prepared in MBS.  Applications lasted for 15–60 s followed by 6 
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to 10 min washout periods to allow for complete receptor resensitization.  Currents were 
acquired using either a Powerlab 4/30 digitizer with LabChart version 7 software 
(ADInstruments, Bella Vista, NSW, Australia).  Peak currents were measured and used in 
data analysis.	

Outside-out patches were pulled from the animal pole of Xenopus oocytes 
expressing WT, R131D, or D97R/R131D α1 homomeric WT GlyRs.  Prior to recording, 
the oocyte was placed in a high-osmolarity stripping solution to aid in manual removal of 
the vitelline membrane using forceps.  Patch pipettes were pulled from thick-walled 
borosilicate glass (WPI, Sarasota, FL) using a P-97 Flaming/Brown Micropipette Puller 
(Sutter Instruments).  Pipettes were coated with wax or with Sylgard 184 (Dow Corning, 
Midland, MI) just above the tips and fire-polished with an MF-830 Microforge 
(Narishige, Japan) to obtain a smooth tip with resistances of 5 to 15 MΩ.  Outside-out 
patches were held at –80 mV, and recordings were made according to standard methods 
(Hamill et al., 1981) using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, 
CA).  Data was digitized at 50 kHz with a Digidata 1322A (Molecular Devices), low-pass 
filtered at 5 kHz, and recorded on a PC hard drive using pClamp 9 software (Molecular 
Devices).  Taurine solutions were prepared in external solution + 2.5 mM tricine (to 
chelate free zinc) before being perfused over outside-out patches using an SF-77B 
Perfusion Fast Step apparatus (Warner Instruments, Hamden, CT). 	

Data were analyzed using the single channel analysis programs in QUB (Qin et 
al., 2000a, 2000b); version 1.5.0.0 was used for preprocessing, and open probability 
determination.  Tracings were first baseline-corrected and clusters were selected by eye 
that only had one channel present.  These clusters were idealized using the segmental-k-
means (SKM) algorithm (Qin et al., 2000a, 2000b).  Data were idealized with a simple 
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two-state C ↔ O model.  Multiple exponentials were subsequently fit and added 
sequentially to form a star model (closed state as the center) using the maximum interval 
likelihood (MIL) method after imposing a deadtime resolution of 60 μS.  When this 
model was complete, as determined by log likelihood, the data were re-idealized and used 
for dwell time analyses.  Dwell time distributions were constructed using a log time x-
axis and a square-root count/total y-axis, and fit with a mixture of exponentials 
components using the MIL function.  Clusters were defined as being separated by closed-
time durations equal to or longer than 10 ms, based on previously determined τcrit values 
(Welsh et al., 2009).  Po values were determined using Equation 2.4.	

A homology model of GlyR α1 was built by threading the GlyR primary sequence 
onto an x-ray crystal structure template using the Modeler module of Discovery Studio 
(Todorovic et al., 2010). The template we used was the prokaryotic ligand-gated ion 









6.3.1 – R131D GLYR MUTATION INCREASES TAURINE EFFICACY	
!
The putative location of the R131 residue in relation to D97 and the previously 
studied R119 can be seen in Fig. 6.1.  We have previously verified proximity of these 
residues using cysteine substitutions at these residues to form disulfide bonds (Todorovic, 
2010).  Varying concentrations of glycine and taurine were assayed on homomeric 
R131D α1 GlyR and used to generate concentration-response curves, as seen in Fig. 6.2. 
Unlike the R119E mutant receptor, R131D GlyR have a glycine concentration-response 
curve similar to that of WT receptors (Welsh et al., 2010; Kirson et al., 2012), with an 
EC50 for glycine of 0.35 ± 0.08 mM and a Hill coefficient, nH of 1.43 ± 0.42.  While 
taurine responses could not be fit with a concentration response curve, the graph does 
show that taurine responses are somewhat right shifted from glycine responses with 






Figure 6.1 – Homology model of the α1 GlyR intersubunit interface	

A) A homology model of GlyR was built as described in chapter 6.2. Here two of 
the five subunits of the homopentamer are shown (side view) with a ribbon 
structure to highlight the intersubunit interface where R131 is located in 
proximity to D97 and R119. The (+) and (−) interfaces of adjacent subunits are 
colored purple and green respectively.  Amino acids D97, R131, and R119 have 
colored backbones of red, green, and blue respectively. Nitrogen atoms are 
depicted in light blue, oxygen in red, carbon in gray, and hydrogen in white. B) 





Figure 6.2 – R131D GlyR do not affect glycine currents while increasing taurine 
peak currents	

Open symbols represent glycine-mediated responses, and filled symbols show 
taurine-mediated responses.  Line is a logistic fit to the glycine set of data.  
Glycine activation of the GlyR produced an EC50 of 0.35 mM with a Hill 
coefficient (nH) of 1.43. Data are shown as mean ± SEM of 3–8 oocytes.  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6.3.2 – D97R/R131D GLYR MUTATION INCREASES TAURINE EFFICACY	
!
We next investigated the double mutant D97R/R131D GlyR.  With this double 
mutation, the putative intersubunit electrostatic bond is repaired, which we hypothesized 
would decrease spontaneous activity and, unlike the D97R/R119E mutant, would retain 
normal glycine response behavior.  We again generated concentration response curves for 
varying concentrations of both glycine and taurine as seen in Fig. 6.3.  Again, similar to 
the R131D single mutant, the glycine concentration response curve were very similar to 
WT GlyR with an EC50 of 0.25 ± 0.05 mM and an nH of 1.42 ± 0.39.  The taurine 
concentration response curve had an EC50 of 1.59 ± 0.20 mM and an nH of 0.91 ± 0.11. 
This EC50 is again close to previously determined taurine EC50 on WT GlyR (Welsh et al., 
2010; Kirson et al., 2012), though the Hill coefficient is slightly decreased, indicating a 
modest loss of cooperatively of taurine binding.  Again, as with the single R131D mutant, 






Figure 6.3 – D97R/R131D GlyR do not affect glycine currents while increasing 
taurine peak currents	

Open symbols represent glycine-mediated responses, and filled symbols show 
taurine-mediated responses.  Lines are a logistic fit to the glycine (solid) and 
taurine (dashed) sets of data.  Glycine activation of the GlyR produced an EC50 of 
0.25 mM with a Hill coefficient (nH) of 1.42. Taurine activation of the GlyR 
produced an EC50 of 1.59 mM with a Hill coefficient (nH) of 0.91.  Data are 
shown as mean ± SEM of 3–9 oocytes.  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6.3.3 – R131D AND D97R/R131D GLYR SINGLE CHANNEL CHARACTERIZATION	
!
Outside out patches were pulled from Xenopus oocytes expressing either the 
R131D or D97R/R131D GlyR and exposed to 100 mM taurine.  To date, clusters from 
only a single patch for each mutant have been obtained and analyzed, thus the following 
characterization will describe each patch as an example for the two mutants.  An example 
tracing for each mutant activated by 100 mM taurine can be seen in Fig. 6.4 below.	

Recordings from both mutants were obtained first in the presence of no agonist, 
with only external solution being applied to the patch, in order to determine spontaneous 
activity of these mutants.  We have previously examined spontaneous activity of these 
mutants on the whole cell level, noting that holding currents for R131D GlyR expressing 
oocytes are larger than for WT GlyR expressing oocytes or uninjected oocytes 
(Todorovic, 2010).  However, for both the R131D and D97R/R131D patches, no 
spontaneous cluster activity was seen in the absence of agonist.	

For both R131D and D97R/R131D mutant GlyR, taurine-activated clusters were 
long lived, with short and sparse closings (Fig. 6.4).  Mean open times were 115.44 ms 
for taurine-activated R131D GlyR and 141.92 ms for taurine-activated D97R/R131D 
GlyR.  Mean closed times were 0.27 ms for R131D GlyR and 0.34 ms for D97R/R131D. 
Intracluster Po for taurine-activated R131D GlyR was 0.998 and was 0.997 for D97R/
R131D GlyR when activated by saturating taurine.  These long open times for these high 
Po clusters resulted in very few closing events that made dwell time analyses unreliable, 
thus these analyses were not conducted.  Equation 1.4 would then give efficacy values (E) 






Figure 6.4 – Sample tracings of taurine-activated R131D and D97R/R131D GlyR	

Representative tracings show ~12–15 s of single channel responses to 100 mM 
taurine for homomeric R131D α1 GlyR (A), and homomeric D97R/R131D α1 
GlyR (B). The red line above each top trace denotes the ~1 s expanded view seen 





6.3.4 – TAURINE RELATIVE EFFICACY TO GLYCINE IS DIRECTLY AFFECTED BY 
TEMPERATURE	
!
Disruption of the closed conformation electrostatic bond between D97 and R131 
enhances taurine efficacy.  We therefore reasoned that taurine partial agonism may result 
from a decreased ability to break this bond relative to glycine.  Thus, we hypothesized 
that any experimental modification that weakens this interaction would enhance taurine’s 
ability to break this bond, and increase taurine efficacy relative to glycine.  Thus we 
examined the effects of taurine and glycine activation of the GlyR in a variety of 
temperatures.  Fig. 6.5A shows the effects of recording whole-cell currents in oocytes at 
temperatures ranging from 10 – 30°C using saturating concentrations of glycine or 
taurine.  Absolute glycine currents in WT GlyR were minimally affected by temperature 
(38.2 ± 7.9% potentiation, comparing 10°C with 30°C), but there was a significant [t(6) = 
3.75, p<0.01] increase seen in taurine’s ability to open the GlyR channels under warmer 
conditions (265.9 ± 60.3% potentiation).  Maximal taurine responses were normalized 
against maximal glycine responses at each temperature (Fig. 6.5B).  Taurine’s efficacy 
relative to glycine was clearly dependent on temperature, ranging from approximately 





Figure 6.5 – Dependence of taurine efficacy on temperature	

A) Absolute GlyR current responses to 100 mM taurine increase with 
temperature. Each symbol represents a different oocyte, with open symbols 
showing current response to 10 mM glycine and closed symbols showing current 
response to 100 mM taurine. B) Average responses to 100 mM taurine as a 
percentage of the response to 10 mM glycine increase with increasing 
temperature. Circles and the solid line show the results from a set of oocytes 
tested at 10°C, 20°C, and 30°C (n = 4 oocytes), while squares and the dashed line 









In this chapter we have shown that disruption of the putative electrostatic bond 
between residues D97 and R131 of the α1 GlyR increases taurine efficacy.  This finding 
is in agreement with our previous investigation of mutations at the D97R residue (Welsh 
et al., In prep).  This indicates that the intersubunit interface region where binding occurs 
may be an important determinant of agonist efficacy.  The case for an early determination 
of agonist efficacy would be in agreement with the findings from Lape et al. (2008) that 
place the mechanism of partial agonism in taurine’s reduced ability, relative to glycine, to 
cause a transition to an additional intermediate closed state.  Disruption of this 
electrostatic bond would essentially transition the GlyR to the “flipped” state, where 
glycine and taurine are similar in their efficacy at moving to the open state.  However, if 
disruption of the D97–R131 interaction results in the flipped state, then we would expect 
behavior of the R131D single mutant to parallel the behavior of the D97R single mutant. 
Unfortunately, unlike D97R, we do not see clear single channel open clusters in the 
absence of agonist for R131D single channel recordings.	

Interestingly, when this electrostatic bond is restored with the double mutation 
D97R/R131D, taurine retains high efficacy.  However, in both the R131D single mutant 
(disruption of bond) and the D97R/R131D double mutant (restored bond) glycine-
mediated responses at the whole cell level were essentially normal.  An implication of 
this finding is that disruption of the D97–R131 interaction is not indicative of the 
intermediate flipped state.  Restoration of the electrostatic interaction with the double 
mutant D97R/R131D would theoretically reduce taurine efficacy back to being a partial 
agonist.  Perhaps then, the conserved D97 residue is stabilized in the intersubunit 
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interface by multiple residues from the complementary subunit.  For example, R119 and 
R131 may both interact with D97 to hold the receptor in the closed state.  Mutation of 
D97 would disrupt all interactions, and result in spontaneous activity and increased 
efficacy of partial agonists.  Mutation of either R119 or R131 alone would only weaken 
the interactions, resulting in less spontaneous activity but increased efficacy of partial 
agonists.  Double mutations involving D97 and one of the binding partners would 
artificially create the conditions of a single mutation to one of the positively charged 
residues, with a functional bond to reduce spontaneous activity, but a disrupted 
interaction with the other binding partner resulting in increased partial agonist efficacy. 	

Another implication of this study is that the R131 residue is not directly involved 
in glycine binding as concentration response curves were not changed.  This finding is in 
stark contrast to mutations at the R119 residue, that greatly right shifted concentration 
response curves (Todorovic et al., 2010).  However, R131 may have some effect on 
taurine binding.  Efficacy for taurine on these mutants was extraordinarily high.  Based 
on equation 1.3, if taurine efficacy alone was increased, EC50 of the taurine concentration 
response curve would be expected to decrease.  To retain the same EC50 as seen for 
taurine-activation of the double mutant D97R/R131D, an appropriate increase in Kd 
would be necessary to balance the increase in E.  Interestingly, the nH was 
correspondingly decreased for taurine actions on this double mutant.  Thus the decrease 
in taurine affinity in this mutant may be due to a decreased cooperativity for additional 
taurine molecules to bind.	

Overall, the data presented here suggest that these charged residues in the 
intersubunit interface play a critical role not only in keeping the receptor in the closed 
state, but also in determining agonist efficacy.  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The collective knowledge regarding the structure and function of ion channels is 
continuously increasing both in scope and detail.  The research presented in this 
dissertation provides novel insight to both the activation and modulation mechanisms of 
the glycine receptor (GlyR).  The overall conclusions from these studies can be 
summarized in three main points.  First, allosteric modulators differentially affect the 
GlyR when activated by full vs. partial agonists, such as taurine.  Second, two example 
allosteric modulators, ethanol and isoflurane, enhance taurine-activated GlyR currents by 
increasing efficacy, thereby stabilizing the open state of the receptor.  Third, the 
disruption of a single electrostatic interaction near the ligand-binding region in the 
extracellular domain is sufficient to increase the efficacy of partial agonists, such as 
taurine, implicating this region for agonist efficacy determination.  Together these results 
increase our understanding of the relationship between GlyR activation and the 





7.2 – Allosteric Modulation of Partial Agonist Action on the GlyR	

!
Drugs of abuse, including alcohol, co-opt the natural brain reward system leading 
to addiction which can have large individual and societal implications.  The mesolimbic 
system, believed to be responsible for reward has been studied extensively, revealing the 
release of dopamine into the nucleus accumbens (NAcc) to be an important signal 
modulated by drugs of abuse.  Recently, evidence for GlyR involvement in this process 
has been found (Söderpalm and Ericson, 2013).  GlyRs are expressed in the nucleus 
accumbens (Waldvogel et al., 2007), likely by medium spiny neurons (MSNs) that project 
to the ventral tegmental area (VTA).  The MSNs are gabaergic, forming inhibitory 
synapses onto either the dopaminergic neurons of the VTA , that release dopamine into 
the NAcc, or cholinergic neurons that stimulate the dopaminergic VTA neurons.  Drugs of 
abuse that enhance GlyR functioning cause inhibition of the MSNs, resulting in a 
reduction of GABA release  into the VTA.  The neurons of the VTA, now released from 
inhibition by GABA, increase firing and subsequent release of dopamine into the NAcc 
(Söderpalm and Ericson, 2013).  	

This effect has been best characterized for ethanol enhancement of GlyRs in the 
NAcc (Molander et al., 2005, 2007).  However, one recent study has also found 
implications for GlyR involvement in cannabinoid and nicotine effects on dopamine 
release in the NAcc (Jonsson et al., 2014).  An ethanol-induced taurine release into the 
NAcc was found to be necessary for ethanol-induced dopamine release there, thus 
implicating the taurine-activated GlyR for ethanol’s effects on dopamine signaling 
(Ericson et al., 2011).  Interestingly, administration of both nicotine and cocaine result in 
a release of taurine in the NAcc (Kashkin and De Witte, 2005; Li et al., 2012).  Thus, the 
  	
150
taurine-activated GlyR may be of importance in regulating the rewarding effects of 
multiple drugs of abuse.  The data in this dissertation adds to the understanding of ethanol 
and other drug modulation of the taurine-activated GlyR, which had not been well 
characterized previously.	

The major finding in Chapter 3 was that alcohol, anesthetics, and inhalants 
enhance the efficacy of maximally-effective taurine concentrations, while having no 
effect on maximally-effective glycine concentrations.  Enhancement of sub-maximal 
glycine currents by ethanol, with a lack of enhancement seen at saturating glycine 
concentrations, had been established previously (Mascia et al., 1996a).  Interestingly, we 
previously found that ethanol enhancement of sub-maximal concentrations of glycine and 
taurine were similar (Welsh et al., 2010).  Taurine, as a partial agonist on GlyR, elicits 
currents whose maximal peak is much less than half the peak currents elicited by 
saturating glycine.  This difference in current peak is potential room in which an 
allosteric modulator might enhance taurine currents.  While we saw large potentiation of 
taurine responses at saturating concentrations, peak current levels of taurine + modulator 
were never able to match peak glycine current levels.  The discrepancy between these 
levels warrants further research.  Though higher concentrations of a very potent drug like 
one of the anesthetics may have been able to do it, high concentrations of these 
compounds also run the risk of damaging oocyte integrity.	

Some research into the activation of the GlyR has implicated separate activation 
pathways for glycine and taurine, finding residues that when mutated seemed to convert 
taurine from a partial agonist into an antagonist (Lynch et al., 1997; Absalom et al., 
2003).  A separate pathway for taurine and glycine activation might explain differences in 
allosteric modulation.  Though mutations to the alcohol binding pocket altered glycine 
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and taurine modulation by alcohol, isoflurane and TCE in similar ways (Fig. 3.10), 
indicating identical pathways regarding allosteric modulation by these compounds.  Other 
allosteric modulators may work in similar fashion.  Laube et al. (2000) found that zinc, 
also had differential effects on taurine-activated GlyR compared to glycine-activated 
GlyR.  Zinc may have physiological implications in GlyR modulation as it is not only 
released from within some synaptic vesicles, but also present throughout the CNS at 
concentrations known to potentiate GlyR responses (Kay, 2004; Frederickson et al., 
2006a, 2006b).  Examination of the effects of zinc in combination with other allosteric 
modulators on taurine-activated GlyR was the focus of Chapter 4.	

Zinc is not only found at GlyR potentiating concentrations in the CNS, it is also 
found at these low levels as a contaminant throughout the environment, including all 
buffer solutions.  At the time of conducting the research in Chapter 4, the contaminating 
concentration of zinc in our buffers was unable to be exactly determined, though it was 
found to be in the potentiating range of the GlyR (McCracken et al., 2010).  Thus we 
used three buffers with different zinc concentrations to examine combinatorial effects 
with other allosteric modulators.  We found that zinc, like the drug of abuse modulators, 
enhanced maximally-effective taurine currents with no effect on saturating glycine 
currents.  Additionally, a potentiating concentration of zinc decreased further potentiation 
of maximally-effective taurine-mediated currents by ethanol, isoflurane, and toluene.	

This effect was best explained by a zinc-induced increase in taurine efficacy 
(Laube et al., 2000) masking some of the further efficacy increase seen with the drugs of 
abuse.  This data supports the idea that lack of allosteric modulation at saturating glycine 
concentrations is due simply to a ceiling effect for maximum generated currents.  The 
combinatorial zinc and drugs of abuse experiments also indicated that contaminating 
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levels of zinc in our buffers were low, as potentiation of taurine-activated GlyR by drugs 
of abuse was similar to potentiation seen when all zinc was chelated by tricine. 
Subsequent to this study, contaminating zinc concentrations in buffer were determined by 
inductively-coupled plasma mass spectrometry (ICP-MS) and found to be ~45 nM 
(Cornelison and Mihic, 2014).	

!




Ethanol is the most commonly used drug in society, but the biological 
mechanisms underlying the behavioral changes seen with alcohol use are still not well 
understood.  Ethanol is a “dirty” drug in that it has numerous molecular targets.  Many of 
these targets are known including proteins such as ion channels, enzymes, etc.  While the 
contribution of ethanol’s effects on each target to the general effects of ethanol are not 
fully identified, even the mechanism by which ethanol exerts its effects on individual ion 
channels has not been fully characterized.  There is a wealth of evidence investigating the 
effects of ethanol on GlyR at the cellular level and system level, but the mechanisms by 
which ethanol exerts its effects on a single GlyR are few.	

This gap in knowledge is mirrored for anesthetics like isoflurane.  The 
mechanisms by which anesthetics cause general anesthesia is poorly understood, with 
many conflicting theories to how these compounds act.  Like ethanol, anesthetics have 
many targets including ion channels.  Structural information regarding anesthetic binding 
to cys-loop receptors has been recently found with crystal structures of GLIC bound by 
propofol and desflurane (Nury et al., 2011).  However, even knowing the binding location 
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of an anesthetic does not illuminate the effects it has once bound to the ion channel.  The 
data in this dissertation directly address the mechanism of ethanol’s and isoflurane’s 
enhancement of taurine-activated GlyR function.	

The allosteric modulator enhancement of GlyR currents elicited by maximally-
effective taurine concentrations seen in Chapters 3 and 4 could have been explained by 
multiple mechanisms on single GlyR, which were tested in Chapter 5.  First, a decrease in 
the rate of desensitization could cause an increase in peak current.  However, as seen in 
Chapter 3, ethanol did not affect desensitization rates and isoflurane increased 
desensitization rates, which as a solitary effect would result in decreased peak currents. 
In the experiments from Chapter 5, we used saturating concentrations of taurine to elicit a 
maximum effect from GlyR.  However this also has an added effect of eliminating the 
unbound closed state from consideration.  When this high concentration is continuously 
applied, receptors can only be in one of three bound states: closed, open, or desensitized. 
When taurine binds the receptor, and the channel opens beginning a cluster of activity, the 
channel flickers between the bound open and closed states.  This cluster of activity comes 
to an end with receptor desensitization.  Were a taurine molecule to unbind and the GlyR 
resensitize to a closed state, there is so much agonist around that taurine would bind 
almost instantaneously and begin another cluster of activity.  Thus any intercluster closed 
times are actually desensitized times.  While it is conceivable to measure these 
intercluster desensitized times and perform analyses similar to dwell time analyses, in 
practice measuring these desensitized times becomes very difficult.  The number of 
channels in a patch becomes an issue of great importance.  While we may assume all 
GlyR in a patch are the same and analyze all single opening clusters as example behavior, 
a second channel resensitizing and beginning a cluster of activity in the middle of the first 
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channel’s desensitization period is problematic.  Additionally, consistently high patch 
integrity would be needed for these experiments.  If only a few desensitized periods per 
patch are found before patch death, analysis would be very difficult.  Especially if each 
desensitized period is long lived giving a single sample of a long time constant.  Still, 
though difficult, experiments such as this are needed to better understand desensitization 
of GlyR and any effects of allosteric modulators on this process.	

An increase in channel conductance could also explain enhancement of max 
taurine currents.  We found that neither ethanol nor isoflurane had a significant effect on 
conductance level.  No allosteric modulator found so far has caused a change to GlyR 
conductance.  Generally structural changes to the pore itself are needed to drastically 
change conductance states, such as changing subunit composition or mutations to pore 
residues (Lynch, 2004).  Additionally, if either drug were somehow changing 
conductance at the pore, it is likely it would have the same effect on the glycine-activated 
GlyR as changes to the pore seem to affect both agonists equally (Lynch, 2004).	

The final possibility for seeing enhancement of max taurine currents is 
stabilization of the open state.  This effect is the main mechanism of action we found for 
both ethanol and isoflurane.  Both drugs increase the likelihood of longer lived open 
states, increasing efficacy and thus the Po of the taurine-activated GlyR.  This finding 
provides the first direct evidence we are aware of for differential effects of an allosteric 
modulator on the GlyR based on agonist.  While zinc potentiation of saturating taurine 
currents was found at the single channel level to be due to zinc enhancement of taurine 
Po, zinc showed this same enhancement of glycine Po (Laube et al., 2000).  We have 
previously examined the effects of ethanol on sub-maximal glycine activation of single 
GlyR, finding no effects on glycine efficacy (Welsh et al., 2009), even though there is no 
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ceiling effect as seen with saturating glycine.  Thus, the mechanism of ethanol 
enhancement of the taurine-activated GlyR is separate from the mechanism of glycine-
activated GlyR enhancement, and in light of the possible role of taurine-activated GlyR in 
the rewarding effects of ethanol (Ericson et al., 2011), these differences must be 
considered when examining the effects of ethanol.	

!
7.4 – Partial Agonist Efficacy of the GlyR	

!
A central goal of single channel electrophysiology has been to separate the 
phenomena of binding and gating.  Mutational studies often give some evidence of 
specific residue and region contributions to each process.  However, it is difficult to 
predict all possible changes to the three dimensional structure caused by a single point 
mutation.  Inability to obtain direct structural information for all channels, like the GlyR, 
aids in this difficulty.  Thus partial agonists serve as an interesting tool to examine 
differences in channel kinetics without a primary structural change to the ion channel. 
For the cys-loop receptors, the flip model of partial agonism seems to fit well for both 
GlyR and nAChR partial agonists (Lape et al., 2008).  If the structural basis of the flipped 
to open transition is believed to be the final gating step involving movement of the TM 
domains to open the channel, then the closed to flipped transition occurs somewhere 
within the ligand-binding domain during the conformational changes that convey the 
binding signal to the TM domains.	

We have now identified multiple residues (Chapter 6) near the ligand-binding 
domain that are important for holding the channel in the closed state as well as affecting 
agonist efficacy.  It is of note that mutations to the R131 residue greatly affected taurine 
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efficacy while seemingly having no effect on glycine-activation at the whole cell level. 
Single channel studies of these R131 mutants using glycine are underway, and it will be 
interesting to see if glycine efficacy is greatly increased with a corresponding decrease in 
affinity, like taurine, as EC50s remain unchanged compared to WT GlyR.  If not, this 
would be good evidence for differential GlyR activation pathways for glycine and 
taurine.  This notion is supported by the temperature effects on taurine efficacy relative to 
glycine.  While changing temperature of the environment will change intrinsic energy of 
the GlyR, resulting in changes to flexibility of the structure and speed of movement, these 
changes would normally be assumed to be agonist independent.	

!
7.5 – Clinical Implications	

!
This dissertation has provided research into the effects of allosteric modulators on 
partial agonists of the GlyR, as well as research into the nature of partial agonism at the 
GlyR.  It is worth noting then how the knowledge gained in this dissertation may be put 
to practical use.  There are three realms involving human health which the research in this 
dissertation may pertain to:  Addiction, pain, and the startle disease hyperekplexia.	

It has previously been noted in this dissertation that GlyR in the nucleus 
accumbens has been implicated as having an endogenous role in the rewarding effects of 
ethanol (Molander et al., 2005, 2007), and that specifically, ethanol modulation of taurine 
activation of the GlyR may be responsible for the reward signal of increased dopamine 
release into the NAcc (Ericson et al., 2011).  GlyR have been implicated in the dopamine 
elevating effects of cannabinoids and nicotine, and nicotine and other drugs of abuse alter 
taurine levels in the NAcc (Kashkin and De Witte, 2005; Li et al., 2012; Bu et al., 2013; 
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Jonsson et al., 2014).  Thus it is worth considering whether taurine may be the 
endogenous player for these GlyR.  Taurine and GlyR effects are not limited to the NAcc. 
Functional GlyR are also expressed in the hippocampus, a brain area important for 
memory, and the prefrontal cortex, a brain area important for complex cognitive 
processes like decision making (Malosio et al., 1991; Baer et al., 2009; Keck and White, 
2009; Lu and Ye, 2011).  These regions are thus important for other effects of drugs of 
abuse such as impaired decision making and memory loss, and GlyR have been 
implicated in ethanol effects in one of these regions (Badanich et al., 2013).  Taurine 
levels are also altered following administration of drugs of abuse in these areas 
(Dahchour and De Witte, 2003; Bu et al., 2013).  Thus it is possible that changes to 
taurine-activated GlyR functioning may be involved in the effects of multiple drugs of 
abuse.  Then the taurine-activated GlyR may be an important site of intervention into the 
effects of drugs of abuse and addiction.  The research shown in this dissertation makes 
clear that the taurine-activated GlyR has functional differences from the glycine-activated 
GlyR, thus targeting of GlyR in general may be insufficient, as taurine specific changes 
are warranted.  There is some evidence that extrasynaptic homomeric α2 GlyR may be 
more involved in these processes than synaptic β containing GlyR (Jonsson et al., 2012). 
However, though taurine efficacy relative to glycine is lower in α2 containing receptors, 
modulator enhancement of saturating taurine concentrations is still seen in these receptors 
(Fig. 4.4).	

In the spinal cord, GlyR play are important in the role of regulating pain-signaling 
pathways.  Nociceptors that detect noxious stimuli in the periphery send signals to the 
dorsal horn of the spinal cord and then towards higher brain regions.  If this circuit 
becomes sensitized due to decreased glycine release or decreased GlyR sensitivity, 
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persistent neuropathic pain may occur.  For example, the major inflammation related pain 
pathway involves the release of prostaglandins that activate a signal cascade ending in 
inhibition of α3 containing GlyR, resulting in a disinhibition of dorsal horn neurons; a 
mechanism that has been implicated in pain sensitization (Ahmadi et al., 2002; Zeilhofer, 
2005).  Thus, α3 containing GlyR are a promising target for analgesia.  Taurine efficacy 
relative to glycine on α3 containing GlyR is much lower than for α1 GlyR (Chen et al., 
2009).  However, taurine administration has anti-nociceptive effects for multiple models 
of neuropathic pain, acting on GlyR (Terada et al., 2011).  Even at this low efficacy on α3 
GlyR, taurine has a noted effect in the treatment of pain, and it is likely that allosteric 
modulator enhancement of taurine-mediated responses would be present for α3 
containing GlyR as it was for both α1 and α2 containing GlyR.  Thus selective 
potentiation of the taurine-activated GlyR similar to the results seen in this dissertation 
may be useful in treating neuropathic pain.	

Hyperekplexia is a hereditary disease where the startle response to unexpected 
stimuli is greatly exaggerated.  This disorder is caused by an ever increasing number of 
mutations or deletions to GlyR, that all result in decreased GlyR functioning (Bode and 
Lynch, 2014).  Recently, one hyperekplexia related GlyR mutation, W170S in the α1 
subunit, was found to selectively remove zinc potentiation of GlyR, while agonist 
sensitivity to glycine, β-alanine, and taurine remained normal (Zhou et al., 2013).  As 
zinc is found at GlyR potentiating levels in the nervous system, this mutation causes 
hyperekplexia by a loss of allosteric modulation which results in a decreased GlyR 
current in vivo.  The research in this dissertation into the effects of zinc in combination 
with other allosteric modulators suggests that taurine-activated GlyR currents in this 
mutant could be potentiated with another allosteric modulator to counteract the deficiency 
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in zinc potentiation.  Thus, allosteric modulation of taurine-activated GlyR may be useful 
in developing treatment for some forms of hyperekplexia.	

!
7.6 – Future Directions	

!
The research presented in this dissertation has added to our understanding of 
GlyR partial agonism and how these signals are modulated by various allosteric 
modulators.  However, there are many questions that arise from this research that should 




1. We have used taurine exclusively as an example of a partial agonist. 
Although taurine is of particular interest due to its biological prevalence and role in 
GlyR activation, we have seen that differences in agonists are not simply due to 
efficacy changes.  Thus it would be useful to examine how allosteric modulation 
affects other partial agonist action on the GlyR, using compounds such as β-alanine 
(higher efficacy than taurine), β-ABA or β-AIBA (both lower efficacy than taurine).	

!
2. We only tested allosteric modulators of two different mechanisms; drugs of 
abuse that bind in the alcohol/anesthetic binding pocket and the divalent cation zinc. 
Investigation of other classes of allosteric modulators with different mechanisms of 
action, such as neurosteroids, would add greatly to the understanding of allosteric 
modulation of partial agonists at the GlyR.  Additionally, we only used positive 
allosteric modulators in our studies.  Negative allosteric modulators of physiological 
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relevance on the GlyR, like caffeine, would expand understanding of modulation of 
partial agonism of GlyR as well.	

!
3. In our single channel analysis, we did not fit any specific kinetic mechanism 
preferring to remain descriptive of changes with allosteric modulators.  At our high 
concentrations of taurine, we excluded binding effects thus only examining changes 
in efficacy on a descriptive model of the data.  It would be of use to examine a full 
range of concentrations of taurine and glycine with allosteric modulators in single 
channel analysis of the GlyR.  This full data set would allow us to determine not only 
efficacy changes but also affinity changes, and could be fit simultaneously to a kinetic 




4. As previously mentioned, rigorous characterization of desensitization of the 
glycine- and taurine-activated GlyR with and without allosteric modulators is 
necessary at the whole cell and single channel levels.  However, there are many 
problems associated with these types of experiments as described in Chapter 7.3. 
Advanced techniques or advances in structural identification may be necessary to 
accomplish these goals, but this remains a major question in understanding GlyR.	

!
5. Further single channel analysis of the charged residues in the intersubunit 
interface are necessary.  For example, would a double mutation to R119 and R131 
result in a spontaneously active GlyR similar to D97R, and would taurine have an 
increased efficacy on this mutant?  This particular double mutation may not be 
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tractable as R119 mutations greatly right shift concentration response curves, but 
D97R behavior should be mirrored by some combination of residues on the 
complementary side of the interface if this electrostatic interaction is truly key to 
keeping the receptor in the closed state.  A related question is to attempt to identify 
residues that are important for keeping the receptor in the open state.  Likely there are 
some in the TM regions where the gating action happens, but do these residues 
important for closing bind to alternative partners after a conformational change to the 
open state?  If so, could that interaction be strengthened, resulting in a tonically 
active receptor?  Such a receptor would be very useful in studying channel activation 
and structural changes as a result of binding, as well as desensitization assuming the 
mutation did not affect this state.	

!
6. The agonist efficacy increasing effects of R131 mutations could be 
investigated further.  In particular, it is interesting to consider the implications of 
decrease to the Hill coefficient for taurine.  This decrease would traditionally be 
associated with a loss of cooperativity in taurine binding.  Could this decrease be 
linked to high taurine efficacy at opening the channel?  This could mean that unlike 
the WT GlyR, a single taurine molecule might be able to open the channel.  A double 
mutation could be created with one of the previously mentioned residues that 
eliminates taurine agonism and R131D to increase efficacy at opening the channel. 
Mixed ratios of these double mutants and WT GlyR subunits could result in receptors 
that have only one or two taurine binding sites.  An investigation of whether one or 





7. In an attempt to expand the scope of the work in this dissertation, the 
experimental ideas should be utilized at levels beyond the single channel and single 
cell.  Investigating the effects of allosteric modulators on taurine-activated GlyR can 
be accomplished first in slice recordings to understand effects on circuits of neurons, 
then in in vivo experiments to attempt to link potentiation of taurine-activated GlyR 
to specific behaviors.  This would be particularly useful in the mesolimbic system 
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